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Abstract 
This work describes the creation of a three-dimensional model of the 
children’s brain tumour medulloblastoma using primarily human cells. This 
in vitro cell culture model was created as a platform for testing novel drug 
delivery systems for local delivery in the brain. The aim of the local 
delivery strategy was to reduce radiotherapy through the use of 
nanoparticle-based chemotherapy. The nanoparticles would be delivered 
after surgery in the cavity left by the excised tumour tissue. The model 
was intended to evaluate the selective cytotoxicity of advanced drug 
delivery systems towards tumour tissue and the benefit of nanoparticle 
therapy compared to free drug. 
Normal tissue was modelled using human foetal brain tissue and tumour 
tissue was represented by a variety of medulloblastoma cell lines. Both 
were cultured as three-dimensional spheroids free of artificial matrix in 
ultra-low attachment plates.  The tumour and normal cells could be 
cultured either separately or together and the viability for each cell 
population determined using a battery of methods. Co-cultures of both cell 
types had the additional benefit of mimicking the interaction between 
normal and tumour tissue. 
The use of physiologically relevant single and co-culture in vitro models 
could provide information on the relative safety and efficacy of novel brain 
tumour treatments. The high-throughput platforms used, the algorithms 
and the validation of a battery of tests in 3D may be extrapolated to other 
cancer models as well. Moreover the universal marking procedure 
employed can be employed to label, culture and analyse any two cell 
types, while preserving tissue heterogeneity and viability. 
The key benefit from this thesis is the framework for designing in vitro 
models of tumours that include normal tissue as an internal control. This is 
an important contribution that can substantiate IC50 values by putting 
them in the context of drug safety and efficacy. It also highlights the 
minimum checks and feasibility experiments that need to be done before 
an in vitro assay is accepted for 3D spheroids.   
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Chapter 1.  Introduction 
Cancer is one of the leading causes of morbidity and mortality in children. 
The 2012 World Health Organisation (WHO) GLOBOCAN report estimates 
that each year 160, 000 children are diagnosed with cancer 
worldwide[1]. Of these approximately 30% are comprised of acute 
lymphoblastic leukaemia, closely followed by central nervous system 
(CNS) malignancies (25%)[1], [2]. The most common paediatric 
malignant brain tumour is medulloblastoma and the number of new cases 
totals more than 5000 children around the globe, with 500 in the US, 500 
in the EU and 80-90 new patients per year in the UK[1]–[4]. 
Section 1.1  Medulloblastoma  
1.1.1 Medulloblastoma overview 
Medulloblastoma is an embryonal tumour of the cerebellum that has two 
peaks in incidence around the age of 4 and the age of 7, followed by a 
rapid decline in patients aged 20-30 years. It is referred to as a posterior 
fossa tumour since it occurs in the cerebellum which is situated in the 
posterior fossa of the brain (Figure 1-1). The posterior fossa is an 
intracranial cavity formed by the tentorium cerebelli and the foramen 
magnum which hosts the cerebellum, the brain stem and the fourth 
ventricle of the brain. The tentorium cerebelli is a fold of the dura matter 
which covers the cerebellum and divides it from the cerebrum. Tumours 
located below the tentorium, like medulloblastoma, are called 
infratentorial and are more common in childhood. In contrast, tumours 
located above the tentorium are supratentorial and are more prevalent in 
adults[5].  
Patients usually present with a combination of headache, vomiting, 
nystagmus often accompanied with posture and balance abnormalities 
(broad stand, unsteady gait and tendency to fall backward). In advanced 
cases the tumour could obstruct normal CSF flow from the apertures of 
the fourth ventricle. The flow impediment usually leads to increased 
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intracranial pressure and hydrocephalus. The increase of pressure in the 
brain can cause neural damage and requires surgical intervention to 
redirect the flow of CSF via catheters (shunting). Upon MRI scan, 
medulloblastoma is seen as a posterior fossa mass in the cerebellum and 
the fourth ventricle (Figure 1-2). 
 
Figure 1-1. Mid-sagittal (side) view of the human brain. The tentorium cerebelli is a fold in 
the dura matter that splits the brain into a supra- and infratentorial part, above and 
below the tentorium respectively. Medulloblastoma arises infratentorially in the posterior 
fossa, usually affecting the cerebellum and the roof of the fourth ventricle. CSF flows from 
the lateral and third ventricle into the fourth ventricle through the cerebral aqueduct. 
From there the CSF bathes the subarachnoid space in the brain through the median and 
lateral apertures, it also drains into the central canal of the spinal cord. Image for the 
National Cancer Institute © (2010) Terese Winslow, U.S. Govt. has certain rights. 
Introduction 
 3   
  
 
Figure 1-2. MRI Image showing medulloblastoma with CSF flow obstruction. A 
Gadolinium-based MRI contrast agent has been used to identify the tumour (white 
arrow). The blood vessels of tumours often have an incomplete basement membrane, 
permeable to the contrast agent[6]. Image from Radiopaedia.org, Dr Paresh K. Desai 
The WHO classifies medulloblastoma as a grade IV tumour. It has been 
given the highest ranking based on its rapid division, propensity to 
invade the adjacent tissues and metastasize in over 30% of cases[7]. 
Medulloblastoma tumours most frequently develop in the median part of 
the cerebellum (vermis) or the roof of the fourth ventricle and proceed to 
invade the adjacent tissues. Nevertheless, a small percentage of 
medulloblastoma cases occur in adults, in whom tumours may develop in 
one of the cerebellar hemispheres. Chang et al[8] established a staging 
system based on tumour size, invasion of the neighbouring tissues and 
metastasis in 1969 (Table 1-1). The Chang staging system has been 
successfully applied for patient risk stratification and low T and M stages 
were found to be good prognostic factors for disease outcome[9]. The 
risk stratification system is later used to determine the intensity of 
therapy. 
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Stage Definition 
Tumour  
T1 Tumour≤3cm in diameter and limited to the midline position in the vermis, roof of 
the fourth ventricle and (less frequently) to the cerebellar hemispheres 
T2 Tumour≥3cm in diameter, further invading one adjacent structure or partially filling 
the fourth ventricle 
T3 Divided in to 3a and 3b 
T3a Filling the fourth ventricle with extension into the aqueduct of Sylvius, foramen of 
Magendie or foramen of Luschka, thus producing marked internal hydrocephalus 
T3b Tumour arising from the flow of the fourth ventricle of brain stem and filling the 
fourth ventricle 
T4 Tumour further spreading through the aqueduct of Sylvius to involve third ventricle of 
midbrain or tumour extending to the upper cervical cord 
Metastasis  
M0 No evidence of gross subarachnoid of haematogenous metastasis 
M1 Microscopic tumour cells found in CSF 
M2 Gross nodular seedlings demonstrated in cerebella, cerebral, subarachnoid space of 
ventricles 
M3 Gross nodular seeding in the spinal subarachnoid space 
M4 Extraneural metastasis 
Table 1-1 Staging system for medulloblastoma proposed by Chang et al[8]. 
 
In current clinical practice full brain and spine MRIs are used to pinpoint 
tumour staging, while a CSF biopsy can be utilised to distinguish between 
M0 and M1 stage even before surgery, provided there is no CSF flow 
obstruction.  
A definitive medulloblastoma diagnosis can be obtained upon histological 
examination of the tumour after surgery. Medulloblastoma is 
characterised by small, densely packed cells with prominent nuclei and a 
high number of mitotic and apoptotic cells in the tissue. According to the 
latest 2007 WHO classification[7] medulloblastoma is divided in four 
groups dependent on its histopathological features (Figure 1-3). Classical 
medulloblastoma (Figure 1-3A and A’) accounts for three-quarters of 
cases and is characterised by sheets of poorly differentiated overlapping 
cells with big nuclei and small cytoplasmic fraction which can often 
arrange in rosettes or palisading structures[10]. 
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Figure 1-3. Histopathological types of medulloblastoma according to the 2007 WHO 
classification. A-classical medulloblastoma with sheets of undifferentiated small cells with 
high nuclear:cytoplasmic ratio; A’-classical medulloblastoma with characteristic Homer-
Wright (neuroblastic) rosettes; B-desmoplastic medulloblastoma with nodules; C-
medulloblastoma with extensive nodularity; D-large-cell anaplastic medulloblastoma with 
big nuclei and “cell wrapping” ( black arrow). Images adapted from Ellison[11] with 
permission by Wiley. 
Desmoplastic (nodular) medulloblastoma (Figure 1-3B) is found in 7% of 
cases and is characterised by a biphasic distribution of cells in nodules 
and nodule-free regions, differentiated by reticulin staining. Desmoplastic 
medulloblastoma can exhibit different degrees of nodularity and is often 
associated with neural lineage differentiation in the nodules and more 
rarely, astrocytic differentiation in the internodular regions. The MBEN 
(Figure 1-3C- medulloblastoma with extensive nodularity) type is 
considered to be an extreme form of the nodular medulloblastoma, it is 
Introduction 
 6   
  
relatively rare (3% of cases) and is associated with infants in whom it 
usually carries a good prognosis. In contrast, the combined category of 
large cell/anaplastic medulloblastoma (Figure 1-3D) is more common 
(10-22%) and indicates high risk patients independent of metastatic 
status[12]. It is characterised with abundance of larger cells, polymorphic 
nuclei and high mitotic index. 
Despite offering some predictive potential in cases of large-cell/anaplastic 
and MBEN disease, the histopathological classification fails to stratify 
more than 70% of patients who present with classical medulloblastoma. 
In this regard, novel insights into the molecular biology of 
medulloblastoma allow for more precise patient risk stratification and 
provide important clues for improved treatment.   
1.1.2 Biological basis of medulloblastoma subtypes 
The extensive studies on the medulloblastoma genome in the first decade 
of the 21st century and broad international collaboration led to the 
publication of a scientific consensus paper in 2012 indicating that 
medulloblastoma is comprised of at least four main molecularly distinct 
subgroups[13]. The subgroups differ in the activation of core biological 
pathways, their clinical presentation and the therapy outcome (Figure 
1-4). 
The WNT subgroup is found in 10% of medulloblastoma cases and 
currently has the best prognosis with over 95% progression-free 
survival[14]. It is named after the disturbed canonical WNT pathway and 
is associated with classical histology, mutations in exon 3 of CTNBB1, 
nuclear expression of β-catenin and monosomy 6 (loss of chromosome 
6). Recent studies have reported that patients with WNT driven 
medulloblastoma have leaky blood vessels lacking the markers associated 
with an intact blood-brain barrier[15]. This could possibly explain the 
increased chemosensitivity of those tumours and the favourable 
prognosis for patients. 
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Figure 1-4. The four molecular subgroups of medulloblastoma- cytogenetic profile, demographic and clinical features summary. CDK6, cyclin-dependent 
kinase 6; CGNPs, cerebellar granule neuron precursors; CTDNEP1, CTD nuclear envelope phosphatase 1; CTNNB1, β-catenin; EGL, external granule cell 
layer; GLI2, GLI family zinc finger 2; KDM6A, lysine-specific demethylase 6A; LCA, large cell and anaplastic; LDB1, LIM domain binding 1; LRP1B, low 
density lipoprotein receptor-related protein 1B; MBEN, medulloblastoma with extensive nodularity; MLL, mixed lineage leukaemia; OTX2, orthodenticle 
homeobox 2; PTCH1, patched 1; SCNA, somatic copy number aberration; SHH, sonic hedgehog; SNCAIP, α-synuclein interacting protein; SPTB, spectrin-
β erythrocytic; SVZ, subventricular zone; TCF4, transcription factor 4; TNXB, tenascin XB. Adapted from [16] with permission by Macmillan publishers.
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The SHH (sonic hedgehog) pathway is disturbed in 30% of patients and 
the group combines a very heterogeneous set of patients. Sonic 
hedgehog binds to Patched (PTCH1) receptors on the cell membrane 
which activates the signal mediator Smoothened (SMO). In turn SMO 
activates glioma associated oncogene (GLI) transcription factors which 
translocate to the nucleus and activate gene expression. GLI factors can 
be transported out of the nucleus by Suppressor of fused (SUFU) which 
inhibits the SHH pathway. The SHH pathway is essential in neurogenesis 
and the formation of many organs during development. Patients with 
medulloblastoma can have mutations in PTCH1, SMO, SUFU, GLI1, GLI2 
leading to the heterogeneity of disease presentation, response to therapy 
and outcome for patients[17].  
 
Figure 1-5.Incidence and most common mutations in patients with SHH medulloblastoma 
dependent on age. Red line shows the distribution for all cases. Infants with PTCH1 and 
SUFU mutations are shown by the blue line; children with PTCH1 and TP53 mutations are 
plotted with the purple line and adult cases with PTCH1 and SMO mutations (green line). 
Adapted from[17] with permission by Elsevier.   
Initial studies with SMO inhibitors have highlighted the limitations of 
targeting a single player in the SHH pathway. The drug GDC-0449 
(Vismodegib) was used to block SMO in patients with constantly activated 
PTCH1. Despite the initial rapid and significant response, the tumours 
returned within months[18].  This shortcoming combined with the 
possible effects on bone growth[19] may limit the usefulness of SMO 
inhibitors in patients with mutations downstream of the target. 
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Treatment of children (4-15 years old) with SHH mutations poses 
additional difficulties because patients often exhibit mutations in TP53 
(Li-Fraumeni syndrome)[20]. Since TP53 is responsible for DNA repair 
and initiation of apoptosis upon identification of DNA damage, those 
patients are especially susceptible to secondary malignancies and should 
be spared from radiotherapy and alkylating chemotherapy[21].  
Other factors that may place patients from the SHH group into a high-risk 
category include GLI2 amplification and 14q chromosome loss[22].The 
advances made in the molecular biology of the SHH group are bound to 
bear fruit and careful patient characterisation along with multimodal 
therapies would be the key in improving survival for this group of 
patients. For example, the tumours in this group have been shown to 
recur mostly locally making them candidates for local therapy 
approaches, increased tumour bed irradiation and aggressive 
surgery[23]. 
Group 3 encompasses around 25% of medulloblastoma patients, it is 
often driven by MYC amplifications and carries the worst outcome for 
patients with around 50% survival. The presence of large cell anaplastic 
morphology, isochromosome 17 or MYC amplifications are all thought to 
confer a higher risk to patients. The tumours in this group often recur in 
the pia and arachnoid mater leading to leptomeningeal metastasis. In this 
regard, CSF prophylaxis in the form of intra-CSF chemotherapy may be a 
promising treatment to reduce mortality. 
Group 4 is the most common group (35% patients) with classical 
histological features, frequent incidence of isochromosome 17q and 
intermediate survival. Chromosome 11 loss or chromosome 17 gain were 
found to carry a good prognosis within this Group, while M1 status was 
found to determine high-risk patients. Apart from these considerations 
and the characteristic MYCN amplifications this continues to be the least 
biologically understood group of medulloblastoma. 
The utility of the biological classification of medulloblastoma lies in the 
improvement of patient stratification and the possibility to tailor 
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treatment based on subgroup, risk of relapse and signal transduction 
mechanisms(Table 1-2 and Table 1-3). 
 Low risk Standard risk High-risk (any trait) 
Age >7 3-7 <3 
M-status M0 M0 M1-4` 
Resection degree <1.5cm2 <1.5cm2 >1.5cm2 
Histopathology 
β-catenin nuclear 
staining 
 
Classic 
<3years and MBEN 
Large-cell/anaplastic 
Subgroup WNT- CTNNB1(exon 3)  
MYC/MYCN, amplification 
GLI2 amplification 
Therapy Reduced Standard 
Aggressive/ 
Novel treatments 
Survival >90% 70-80% 30-60% 
Table 1-2. Clinically used patient risk stratification for medulloblastoma. Adapted from[6]. 
M-status is determined from cytological examination of the CSF and preoperative MRI. 
MBEN-medulloblastoma with extensive nodularity. WNT-signalling pathways is most 
reliably diagnosed through direct sequencing of β-catenin 1 (CTNNB1). MYC v-myc avian 
myelocytomatosis viral oncogene homolog, MYCN is the neuroblastoma derived homolog 
of MYC. Any single feature of the high risk group is enough to stratify a patient as high-
risk 
 Low Risk Standard Risk High-risk 
WNT Mo, Non LC/A M+, LC/A N/A 
SHH 
M0, non GLI2 
Non Chr14q loss 
M0 and either 
GLI2 ampl 
Or 14 loss 
M+ 
TP53- 
GLI2 amplification 
14q loss 
Group 3 N/A 
M0, non LC/A 
non-MYC/MYCN 
non iso17q 
M+ 
LC/A 
Iso17q 
Group 4 
Either Chr11 loss 
Chr17 gain 
M0 
Neither Chr 11 loss 
,nor Chr 17 gain ;M0 
M+ 
Table 1-3. Proposed further patient risk stratification within medulloblastoma subgroups 
as reported by[22] and[21]. LC/A-large cell anaplastic; GLI- glioma associate oncogene, 
TP53-tumour protein 53 (Li-Fraumeni syndrome) 
1.1.3 Treatment modalities 
In the beginning of the 20th century, when medulloblastoma was first 
described by Wright[24] and later classified and treated by Cushing and 
Bailey[25], the disease carried a poor prognosis with survival measured 
in months and high percentage of operative mortality.  The combination 
of surgery and radiotherapy in the middle of the century led to five-year 
survival rates of 40%[26]. The currently reported five year survival 
figures are between 50% (for high risk patients) up to 90% (low risk 
patients) and have been achieved through a combination of surgery, 
radiotherapy and chemotherapy[6]. While each modality is essential for 
prolonging patient survival, cure often comes at the expense of a 
multitude of side effects. 
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1.1.3.1 Surgery 
Surgical removal of the tumour has been the mainstay of treatment since 
the initial work of Bailey and Cushing[25]. It serves to provide tissue for 
diagnosis, relieve the blocked CSF flow (through shunting) and reduce 
tumour burden to numbers low enough for radio- and chemotherapy to 
control[6]. Complete surgical resection along with the patient’s 
metastatic index have been the most robust predictors of disease 
outcome[27]. The goal has been set to less than 1.5cm2 of residual 
tumour burden as determined by a postoperative MRI[9]. Despite the 
good prognosis associated with radical resections, nearly a quarter of 
patients are at risk of developing cerebellar mutism[28]. Cerebellar 
mutism, also known as “posterior fossa syndrome”, appears within a few 
days of surgery and manifests with transient mutism, ataxia, hypotonia 
and emotional lability. While most symptoms subside within 4 weeks, 
speech impediments may persist for over a year and cognitive 
development may be impaired in the long term[29]. Damage to the 
dentato-thalamo-cortical pathway has been implicated to result in 
posterior fossa syndrome and surgical techniques which avoid splitting 
the cerebellar vermis have been suggested to minimize cerebellar 
mutism[30]. 
1.1.3.2 Radiotherapy 
The second pillar of medulloblastoma treatment is radiotherapy and 
improvements in the delivery of radiation have been instrumental in 
increasing patient survival throughout the last century[31]. The essential 
role of radiotherapy is attributable to the radiosensitivity of 
medulloblastoma and its tendency to metastasize within the CNS. While 
patients in the 1940s received mostly local radiotherapy and survival 
rates were below 5%, the introduction of full craniospinal irradiation(CSI) 
in the 50s and 60s brought survival up to 40%[26], [32]. The general 
strategy in medulloblastoma radiotherapy has remained unchanged since 
then and includes full craniospinal irradiation supplemented with a local 
boost dose to the location of the tumour[33]. What has evolved is the 
greater appreciation of the adverse effects of radiotherapy and the 
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strategies to maximise the benefits of this treatment modality while 
keeping the risks low. 
As soon as patients started surviving from medulloblastoma longer than a 
few months it became apparent that their cognitive development[34], 
growth[35] and endocrine functioning[36] were impaired and that 
survivors were developing secondary malignancies[37]. The initial 
optimism of the 1960s[26] was toned down by the end of the 20th 
century when the reduction of the quality of life of medulloblastoma 
survivors became widely recognised[38]–[43]. Progressive reduction of 
the patient’s intelligence quotient (IQ) and deterioration in fine motor 
skills were set on a background of radiation related morbidity[44] and 
social isolation[45]. 
The serious late side effects of radiotherapy (sequelae) necessitated the 
development of strategies aimed at reducing the impact of CSI on the 
normal tissue by utilising increasingly smaller doses of radiation and 
minimising normal tissue damage. Radiotherapy is not recommended for 
children under 3 years due to unacceptable toxicity[46]. For older 
children reductions of the craniospinal dose from 36 Gy, to 24 Gy and 
eventually to 18 Gy are being explored as well as confining the traditional 
posterior fossa boost (total dose 50-55Gy) to the tumour bed only[47]. 
Regardless of CSI dose reduction a study by Gajjar et al[48] found 3-4 IQ 
points/year decrease in various domains for patients aged 3-7 years and 
2 IQ points/year decrease for older patients. On the other hand, a recent 
study utilising reduced CSI (23.4Gy) comparing irradiation of the whole 
posterior fossa to focusing the boost solely on the tumour bed has shown 
less neurocognitive damage in the group receiving radiation to the 
tumour bed only[49]. 
Apart from radiotherapy dose reduction, refinements to the amount of 
radiation delivered to the normal tissue have been crucial in controlling 
adverse effects for patients. For instance, the introduction of conformal 
radiation allowed oncologists to use multiple beam paths to focus 
radiation at the posterior fossa thus limiting the exposure of vital 
tissues[6]. Three-dimensional conformal radiation (3D-CRT) requires 
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brain imaging from CT or MRI to build a three-dimensional model of the 
patient’s brain. Afterwards multiple high energy x-ray beams are 
arranged so that they intersect at the tumour bed and posterior fossa 
while limiting exposure to the cochlea and hypothalamus[50]. An even 
more advanced modality is intensity modulated radiation therapy (IMRT) 
which uses more beams, achieves a more conformal dose and allows for 
sophisticated radiation dose shaping[51]. Nevertheless IMRT delivers a 
higher integral dose of radiation compared to 3D-CRT and while it can be 
set up to spare certain areas (the cochlea and optical nerves) it exposes 
others (like the temporal lobes) to additional radiation which may 
potentially contribute to cognitive decline[52]–[55]. 
Radiation exposure of a growing number of brain areas is increasingly 
recognised to significantly contribute to quality of life decrease. For this 
reason, specific dosing strategies are developed to minimize normal 
tissue exposure. For example, sparing the hippocampus is now thought 
to be essential in order to minimize IQ decline and memory impairments 
in patients[56]. The list of sites at risk from brain irradiation includes the 
eyes, SVZ (subventricular zone), cochlea, pituitary gland, parotids, optic 
nerves, brainstem, and the cerebrum. The organs at risk from irradiating 
the spine include the heart, lungs, liver, kidneys and gonads. Clearly the 
list is going to expand as more information on cognitive decline and 
secondary malignancies becomes available for survivors.  
A promising strategy to decrease normal tissue exposure to ionising 
radiation is substituting x-ray photons with proton radiation (Figure 1-6). 
When high energy x-ray photons enter the tissue they deposit energy 
throughout their path. In reality the maximum energy release depth for 6 
MV photons is 1.5cm. After the maximum, the energy of photons starts 
to decrease gradually as the x-rays pass through the tumour and exit the 
body. In contrast, protons, which have a positive charge and a defined 
mass, travel through the body depositing a small amount of radiation and 
release most of their energy at a defined position in a sharp peak, called 
the Brag peak. When multiple proton beams are combined a spread-out 
Brag peak profile (SOBP) is constructed. The advantage of protons is that 
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the dose can be focused on the tumour and unlike photons there is no 
exit dose through the normal tissues. 
 
Figure 1-6 Energy dissipation of protons and photon radiation in tissues. The spread-out 
Bragg peak (SOBP, red), is made up of the sum of individual (pristine) proton Brag peaks 
(blue). A conventional 10 MV photon beam is depicted in black. The dashed lines (black) 
indicate the clinical acceptable variation in the plateau dose of ±2%. The dot–dashed 
lines (green) indicate the 90% dose and spatial, range and modulation width, intervals. 
The SOBP dose distribution of even a single field can provide complete target volume 
coverage in depth and lateral dimensions, in sharp contrast to a single photon dose 
distribution; only a composite set of photon fields can deliver a clinical target dose 
distribution. Note the absence of dose beyond the distal fall-off edge of the SOBP. 
Adapted from [57] with permission by Macmillan publishers. 
The utility of protons in radiotherapy was initially recognised in 1946 by 
Robert Wilson[58] and despite the fact that the first patients were 
treated in 1954, the procedure only gained FDA approval in 1988. The 
theoretical benefit of using protons in medulloblastoma stems from the 
lack of exit dose, especially in preserving the cochlea and hippocampus of 
patients[56][59]–[61]. The argument for utilising protons for irradiating 
the spine is even stronger since that will potentially limit exposure of the 
lung, heart, kidneys and gonads of patients (Figure 1-7). 
Introduction 
 15   
  
 
Figure 1-7 Isodose distribution in the sagittal projection along the spinal column for (a) X-
rays, (b) IMRT, and (c) protons. Adapted from [60] with permission from Elsevier.  
Although the hopes for proton therapy are still high[62], recent data has 
indicated increased risks of brain stem necrosis[63], [64] and 4-6 
point/year IQ neurocognitive decline in patients treated with proton 
radiation[65]. The debate for the practical benefit of proton therapy is 
still ongoing[66], [67] and concerns have been raised regarding the risks 
of secondary malignancies due to neutron scattering[68], [69]. While the 
dose to distal structures is minimized with protons, the tumour bed and 
the neighbouring tissue still have to receive a substantial radiation dose. 
This is because the nature of craniospinal radiation postulates a certain 
dose (18-24 Gy, up to 36 Gy in high-risk patients) to the whole neuraxis 
in order to prevent recurrences. In this respect protons are merely a step 
forward in decreasing certain side effects but will largely exhibit the 
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plethora of off-target toxicity problems characterising ionising radiation in 
general. 
Regardless of the type of radiation, irradiating the brain shows a dose-
dependent decrease in cognitive functioning and academic achievement. 
The age of the patient and the distribution of radiation to the adjacent 
normal tissue are equally important to predict declines in the quality of 
survivorship[70]. In addition to efforts on refining radiotherapy, 
strategies to reduce the total dose of radiation should be actively pursued 
in order to improve the quality of life for patients. 
1.1.3.3 Chemotherapy 
In this regard, chemotherapy is the main modality that has the capability 
of reducing and partially replacing radiotherapy. Initial chemotherapy 
regimens struggled to achieve statistically significant benefit in patient 
survival compared to radiotherapy alone[71], [72]. In those first large 
studies improvement was only detected for high-risk patients with brain 
stem involvement, subtotal resection and metastasis. As a turning point, 
the premature termination of a study aiming to reduce radiotherapy and 
omit chemotherapy gave some clues that chemotherapy was indeed an 
essential modality[73].  
Later, the SIOP III trial[74], employing etoposide among other 
chemotherapeutics,  showed an improvement in progression free survival 
with combination therapy over radiotherapy alone. At the same time the 
CCG-9892[75] and CCG 921[9] studies reported 5-year survival rates 
above 80% and showed the feasibility of reducing craniospinal 
radiotherapy to 23.4 Gy for standard risk patients when cisplatin, 
vincristine and either lomustine or cyclophosphamide were combined. 
The following SIOP IV trail confirmed the high survival rates for average-
risk patients but did not find any advantage of hyper-fractionating 
radiotherapy[76]. Despite the reassuring survival figures from the 
combination of chemotherapy and radiation, patients were experiencing 
increased risks of secondary malignancies[44] and decline in intellectual 
abilities and academic achievement[77]. The latest trials are building on 
the experience from the previous studies and will be exploring options to 
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further decrease radiotherapy (18Gy CSI dose) for standard-risk patients 
with the help of intensified chemotherapy combinations 
(ClinicalTrials.gov/NCT00085735). 
In contrast to standard and low risk patients, who have a relatively good 
prognosis, survival for high-risk patients ranges from 30 to 60%[78]–
[80]. The protocols for high-risk patients usually use high dose 
radiotherapy and aggressive chemotherapy regimens with stem cell 
rescue. The dose and schedule of the chemotherapeutics are usually 
determined by the extent of side effects and bring patients to the very 
limit of their endurance.  
Another challenging group of patients is comprised of children under 3-4 
years in whom radiotherapy is contraindicated due to severe 
neurocognitive impairment. Apart from a small subgroup of patients with 
medulloblastoma with extensive nodularity, most patients have a poor 
prognosis and 5-year survival rates generally vary around 50% 
depending on confounding factors[81].  
Systemic chemotherapy exposes the whole body to the drug and 
produces a variety of adverse effects that limit dosing, disrupt 
chemotherapy schedule and can sometimes have a lethal outcome. There 
are a variety of factors that play a role in the adverse effects of 
chemotherapy. The most important are the distribution of drugs in the 
body, metabolism to toxic metabolites, pharmacodynamic interactions 
with targets in normal cells and the variability in dose needed to 
eliminate the tumours. All of these factors are interdependent and they 
interact with indicators such as the age, health, genetic profile of the 
patient as well as previous and concomitant therapy. The border between 
treatment success and failure is often very thin. 
The most commonly used drugs in medulloblastoma therapy are 
vincristine, platinum compounds (cisplatin and carboplatin), alkylating 
agents (nitrosoureas, procarbazine, cyclophosphamide) and 
topoisomerase inhibitors (mainly etoposide). None of these drugs is used 
as a single agent, they are most commonly combined in various 
protocols. 
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Chemotherapy is normally administered either orally or by injection and 
the drugs distribute throughout the whole body before they reach their 
target: leftover tumour tissue and single tumour cells in the central 
nervous system. In this regard the blood-brain barrier (BBB) poses the 
greatest obstacle to chemotherapy as drug penetration is often limited 
due to the tight junctions of the blood vessels of the brain. The BBB limits 
the transport of drugs with Mw higher than 400 Da and normally excludes 
hydrophilic, charged and  highly protein-bound  drugs[82]. Moreover, 
specialised transporter molecules in the endothelial cells actively 
transport most cytotoxics out of the brain as soon as they try to diffuse 
through the barrier. This efflux is accomplished through the superfamily 
of ATP-binding cassette (ABC) transporters like the P-glycoprotein pump 
(P-gp, ABCB1), the multi drug-resistant protein family (MRPs, ABCC) and 
the breast cancer resistance protein (BCRP, ABCG2) [83].  On the other 
hand, brain tumours are thought to have leakier blood vessels and an 
incomplete blood-brain barrier[84]. While the extent of the permeability 
has been reported to vary both between and within tumours[85], the 
extent of drug distribution within the tumour may be diminished due to 
increased interstitial pressure[86]. Furthermore, tumour clusters below 
250µm in diameter may lack blood vessels and will be shielded by the 
intact normal BBB[87]. All of these pharmacokinetic limitations have 
necessitated the use of high systemic doses so that the fraction reaching 
the tumour can exhibit some meaningful pharmacological action. This in 
turn leads to large amounts of drugs distributing throughout the body 
and exerting a series of side effects. 
Dividing tissues like the bone marrow receive the primary assault and 
myelosuppression with leukopenia, neutropenia, thrombocytopenia and 
anaemia are the primary dose-limiting toxicities of most 
chemotherapeutics used in medulloblastoma. The specific side effects for 
the most common drugs used in medulloblastoma chemotherapy will be 
given below as an illustration of the multitude of organs affected by 
systemic protocols. 
The alkylating nitrosoureas, carmustine and lomustine, are particularly 
notorious for causing prolonged myelosuppression. Lomustine can be 
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administered orally and is the drug of choice in medulloblastoma.  The 
main strength of the nitrosoureas stems from their lipophilicity and ability 
to cross the BBB thereby exerting control over macroscopic vascularised 
cerebral lesions[88]–[90]. The nitrosoureas are alkylating cytotoxics, 
which are related to the nitrogen mustards. The alkylating antineoplastic 
drugs were the first modern anticancer class introduced through the work 
of Goodman and Gilman in 1942-1946[91]. The nitrosoureas release a 
reactive 2-chloroethyldiazonium ion which reacts with DNA mainly 
alkylating guanine residues and crosslinking DNA strands through the 
2-chloroethyl moiety[92]. The alkylated DNA can be repaired by 06-
methylguanine-methyltransferase (MGMT) which is often expressed in 
medulloblastoma and is one of the mechanisms contributing to resistance 
to chemotherapy[93]. Apart from myelosuppression, additional side 
effects like gastrointestinal disturbances, liver toxicity and lung fibrosis 
may limit treatment. Furthermore, alkylating agents increase the risk of 
secondary malignancies and may affect fertility in boys and girls[94], 
[95]. 
Cyclophosphamide is another example of an alkylating drug used in 
medulloblastoma. It requires hepatic activation to 4-
hydroxycyclophosphamide which is later metabolised in tumour cells to 
phosphoramide mustard (Figure 1-8). The last step is hypothesized to 
confer some degree of selectivity of cyclophosphamide towards normal 
cells which are believed to express higher levels of the detoxifying 
enzymes aldehyde dehydrogenase and glutathione transferase[96]. Initial 
studies using radiolabelled cyclophosphamide indicated penetration into 
brain tumours[97], but this statement has been questioned lately as 
detection of inactive metabolites may have given rise to false-positive 
results[98]. The argument for the use of cyclophosphamide comes from a 
large study where over 300 patients were given either Regimen A 
(vincristine, cisplatin and lomustine) or Regimen B (vincristine, cisplatin 
and cyclophosphamide)[44], [99]. Despite the proven CNS distribution of 
lomustine and the doubtful results for cyclophosphamide, patient survival 
and secondary malignancies were the same in both groups. In addition to 
the similar efficacy to the nitrosoureas, cyclophosphamide has 
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comparable toxicity and adverse effects. The only notable difference 
being increased risk of haemorrhagic cystitis due to acrolein release 
during metabolism (Figure 1-8). 
 
Figure 1-8. Metabolism and activation of cyclophosphamide. Cyclophosphamide requires 
activation by hepatic CYP2B enzymes. The 4-hydroxy derivative can be degraded to 
inactive metabolites in normal cells by the enzymes aldehyde dehydrogenase, glutathione 
transferase and others. The active metabolite phosphoramide mustard is thought to 
confer cytotoxic action, while acrolein has been implicated in causing haemorrhagic 
cystitis in patients. Figure adapted from[96] 
In contrast, vincristine behaves very differently to the alkylating drugs 
and is the medulloblastoma chemotherapeutic exhibiting the least 
amount of myelosuppression. The low toxicity towards the bone marrow 
allows vincristine to be administered during radiotherapy. The dose 
limiting toxicity is severe peripheral neurotoxicity manifesting with foot 
drop, muscle weakness, constipation, ileus and neuropathy. Vincristine 
blocks the polymerization of tubulin and arrests mitotic cells in 
metaphase. The heightened toxicity to neurons may be explained by 
inhibition of tubulin polymerization in postmitotic neurons resulting in 
axioplasmic transport inhibition in the axons[100], [101]. The effects of 
vincristine are confined to the peripheral nervous system because 
vincristine does not cross the intact BBB[102]. Still, if the drug is injected 
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in the CSF it is almost 100% lethal to patients[103]. The propensity of 
some medulloblastoma cells to differentiate towards the neural 
lineage[11] and the heightened toxicity of vincristine to both dividing and 
neuronal cells serves to explain the central role of vincristine use in 
medulloblastoma chemotherapy. Nevertheless, the utilisation of 
vincristine in brain tumours relies on the hypothesis that the latter have a 
leaky BBB. The intratumoral distribution of vincristine would be 
potentially augmented if the blood-tumour barrier were to be disrupted 
by radiation[104]. Many researchers have tried to determine the 
distribution of vincristine in brain tumours by using rodent glioma models 
and have reached conflicting conclusions[105], [106]. A study in humans 
using the related drug vinblastine has found detectable levels in 
intracerebral tumours[107] and has illustrated the poor utility of using 
CSF concentrations[108] to infer intracerebral or intratumoural levels of 
drugs. It goes without question that any drug, and especially vincristine, 
cannot be expected to eliminate medulloblastoma tumours as a single 
therapeutic. It appears more likely that unprotected peripheral neurons 
will be severely damaged before vincristine has chance to cross the 
heterogeneous blood-tumour barrier and circumvent the increased 
interstitial pressure in brain tumours. 
The third class of essential chemotherapeutics in medulloblastoma 
therapy is the platinum compounds. Most conventional medulloblastoma 
protocols include cisplatin and the drug’s distribution in brain tumours 
has been documented[84], [109]. Cisplatin needs to be activated by 
displacement of the chloride ligands with water. The active metabolite 
forms DNA adducts with purine bases and crosslinks DNA which starts a 
cascade of stress signalling, induction of apoptosis and cell death[110]. 
During treatment cisplatin may lead to dose-limiting myelosuppression, 
neurotoxicity, renal impairment and has a high emetogenic potential. 
Most importantly, the combined insult from cisplatin and radiotherapy to 
the cochlear nerves very often results in hearing loss in patients 
necessitating treatment de-escalation[111]. The ototoxicity is persistent 
and most medulloblastoma survivors require a hearing aid. The toxic 
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effects of cisplatin require mandatory monitoring of renal function and 
hearing as well as the standard blood counts[112]. 
Systemic etoposide is also employed is some regimens, like the SIOP-
PNET-III protocol[74] and extensively in high-risk medulloblastoma 
patients[113] and infants[114]. The use of etoposide along with its most 
pronounced side effects of myelosuppression and increased risk of 
secondary malignancies will be more extensively reviewed in Section 6.1. 
As the biological understanding of medulloblastoma develops further, 
novel targeted agents emerge in prospective treatment strategies[115]. 
While these new drugs hold great promise, the location of the tumours 
behind the blood-brain barrier, the frailty of the paediatric population and 
the relative rarity of the different subtypes may severely delay targeted 
agent introduction into therapy. This is exemplified by the case of SHH 
inhibitors, where development of resistance and suppression of bone 
growth were the main barriers to introduction[18].  
This summary of the most important chemotherapeutics used in 
medulloblastoma outlines their grave systemic side effects. On one hand, 
conventional chemotherapy drugs do not discriminate sufficiently 
between normal and tumour cells and on the other systemic 
administration requires large doses. That is why many clinicians and 
researchers have turned to local delivery in the hope of using less drug 
and delivering drugs closer to their target (Table 1-4). 
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Systemic chemotherapy 
Drug Class Main drugs Mechanism of action Blood-brain barrier 
penetration 
Dose-limiting 
toxicity 
Long-term effects 
Alkylating 
agents 
Carmustine, 
Lomustine, 
Cyclophosphamide 
Alkylating DNA Carmustine, Lomustine  +++ 
Cyclophosphamide   - 
Myelosuppression Secondary 
malignancies 
Infertility 
Vinca alkaloids Vincristine Blocks tubulin 
polymerisation 
- Peripheral 
neurotoxicity 
Neuropathy 
Platinum 
compounds 
Cisplatin 
Carboplatin 
DNA adducts + Myelosuppression 
Ototoxicity 
Nephrotoxicity 
Hearing loss 
 
Podophyllotoxins Etoposide Topoisomerase II 
poison 
- Myelosuppression Secondary 
malignancies 
Local chemotherapy 
Drug Class Main drugs Mechanism of action Evidence in medulloblastoma Dose-limiting 
toxicity 
Long-term effects 
Antifolate Methotrexate Dihydrofolate 
reductase inhibition 
Infants [81] Chemical 
arachnoiditis 
Progressive 
demyelinating 
encephalopathy 
Antimetabolite Cytarabine; 
Depocyte- 
liposomal 
formulation 
Antimetabolite – DNA 
damage 
Leptomeningeal metastasis 
[116], [117] 
Chemical 
arachnoiditis, 
cauda equina 
[118] 
Leukoencephalopathy 
Podophyllotoxins Etoposide Topoisomerase II 
poison 
Feasibility studies [119]–
[121] and alternating with 
cytarabine [122] 
Headache, 
seizures [120] 
Remain to be 
established 
Alkylating 
agents 
Mafosfamide* Alkylating DNA No effect on  survival [123] Headache, 
vomiting, 
irritability [121] 
Remain to be 
established 
                                * no longer on the market 
Table 1-4. Summary of clinically relevant systemic and local chemotherapeutics used in medulloblastoma. 
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Section 1.2  Local therapy 
1.2.1 The rationale for local therapy 
Local drug delivery has emerged because of the problems outlined above 
with poor BBB penetration, blood-tumour barrier heterogeneity, 
increased tumour interstitial pressure and the poor access to tumour 
micrometastases. The idea of delivering treatment where it is needed is 
not new and some of the first antitumour treatments were local. Surgical 
removal of the tumour can be regarded as the ultimate local treatment 
for tumours. The implantation of radioactive elements within tumours is 
known as brachytherapy and was utilised[124] shortly after the discovery 
of radiation by Becquerel in 1896. Brachytherapy is still in use today, 
mostly in localised prostate cancer[125], but has also been tested in 
cases of recurrent medulloblastoma[126] and glioblastoma 
multiforme[127]. As far as local chemotherapy is concerned, one of the 
first chemotherapeutic delivery strategies to be tested in 
medulloblastoma was the administration of intrathecal methotrexate in 
1967[128]. A short overview of the different strategies for local 
chemotherapy will be given below. 
1.2.2 Types of local therapy 
The main types of local chemotherapy depending on the route and place 
of delivery are intrathecal/intra-CSF, intratumoral/interstitial and 
intracavitary chemotherapy.  
1.2.2.1 Intra-cerebrospinal fluid (intra-CSF) therapy  
Intra-cerebrospinal fluid administration can be accomplished by injecting 
a drug either into the cerebrospinal canal (intrathecal) or into the 
ventricles of the brain (intraventricular) administration. Intra-CSF 
delivery is used in the management of pain, spasticity and 
leptomeningeal metastases. Pain and spasticity are thought to be 
controlled by pain signalling in the dorsal horn neurons of the spinal cord. 
That is why opioids[129], the marine snail peptide zoconotide[130] and 
baclofen[131] are delivered intrathecally. In contrast leptomeningeal 
metastasis often involves the whole neuraxis and bolus injections or 
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infusions of antineoplastic drugs are done both intrathecally and 
intraventricularly. 
Since the purpose of antitumoural intra-CSF therapy is to eradicate 
tumour cells in the CSF and CNS, this mode of drug delivery can be 
likened to craniospinal irradiation to a certain extent. The difference 
being that instead of radiation, an anti-cancer drug is used to eradicate 
the tumours. Yet, the effects of chemotherapy can be milder or similar to 
those of radiotherapy depending on the drug exposure, distribution in the 
CSF, meninges and the brain. In addition, the safety and efficacy of intra-
CSF chemotherapy will also depend on the mechanism of drug action and 
its capacity to kill tumour cells without affecting the normal tissues. In 
this respect the main merit of intra-CSF chemotherapy lies in the 
opportunity to concentrate high cytotoxic concentrations in the CSF and 
target floating tumour cells and leptomeningeal micrometastases. These 
small (<500µm) clusters of tumour cells would not have developed their 
own imperfect blood vessels and would normally be shielded from 
systemic chemotherapy. Furthermore, the doses required to reach 
therapeutic levels in the CSF would be much lower than the ones required 
to reach the same level via systemic dosing. Finally, drugs administered 
in the CSF would only penetrate a few millimetres into the brain limiting 
their side effects to the pial and arachnoid cells as well as the small blood 
vessels of the subarachnoid space and potentially sparing most of the 
brain. 
A full review of intrathecal therapy is beyond the scope of this work and 
the interested reader is referred to the excellent work by Conroy et 
al[132]. However a few examples of currently employed intra-CSF 
chemotherapeutics will be given below in order to illustrate the clinical 
use of this mode of local therapy and examine the effects of the direct 
interaction of drugs and the brain. 
Methotrexate was one of the first agents to be used intrathecally in cases 
of leptomeningeal metastasis in leukaemia in the 1950s[133]. It was 
later trialled in medulloblastoma[128], although its use in 
medulloblastoma today is reserved for patients <3 years in whom 
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radiotherapy is contraindicated[81][47]. The side effects of intra-CSF 
methotrexate are divided into acute, sub-acute and chronic depending on 
their time of onset and persistence. The acute side effects start in the 
first 24 hours of administration and present with chemical arachnoiditis- 
seizures, headache, nausea, vomiting and fever. Those symptoms are 
very common and are usually managed with steroids like 
dexamethasone. The sub-acute side effects include speech paralysis and 
paraplegias. Later, patients often develop chronic leukoencephalopathy, 
which may lead to progressive demyelinating encephalopathy and affect 
cognitive functioning[134]–[136]. The neurotoxic side effects of 
methotrexate could be potentiated by previous craniospinal irradiation, 
which limits its utility in medulloblastoma patients. 
Cytarabine (cytosine arabinoside, ara-C) is another drug commonly used 
in intrathecal therapy, with a long history in leukaemia starting in the 
1960s[137]. Compared to intrathecal methotrexate, cytarabine is 
associated with fewer systemic side effects, but the dose-limiting toxicity 
of ara-C is chemically induced arachnoiditis. Cytarabine’s neurotoxic side 
effects are further potentiated in the slow release liposomal formulation 
and require concomitant steroid administration[118]. In haematological 
malignancies intrathecal cytarabine is most commonly included in a 
“triple intrathecal therapy” (TIT) regime alongside intrathecal 
methotrexate and hydrocortisone[138]. The exact benefit of the TIT 
regimen is somewhat controversial with some studies seeing 
improvement in CNS disease status without impact on survival[139]. In 
contrast, others have combined intensified TIT with high dose systemic 
chemotherapy to completely eliminate radiation from ALL 
treatment[140]. The reservations regarding long-term methotrexate 
toxicity in previously irradiated patients have discouraged the adoption of 
TIT in medulloblastoma and have stimulated the use of alternative drugs 
for intrathecal administration. 
Etoposide is a promising chemotherapeutic for intra-CSF delivery with 
numerous feasibility studies showing lack of neurotoxicity[119]–[121]. 
Intra-CSF etoposide delivery achieves cytotoxic etoposide concentrations 
in the cerebrospinal fluid with doses as small as 0.5mg, while systemic 
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etoposide requires three hundred times higher doses and fails to reach 
measurable CSF levels[120]. Recent studies in recurrent embryonal 
tumours have explored alternating administration of intrathecal etoposide 
and liposomal cytarabine to control leptomeningeal metastasis[122]. 
Peyrl et al. supplemented a previously described[141],  metronomic, low-
dose antiangiogenic, systemic, 5-drug regimen with additional intrathecal 
therapy to achieve an augmented CSF control. The antiangiogenic 
systemic therapy was used to inhibit tumour vascularisation while the 
intrathecally delivered etoposide and cytarabine were included to control 
leptomeningeal metastasis.  Interspersing etoposide and cytarabine 
served to space out cytarabine dosing and minimize arachnoiditis while 
maintaining cytotoxic protection in the CSF. In contrast to the sustained 
release profile of liposomal cytarabine, etoposide is quickly eliminated 
from the CSF via bulk flow and tumour exposure to the drug may often 
be suboptimal. The limited half-life necessitates either prolonged 
etoposide infusions or reformulation of the drug in a sustained-release 
form. A far as this research work is concerned, the lack of neurotoxicity 
history for etoposide and the clinical sensitivity of medulloblastoma to the 
drug were the main reasons for selecting it as a model compound in the 
nanoparticle formulation studies later in the project. For a more in-depth 
look at etoposide’s characteristics and formulation strategies see 
Chapter 6. 
As a therapeutic strategy intra-CSF therapy has a few notable 
limitations[142], [143]. Unlike the fast equilibration in the bloodstream, 
drugs in the CSF are not quickly equilibrated and gradients in drug 
distribution may lead to imperfect tumour control. Moreover drugs 
delivered in the CSF would only kill floating cells and small clumps of 
tumour cells because most small molecules would only diffuse through a 
very limited distance into the tissues. Bigger tumour foci having leaky 
blood vessels and disseminated tumour cells and metastases not directly 
in contact with the CSF, may be better controlled by systemic therapy 
administered alongside intra-CSF delivery. The greatest potential of intra-
CSF delivery for medulloblastoma is as an alternative strategy to reduce 
craniospinal irradiation as shown in ALL[140]. In a similar analogy it can 
Introduction 
 28   
  
be hypothesized that posterior fossa boost radiotherapy could be 
decreased by the use of intratumoral and interstitial drug delivery. 
1.2.2.2 Intratumoral, interstitial and intracavitary delivery 
These three types of local delivery often use similar strategies but differ 
in the targeted tissue. Intratumoral delivery involves drug loading directly 
into the tumour tissue. Interstitial therapy is usually accomplished by 
delivering the drug in the extracellular (interstitial) compartment of the 
tissues neighbouring the tumour. In postoperative interstitial 
administration the drug is delivered after resection of the tumour in the 
cavity left by the tumour tissue. A very similar strategy is employed in 
intracavitary therapy where the drug is delivered in a natural body cavity, 
for example the bladder during intravesical therapy for bladder cancer. 
Intratumoral therapy is mostly used in inoperable tumours, or as a 
strategy to downstage tumours to an operable size. It can be 
accomplished by injecting a drug directly into the blood supply of a 
tumour, or directly into the tumour itself. The transcatheter arterial 
chemoembolization strategy (TACE) in inoperable hepatocellular 
carcinomas exploits the double blood-supply of the liver (both through 
the hepatic artery and the portal vein)[144]. TACE is performed by 
injecting a drug dissolved in oil (lipiodol) into the hepatic artery blood 
supply of the tumour and later embolising the artery with gelatine sponge 
microparticles (Gelfoam). Intratumoral injection of ethanol is often 
combined with TACE in the treatment of hepatocellular carcinoma as a 
palliative technique with moderate survival benefit [145].   
The effectiveness of local administration can be maximized if the drug is 
entrapped in a delivery vehicle which provides a sustained release thus 
limiting diffusion into the systemic circulation[146]. Modified intratumoral 
release has been achieved using polymeric matrices[147], gels[148], 
liposomes[149] and emulsions[150]–[152]. Additional pros of sustained 
release local therapy can be expected based on the data from studies 
which have demonstrated that prolonged exposure to low-dose 
chemotherapy can be very effective by suppressing angiogenesis in solid 
tumours[153]. That means that slow release of a relatively small dose of 
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the drug in the tumour may be enough to suppress growth or even 
initiate remission.  
Intracavitary therapy can be delivered in the cavity left by a tumour after 
surgical removal or by delivery in natural a body cavity. For example, 
intravesical therapy for bladder cancer has used chemotherapeutics[154] 
and immunotherapy with Bacillus Calmette–Guérin(BCG)[155] delivered 
directly into the bladder as adjuvant treatment prolonging survival[156].  
Postsurgical intracavitary therapy is an opportunistic strategy where a 
drug delivery system is implanted into the postsurgical tumour cavity to 
destroy the residual cancer tissue there. The first clinically approved 
postoperative intracavitary drug delivery system in brain tumours was 
Gliadel[157]. Gliadel wafers are disc shaped biodegradable polymer 
implants that are impregnated with carmustine. They are instilled into the 
tumour cavity and slowly release carmustine into the adjacent tissue 
reaching higher levels than systemically delivered carmustine. 
Carmustine was chosen based on its lack of neurotoxicity and because it 
gave the longest prolongation of survival in preclinical mouse 
models[158]. Despite the encouraging results in animal models, the 
clinical results in glioblastoma multiforme have been modest with 2-3 
months of increased survival[159]. This has been hypothesized to be due 
to problems with the passive drug diffusion of carmustine penetrating 
only around 1 mm into the adjacent tissues[160]. Gliadel’s main 
advantage over systemic therapy is the lack of myelosuppression and 
pulmonary toxicity. Nevertheless, the wafers have a spectrum of local 
side effects with brain oedema, increased risk of infections and potential 
for hydrocephalus in cases of wafer dislodgement in the ventricles[161]. 
An alternative strategy employed in both intratumoral and interstitial 
drug delivery is to actively inject the drugs through microcatheters 
directly implanted into the brain interstitium or tumour by using 
convection enhanced delivery (CED)[162], [163]. CED perfuses the 
tissues by applying a pressure gradient, resulting in bulk flow and wider 
drug distribution[164]. It is a relatively new technique[165] but holds 
great potential in the delivery of targeted toxins, macromolecules[166] 
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and submicron drug delivery systems[167]. Problems with backflow, 
catheter positioning and leaks have plagued CED in phase III clinical 
studies[168], [169]. Future developments in optimising catheter design 
and placement as well as identifying the best agent for effective 
convection enhanced delivery will probably yield the first breakthrough in 
this therapeutic approach. 
There appear to be two major blocks to the successful implementation of 
local therapy. The first one is related to the drug reaching its target and 
the second one concerns the risk of off-target effects. Even in the most 
advantageous form of local delivery, when the bulk of the tumour has 
been removed and the drug delivery systems is only required to kill the 
remaining residual cancer tissue, drug penetration is a major 
limitation[170]. Although controlled-released small molecule drugs have 
the potential to diffuse relatively quickly in the extracellular matrix 
(ECM), they often remain trapped in the first cell layers or the pores of 
the extracellular matrix of tumours. Moreover, lipophilic drugs, like 
carmustine, can distribute in fatty tissues, cell membranes and the 
myelin sheaths of neurons[171]. The increased interstitial pressure and 
the fibrotic nature of tumour tissue can pose an additional impediment to 
the distribution of local therapy to all cells in the tumour[172]. The 
adverse effects caused by the lack of discrimination between tumour and 
normal tissue embody the second major problem in local therapy. Most 
matrix systems release free cytotoxic drug in the interstitium and affect 
tumour and normal cells alike, potentially causing neurotoxicity, seizures, 
oedema and chemical meningitis. 
The abovementioned limitations can be partially circumvented by using 
advanced delivery systems like drug loaded submicron particles. These 
nanomedicines with their larger size would only enter the larger pores of 
the ECM and could theoretically travel a longer distance in the 
interstitium[173]. They can be co-administered or coated with various 
enzymes to digest the ECM of tumours[174], [175] and can be used to 
exploit biological differences between tumour and normal cells to deliver 
drugs solely to their target. This line of thought was used to form the 
basis of the current project. 
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Section 1.3  Project overview and aims 
1.3.1 Postsurgical NP delivery- project aim 
The ultimate aim of this project is to provide an alternative strategy for 
minimizing irradiation to the posterior fossa of medulloblastoma patients. 
The reduction of radiation will be accomplished by local administration of 
drug-loaded nanoparticles in the cavity left by the tumour after surgical 
removal of medulloblastoma. The purpose of the nanoparticle delivery 
system is to prevent local tumour recurrence by targeting the leftover 
tumour tissue after surgery. The nanoparticles will be administered 
directly onto the tumour bed using a gel or foam-based carrier 
formulation, which will allow the surgeon to close the dural incision 
before the particles are released from the gel into the surrounding 
tissues. The use of nanoparticles would allow the exploitation of 
differential endocytosis rates between tumour and brain tissue thereby 
minimizing normal tissue drug exposure and side effects (Figure 1-9). 
Additional discussion regarding the targeting mechanism will follow later 
in this section and in Chapter 5. 
 
Figure 1-9. Postsurgical local nanoparticle delivery. After surgical removal of the tumour 
there is always some residual tumour tissue left (green), often leading to tumour 
recurrence despite irradiation. Drug-loaded nanoparticles (red) can be applied directly 
onto the tumour bed after surgery to selectively target and kill cancer cells. Targeting can 
be achieved passively, solely on the basis of differential endocytosis rates between normal 
brain tissues and actively proliferating tumours. A gel or foam-based carrier formulation 
(grey) can be used to deliver the nanoparticles and keep them in place for the time 
necessary to close the incision. Figure adapted from the original image by Janet Fong ’09.  
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As seen by Figure 1-9, the local delivery of nanoparticles onto the tumour 
bed has several advantages. It circumvents the blood-brain barrier and 
ensures direct contact between the drug delivery system and its target-
leftover tumour tissue. The targeting in this case is passive, exploiting 
increased endocytosis rates in actively growing tumour cells, compared to 
normal brain. Since the particles are administered interstitially, they do 
not need to extravasate and the mechanism of enhanced-permeation and 
retention (EPR) effect does not play a role. 
1.3.2 Project rationale  
The reasoning behind this projects comes from previous work in the 
group which has exploited the behaviour of nanoparticles made from the 
biodegradable polymer poly(glycerol adipate)[176]. In her doctoral thesis 
Weina Meng was able to demonstrate that fluorescently labelled 
poly(glycerol adipate) nanoparticles had a 6-times higher uptake in 
tumour spheroids compared to normal rat brain[177]. The observed 
enhanced tumour endocytosis effect was strongly dependent on the 
dimensionality of culture and was only observed in physiologically 
relevant three-dimensional tissue models[178], [179]. At the same time, 
another member of the group, Sanyogitta Puri, was working on the 
incorporation of cytotoxic drugs into poly(glycerol adipate) nanoparticles 
and achieved reasonable drug loading with a selection of cytotoxic 
drugs[180]. These previous findings have stimulated the idea that if 
poly(glycerol adipate) nanoparticles were to be loaded with cytotoxic 
drugs, they could be delivered locally to the tumour bed of 
medulloblastoma patients after surgery. A special foam or gel carrier, 
partially inspired by the already available haemostatic systems in 
neurosurgery[181], could be applied directly to the tumour bed and 
contain the nanoparticles for a limited time until dura matter closure.  
Before proceeding with the major milestones of the project a few 
important concepts in nanoparticle delivery will be discussed in order to 
clarify the place of the proposed system in the overarching theme of 
nanomedicines.  
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1.3.2.1 Local nanoparticle delivery overview 
Nanomedicines are defined as nanosized tools (1 to 1000nm) for the 
diagnosis, prevention and treatment of disease[182]. In contrast to the 
conventional 100nm cut-off for colloid systems the upper border is 
widened to 1000nm to include submicron systems that are employed for 
medicinal purposes. The potential of nanomedicines lies in their different 
behaviour in the body when compared to conventional low molecular 
weight (Mw) drugs. 
The majority of small molecule drugs (Mw<500 Da1, logP<5[183]) are 
designed so that they freely distribute between most cells in the body 
being sufficiently hydrophilic to dissolve in the bodily fluids and engage 
with their intracellular targets, while being lipophilic enough to cross 
phospholipid membranes. Cancer therapeutics achieve a certain level of 
specificity by interacting with their specific target. However, cytotoxics 
are largely designed to kill dividing cells on the premise that tumour cells 
divide more rapidly than normal tissues. The side effects of cancer 
therapy come as a direct consequence of the interaction of 
chemotherapeutics with the rapidly dividing cells of the normal 
hematopoietic tissues, gastrointestinal epithelium or off-target effects in 
other tissues (cardiac for anthracyclines, neurons for Vinca alkaloids, 
etc.). The whole-body distribution of small molecule drugs can be likened 
to the grave effects of whole body radiation often causing severe 
suffering or patient death. In this respect advanced drug delivery 
systems exploit certain cancer characteristics to deliver a focused dose of 
the drug to the tumour tissue, while sparing normal organs, much like 
conformal radiation. 
When a drug is transported within a nanocarrier, the large size of the 
drug delivery system limits its distribution in the body as it cannot easily 
transverse most membranes and body barriers. This leads to the 
distribution of nanomedicines in different compartments of the body and 
the effect can be exploited to minimize toxicity and optimise efficacy. On 
the other hand the restricted distribution adds an extra layer of 
                                       
1 Cancer therapeutics of natural sources usually have Mw below 1000 Da. 
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complexity as oral delivery or even extravasation in the case of systemic 
delivery may be hindered by the size of the carrier[184].  
Covering the whole field of nanomedicines with polymer therapeutics, 
drug conjugates, liposomes, dendrimers, nanocapsules and nanoparticles 
is beyond the scope of this work and the interested reader is referred to 
the review by Duncan[185]. This project and the subsequent analysis will 
focus on local delivery of drug loaded nanoparticles which physically 
entrap a cytotoxic drug. The main considerations and key concepts in 
delivering drugs to tumours will be briefly summarized below. 
The choice of using nanoparticles as opposed to any of the other form of 
nanomedicines was driven by the data for selective medulloblastoma 
tumour uptake of fluorescently labelled nanoparticles[177]. Non-covalent 
physical entrapment of the drug was similarly decided based on previous 
experience[180], but also with the intention to preserve drug activity and 
facilitate unhindered dissociation from the carrier. Likewise the 
opportunistic strategy for local interstitial drug delivery after surgery was 
identified as lower risk since it circumvents the blood-brain barrier. 
Although a number of ways to cross or disrupt the BBB have been 
proposed including nasal delivery[186], barrier-disruption[187] and 
nanoparticle coating[188], brain tumour accumulation from these 
systems is generally below 1%. The often cited enhanced permeability 
and retention (EPR) effect[189]- nanoparticle retention due to the leaky 
blood vessels and poor lymphatics in tumours- is not a phenomenon 
explored in this project. This is due to the fact that local interstitial 
delivery does not exploit the vasculature and because the target of this 
drug delivery system is residual cancer tissue which may be microscopic 
without any vessels of its own. Furthermore, receptor-mediated targeting 
was not chosen due to the heterogeneity of medulloblastoma lacking a 
single antigen target, the added complexity of active targeting[190] and 
the poor reported distribution (0.01% of the injected dose) for antibody-
targeted therapeutics[191].  
The altered endocytotic activity of actively proliferating tumour cells as 
opposed to normal tissue is the hypothesized passive targeting strategy 
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for the drug delivery system developed in the present work[192]. This 
mechanism was proposed initially in the 1970s by de Duve and 
Trouet[193], [194]. The fact that the nanoparticles will be delivered 
locally in the cavity of the cerebellum means that they will be subject to 
endocytosis by either tumour cells or normal tissues in the brain. In this 
regard, the studies performed by Meng[177] in three-dimensional culture 
and by Favretto[195] in monolayers have indicated the relatively high 
endocytosis activity in two medulloblastoma cell lines. 
Mammalian cells can internalise nanoparticles via a number of 
endocytosis pathways mediated by clathrin coated pits, caveolin, clathrin 
and caveolin-independent pathways or macropinocytosis[196]. Clathrin-
mediated endocytosis is often referred to as the classical endocytosis 
pathway because it is present in all mammalian cells and is involved in 
receptor-mediated endocytosis of essential nutrients like low density 
lipoproteins and transferrin. The second, caveolin-mediated, pathway is 
interesting because caveolin is not expressed in neurons[197], but SHH 
medulloblastoma cells express this protein[198] which may potentially 
make them more susceptible to NP-based therapy[195], [199]. A related 
strategy that targets caveolin-mediated endocytosis is exploited by the 
clinically available liposomal doxorubicin (Doxyl)[200] and paclitaxel-
carrying albumin nanoparticles (Abraxane)[201]. It can be hypothesized 
that local NP therapy will be most beneficial in high-risk SHH 
medulloblastoma tumours which are known to metastasize mainly 
locally[23] and exhibit abnormal endocytosis activity[195], [197], [198]. 
Once endocytosed, the nanoparticles will normally be transported to the 
endosomes and would finally end up in the lysosomal compartment. In 
this hydrolytic environment the physically entrapped drug will be released 
from its polymeric carrier after degradation of the polymer.  
1.3.2.2 The rationale behind polymer selection 
The initial polymer chosen for this project was poly (glycerol adipate) - a 
predominantly linear polyester of glycerol and adipic acid synthesized 
under mild conditions via a reversible lipase-catalysed reaction[176].  
The polymer has pendant secondary hydroxyl groups in the glycerol 
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moiety that can be substituted with fatty acids and other functionalities 
to customise its physicochemical characteristics. Moreover, studies by 
Meng have indicated that poly(glycerol adipate) nanoparticles are 
selectively taken up by tumour cells as opposed to normal brain 
tissues[177]. Poly (glycerol adipate) has been shown to be rapidly 
hydrolysed in the low pH of the lysosomes by naturally occurring lipases 
thereby releasing its cargo into the cells[179]. The drug was chosen to be 
only physically entrapped in order to maintain its biological activity intact 
and prevent the formation of partially hydrolysed drug derivatives with 
questionable action.  
1.3.2.3 The choice of drug 
Etoposide was initially identified as a drug that has shown little 
neurotoxicity[119]–[121] and has demonstrated efficacy against 
medulloblastoma in patients[81], [202], [203]. As a secondary option, 
the chemically related teniposide was identified as demonstrating higher 
activity in preclinical models but underperforming in the clinic due to its 
lower solubility and suboptimal formulation. More information regarding 
etoposide and teniposide and the strategies for improving their delivery 
will be given in Chapter 6.  
1.3.3 In vitro model requirements 
From the inception of this project it was clear that a suitable 3-D in vitro 
model would need to be used in order to test the safety and toxicity of 
the drug-loaded nanoparticles and compare these against the non-
encapsulated drug. The main purpose of the in vitro models was to be 
able to determine whether a drug delivery system offers selectivity of 
uptake and cytotoxicity towards medulloblastoma tumours compared to 
normal brain tissue. Conveniently, Meng et al. had already established 
some key in vitro models culturing  medulloblastoma spheroids onto rat 
brain slices[177], [178]. These initial models, along with complementary 
research in the group[204]–[206], were instrumental in showing the 
importance of dimensionality not only in representing actual tissues 
rather than simple monolayers but also in altering the behaviour of cells 
and their propensity to take up nanoparticles. However the use of rat 
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brain slices as a surrogate for normal human brain has a number of 
drawbacks. Rodent models are increasingly recognised as poor models of 
human biology[207], [208] and their predictive potential has been 
severely questioned[209]. That is why the exclusive use of human tissue 
was added as an overarching requirement for the in vitro models 
necessitating a redesign of the previous in vitro systems. 
The new model was designed so that it reflects key components of local 
delivery to the brain. The two main elements of the in vitro platform are 
the tumour cells, representing the small avascular tumour 
micrometastases, and the neurospheres representing the normal human 
brain.  
It is important to note that the purpose of creating these models was not 
to study the biological phenomena of hypoxia, change of gene expression 
and stem cell enrichment in spheroids. The main utility of the disease 
model was intended to inform whether the formulation of cytotoxic drugs 
into nanoparticles can improve the selectivity and cytotoxicity of 
chemotherapy. Therefore, the determination of cytotoxicity was selected 
as the main endpoint with the possibility to distinguish apoptosis and 
necrosis as a secondary endpoint for the model. This decision allows for 
comparing normal and tumour tissue on the same scale. However, it 
bears the disadvantage that it may miss a possible impairment of 
functionality in the normal tissue occurring before any evidence of 
cytotoxicity. This downside is partially offset by the use of foetal 
neurospheres enriched for neural progenitors which may possibly be 
more sensitive to cytotoxic insults than fully differentiated cells. A more 
in-depth look into the various endpoints of the models will be given in 
Chapters 3 and 4. 
1.3.3.1 Tumour tissue 
Tumour micrometastases are not composed of cells spreading as a single 
layer. They grow in clusters with their own extracellular matrix, gradients 
of nutrients and oxygen driving different levels of cytotoxic assault 
resistance. Multicellular tumour spheroids, which have been popularised 
by Sutherland in the 1970s[210], recapitulate those features very well 
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compared to monolayers. For example, spheroids mimic natural cell-cell 
and cell-matrix interaction, features not normally found in cells cultured 
on tissue culture plastic[211], [212]. The inclusion of naturally secreted 
extracellular matrix is critical as the nanoparticles will have to transverse 
it to reach all tumour cells and using monolayers will not reflect that 
physiological trait of tumour foci. Small avascular tumour 
micrometastases often display a hypoxic core with quiescent cells which 
are more resistant to radiation and chemotherapy[213]–[215]. In this 
respect, multicellular tumour spheroids can be cultured to sizes beyond 
the diffusion distance of oxygen (300-500 µm) and exhibit similar 
gradients and resistance patterns[216], [217]. In addition, gene 
expression profiles in spheroids have been reported to be closer to those 
of parent tumours compared to monolayers[218], [219]. 
1.3.3.2 Tumour cell line selection 
The ideal representation of human tumours in vitro would be 
accomplished by using primary patient derived tissues. However, these 
are not always readily available and are more suitable for the later stages 
of model development, when culture conditions and procedures are 
optimised. That is why the initial experiments used cell lines with the 
intention to upgrade to patient derived primary tissues upon protocol 
optimisation in the validation stage of the model. Accordingly, a selection 
of medulloblastoma cell lines was chosen for model development 
experiments.  
The DAOY cell line was derived initially from a desmoplastic 
medulloblastoma from a 4-year old boy[220]. Although the parent 
tumour displayed some evidence of glial and neuronal differentiation this 
was not seen in the cell line when cultured in vitro. The DAOY cell line 
has been reported to be tetraploid with multiple genome alterations and 
expressing abnormal SHH signalling with defective TP53[221]–[223]. The 
lack of TP53 probably contributes to the genomic instability of DAOY cells 
and may indicate a possible connection with the relatively rare Li-
Fraumeni syndrome, provided that the change in signalling has not been 
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acquired in vitro. DAOY cells have also been reported to differ from 
patient tumours in their chromosomal aberrations profile[221].  
In view of these concerns the VC312R medulloblastoma cell line was also 
included in the screening[224], although the latter has not been 
associated with any of the medulloblastoma subgroups. However, during 
the first half of the project, it was discovered that the VC312R cell line is 
listed on the International Cell Line Authentication Committee web site as 
a misidentified cell line (www.iclac.org), citing the work by Higgins et 
al[225]. The paper reported that the cell line may have been 
contaminated with rat DNA and, while that has not been confirmed in 
house, a decision was made to terminate its use in future experiments. 
Although, this discovery is very concerning and has revealed a weakness 
in the initial cell line selection, the work performed on the cell line covers 
very basic methodology feasibility studies on spheroid formation and 
spectral dye compatibility and is not intended to be interpreted more 
widely. The experiments performed with the cell line were later repeated 
and reproduced with the UW228-3 cell line which was authenticated in-
house.    
The third cell line employed, UW228-3[226], is reported to be similar to 
either Sonic hedgehog driven (SHH)[227] or Group 3[228] 
medulloblastoma. Adding to the controversy is the finding that in contrast 
to the diploid cells of the parent tumour, UW228-3 cells are aneuploid. 
While gains in MYC expression and chromosomes 1 and 7[226][221] are 
common for Group 3 medulloblastoma, it is possible that those mutations 
were present in a small subgroup of cells within the parent tumour which 
were selected upon in vitro culture. Subgroup affiliation can be used to 
select for patients that are going to benefit the most from local therapy. 
For example, interstitial therapy at the tumour bed may be most 
advantageous in SHH medulloblastoma as it tends to recur mainly locally 
[23]. In contrast, the dismal prognosis and the frequent leptomeningeal 
metastases associated with Group 3 may favour the concomitant use of 
local intra-CSF delivery as well. 
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Nevertheless, the chosen cell lines were solely used as models serving to 
establish the methodology of the assays. This compromise was accepted 
with the vision that subsequent studies would include primary tumour 
tissue from patients. 
1.3.3.3 Normal brain tissue surrogate 
Apart from the target tumour cells, the in vitro testing strategy was 
designed to include a normal tissue component representing the 
non-malignant brain tissue at the site of delivery. This is a vital 
component of the model serving to establish the safety and selectivity of 
treatment and put toxicity in perspective.  
Since miniaturized models of the human brain are still in their 
infancy[229], human foetal brain tissue cultured as neurospheres was 
selected as a surrogate for the developing human brain[230]. This choice 
was dictated by the desire to model the growing brain in children and 
aimed at including the mix of pluripotent, differentiated and mature cells 
forming in neurospheres of human foetal brain tissue [231]. When 
human foetal brain tissue is cultured in serum-free media containing 
basic fibroblast growth factor (bFGF), and epidermal growth factor (EGF), 
the resultant neurospheres become enriched for neural progenitor cells 
which actively divide. The population of dividing progenitors allows them 
to multiply at a reasonable rate and be propagated for screening 
purposes. The terms foetal neurospheres, neural progenitors and neural 
stem cells are used interchangeably throughout this thesis to identify the 
normal brain tissue surrogate component of the model. Both human[232] 
and mouse[233] neural progenitor cells have been used as an in vitro 
models of developmental neurotoxicity and significant interspecies 
differences have been reported[234], [235]. These findings further 
strengthen the choice of human tissue for the models.  
While the neurospheres have been found to contain a mix of progenitors, 
glial and neuronal cells, they were not expected to reach the level of 
specialisation of the tissues in vivo during the duration of the assay. 
There are a number of specialised cells at the site of nanoparticle delivery 
(cerebellar vermis and roof of fourth ventricle). Depending on tumour 
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location and size these may include cells of the cerebellar nuclei, 
cerebellar granular neurons, Purkinje cells, stellate cells, basket cells, 
astrocytes, oligodendrocytes, microglia, ependymal cells covering the 
ventricle, cells of the choroid plexus, etc. Although neurospheres are 
much simpler clumps of progenitors, glial and neuronal cells they have 
the potential to show integral toxicity to the whole mix of cell types. The 
progenitor cells in the developing children’s brain may be an especially 
important collateral damage target as insults to structures known to host 
them have been linked to neurocognitive deficits in medulloblastoma 
patients[236]. 
1.3.3.4 The influence of culture method 
Although there are a variety of methods to grow cells in three-
dimensional cell culture[237]–[239], spheroids were chosen for this in 
vitro model of medulloblastoma due to a number of physiological and 
practical considerations. For instance, scaffold cultures were excluded 
because the addition of naturally-derived or synthetic matrix can 
influence gene expression in a non-physiological way[240], [241]. 
Moreover, matrix and organ-on-a-chip technologies introduce the 
possibility of non-specific drug binding to the scaffold, the PDMS chip or 
tubing[242]. Scaffold-free spheroid culture methods stimulate the cells to 
secrete their own extracellular matrix and exhibit more of the natural 
characteristics of the parent tumour[243], [244]. Chapter 3 will discuss 
the rationale for choosing the right platform for spheroid culture and 
analysis.  
Another important aspect of modelling medulloblastoma is the interaction 
between normal and tumour tissue. Tumour and neural progenitor cell 
spheroids can be cultured together in a co-culture model with increased 
physiological relevance. The interaction between tumour and host tissue 
has been repeatedly demonstrated to affect chemo[245] and 
radiosensitivity[246], proliferation[247], angiogenesis[248], cell 
adhesion[249] and gene expression[250]. In view of these considerations 
the ultimate model of medulloblastoma was envisaged to be a co-culture 
model of normal and tumour tissue where the viability of each cell 
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population can be determined separately. Further considerations about 
the development of the co-culture model will be given in Chapter 4.  
1.3.3.5 Culture media 
The necessity of culturing two cell types together brought forward the 
question of finding a common media composition that can support both 
cell types. The medulloblastoma tumour cell lines are normally cultured in 
adherent monolayers in serum containing media. However multiple 
studies have shown the increased expression of stem cell markers when 
medulloblastoma cell lines were cultured in serum-free media as 
spheroids[251]–[253]. That is why the same media that was employed to 
enrich the neurospheres for progenitor cells was used in the culture of 
the tumour spheroids.  
1.3.4 Project plan- objectives 
The overall aim of this project is to create an in vitro model of 
medulloblastoma suitable for ranking novel nanoparticle formulations 
carrying cytotoxic drugs for local delivery. 
A set of milestones was set-up where both cell types were initially 
cultured separately as spheroids in high-throughput before moving on to 
the more complex co-culture model of the disease. At the same time a 
formulation program was established for the synthesis and substitution of 
the biodegradable polymer and the preparation and characterisation of 
the drug loaded nanoparticles. 
1.3.4.1 Separate 3D cultures of normal and tumour tissue  
The first objective was to reliably and reproducibly culture normal and 
tumour cells in 3D using a format that facilitates the comparison of dose 
response relationships of cytotoxic compounds for both cell types. 
Cell viability was the endpoint and a suite of surrogate measures was 
used including spheroid volume, metabolism and enzymatic activity. 
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1.3.4.2 Co-culture model of medulloblastoma 
The second landmark was the establishment of a co-culture model of 
medulloblastoma. The model included both foetal neurospheres and 
medulloblastoma tumour cells in order to model the interaction between 
normal and tumour tissue. 
The objective was to culture the normal and tumour cells together, 
expose them to cytotoxic insults and determine the viability for each cell 
type within the co-culture separately. 
Intermediate milestones were ensuring reliable marking for both cell 
types and developing the methods to analyse the co-cultures. Special 
emphasis was placed on preserving heterogeneity in view of future 
application for primary cultures.  
1.3.4.3 Loading of nanoparticles with cytotoxic drugs- etoposide 
or analogues 
The nanoparticle formulation work was done in parallel to the cell culture 
experiments. Preliminary aims were to synthesize poly(glycerol adipate) 
and substitute it with different fatty acids. The next step was to load the 
nanoparticles with drugs and characterise the amount of drug loading.  
1.3.4.4 In vitro testing of the nanoparticles 
The objectives were to establish the drug release profile from the 
nanoparticles and test them in the in vitro medulloblastoma model. 
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Chapter 2.  Experimental materials and methods 
Section 2.1  Materials 
2.1.1 Cell culture 
Dulbecco’s Phosphate Buffered Saline (PBS),  Dulbecco’s Modified Eagle’s 
Medium - high glucose (DMEM), Ham’s nutrient mixture F12, L-Glutamine 
solution 200 mM, Penicillin/Streptomycin solution (10,000 units penicillin 
and 10 mg streptomycin/mL), Heparin, Agarose, Sodium pyruvate, 
Trypsin 10X solution 4-nitrophenyl phosphate disodium salt hexahydrate, 
Accutase and etoposide were obtained from Sigma-Aldrich (Dorset,UK). 
Foetal Bovine Serum (FBS), N2 supplement, B27 supplement serum-free 
supplement, DMEM without phenol red, basic human Fibroblast Growth 
Factor (bFGF), human recombinant Epidermal Growth Factor (EGF), 
Accutase and 0.4% Trypan Blue Stain solution were supplied by 
Invitrogen (Paisley, UK). Resazurin was sourced from Acros Organics 
(Loughborough, UK) 
Ultra-low attachment (ULA) 96-well round bottom plates were obtained 
from Corning (Amsterdam, The Netherlands). 
3D-Biomatrix hanging drop plates were obtained by 3D Biomatrix,USA. 
The 3D Petri Dish micromoulds were obtained from Microtissues, 
Providence, US with the help of Rob Pineda from the Laboratory of 
Biophysics and Surface Analysis(LBSA), University of Nottingham. 
2.1.2 Polymer synthesis and nanoparticle studies 
Divinyl adipate (DVA) was obtained from Fluorochem, Glycerol,  
Novozyme 435, Stearoyl chloride, Pyridine, Rhodamine B isothiocyanate 
(RBITC)  and etoposide were obtained from Sigma-Aldrich; 
Tetrahydrofuran (THF), Dichloromethane, Acetone, the Heidolph RZR1 
stirrer and all filters and glassware were obtained from Fisher Scientific 
(Loughborough, UK). All other chemicals used in the preparation of the 
polymer and nanoparticles were obtained from Sigma-Aldrich. 
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Section 2.2  Cell culture 
All experiments were performed in standard cell culture conditions at 
37°C and 5% CO2. 
2.2.1 Human neurospheres (neural stem/progenitor) cells 
Foetal human brain tissue was received from the Joint MRC / Wellcome 
Trust (grant # 099175/Z/12/Z, Ethics committee approval 
08/H0906/21+5, Health Research authority NRES Committee North East 
- Newcastle & North Tyneside 1) Human Developmental Biology 
Resource. The tissue was rinsed in HBSS and the meninges and any 
blood vessels removed. The tissue was chopped using two scalpel blades 
and then mechanically dissociated into a single cell suspension by 
pipetting with a plastic tip (1 mL) pipette. The resultant suspension was 
passed through a cellular sieve (30 µm) and cultured in non-treated 
flasks to form stem cell enriched neurospheres in neural stem cell 
media[230]. 
2.2.2 Neurosphere propagation 
The Neural stem cell (NSC) defined serum-free media was made using 
DMEM/F12 (1:1), B27 (1:50), N2 (1:100), L-Glutamine (2 mM), hEGF 
(20 ng/mL), bFGF (10 ng/mL) and Heparin (5 µg/mL).  
Penicillin/Streptomycin solution (0.4ml per 100ml of media) was added 
during the first two passages of the neurospheres and excluded 
afterwards.  Neurospheres were subcultured for less than 15 passages. 
Briefly, when the neurospheres reached a diameter of 100-300 µm they 
were rinsed with PBS, resuspended in Accutase (1 mL) and agitated for 
5minutes at 37 °C followed by mechanical dissociation. The suspension 
was diluted with fresh NSC media and centrifuged at 300g for 5 minutes. 
The cell pellet was resuspended in Ca2+ and Mg2+ free PBS and the final 
single-cell suspension diluted to the desired concentration with NSC 
media. 
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2.2.3 Culture of human medulloblastoma cell lines 
UW228-3 medulloblastoma cell line [254] was obtained from Prof. Silber 
(University of Washington, Seattle, USA) with the help of the Children’s 
Brain Tumour Research Centre at the University of Nottingham. UW cells 
were cultured in DMEM/F12 media supplemented with L-Glutamine 
(2 mM), sodium pyruvate (1 mM) and FCS (10%). Subculturing was 
performed using 0.025% Trypsin in Ca2+ and Mg2+ free PBS solution for 5 
minutes. 
DAOY cell line was obtained from the ATCC (HTB-186) by Prof. Terry 
Parker. The VC312R2 (VCR) medulloblastoma cells were a gift from Prof. 
Geoff Pilkington (School of Pharmacy and Biomedical Sciences, University 
of Portsmouth, UK). Both cell lines were maintained in 75 cm2 flasks in 
DMEM medium supplemented with 10% Foetal Calf Serum and 200 mM 
glutamine (Full culture medium, FCM) at 37 °C and 5% CO2. 
2.2.4 Mycoplasma testing 
Mycoplasma testing was performed independently by a trained technician 
with a Mycoalert mycoplasma detection kit (Lonza, Rockland, USA) 
according to the manufacturer’s instructions. Cell-free media was 
collected after incubating for 48h with the cells and mixed with equal 
volume (100µl) of Mycoalert reagent in 96-well white plates. 
Luminescence was read on a POLARstar plate reader (BMG Labtech, UK) 
after 5 minutes incubation, (Reading 1) followed by a further 10 minute 
incubation with 100µl Mycoalert substrate. A second luminescence 
reading was then taken (Reading 2) and the ratio of Reading 2/Reading 1 
calculated. Ratios higher than 1.0 indicated the presence of mycoplasma 
contamination. Positive and negative controls were used for validation. 
2.2.5 Cell line authentication 
The human origin of the UW228-3 cell line was established in the lab by 
Ramadhan Othman[255] through sequencing of human β-actin using 
polymerase chain reaction. Moreover the cell line was further 
                                       
2 See Section 1.3.3.2 for the controversies surrounding DAOY and VC312R  
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characterised as Group 3 based on NPR3 positivity[228]. A limitation of 
this work is the lack of cell line authentication for the DAOY and VC312R 
cell lines and the absence of short tandem repeat (STR) analysis.   
Section 2.3  Methods for spheroid production 
2.3.1 Non-adherent cell culture flasks 
Human foetal neural tissue was routinely cultured as neurospheres in 
non-treated cell culture flasks using neural stem cell media and they 
formed numerous spheroids with a broad size distribution. When plated 
at 200-400 kcells/ml they slowly grew to 100-300 µm spheroids before 
being subcultured after a period of 4-7 days.  
UW228-3 and VCR cells also formed heterogeneous neurospheres in 
those conditions. However they grew much quicker, required frequent 
media exchanges and reached 300 µm size within 3-4 days. 
2.3.2 3D Biomatrix hanging drop plates 
 
Figure 2-1. Schematic representation of the 3D Biomatrix system. The 3D Biomatrix 
platform is made up of three plastic plates.  The bottom one is called the tray, forms the 
base and has a channel that acts as a reservoir of water maintaining humidity and 
protecting the hanging drops from evaporating and causing osmotic shock. The middle 
plate has 384 holes where the cell suspension is dispensed and the hanging drops are 
formed. The third plate is a lid that seals the whole system. 
Spheroids were formed according to manufacturer’s instructions[256] 
and the work of Tung et al[257]. A cell suspension was prepared to the 
desired concentration and the reservoirs of the tray and the hanging drop 
plate were prefilled with either molten agarose solution (1%) or PBS. Cell 
suspension (20-30 μL) was pipetted into the holes of the hanging drop 
plates so that the solution would flow and hang to the bottom of the plate 
as shown in Figure 2-2: 
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Figure 2-2 Dispensing cell suspension in order to form hanging drops 
After forming the hanging drops the lid was closed and the whole system 
placed in an incubator at 37 °C and 5% CO2. Gravity brings the cells in 
close contact at the edge of the drop and they start forming spheroids 
within 24h by secreting their own extracellular matrix to hold them 
together. Every other day 7 μL of media were removed and replaced with 
10μL of fresh media. 
2.3.3 3D microtissues agar moulds 
The 3D-petri dish is a system for scaffold-free spheroid production which 
is composed of a plastic micro-mould that is used to cast agarose gels 
Figure 2-3 
 
Figure 2-3 The 3-D petri dish plastic mould and the process of casting an agarose gel for 
culturing spheroids When a cell suspension is dispensed in the rectangular recess(seeding 
chamber) of the agarose gel, the cells settle down in the numerous wells and form 
spheroids in liquid overlay culture. 
Spheroids were formed according to manufacturer’s protocol[258], [259]. 
Both the micro-moulds and the agarose were autoclaved before the 
experiment. The agarose was dissolved in PBS by microwaving until 
boiling. The molten agarose was allowed to cool down to 70 ˚C and 
500 μL of the solution was pipetted into the micro-mould. The micro-
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mould was placed in a 6-well plate in the fridge to cool down and the 
agarose gel gently removed by flexing the assembly. The agarose 3D 
Petri DishTM was then incubated twice with cell culture medium for 15 
minutes and excess media removed. The cell suspension was dispensed 
in the seeding chamber and allowed to settle into the wells for 20 
minutes. Afterwards additional medium enough to cover the petri dish 
was added to the outside of the petri dish. Spheroids were formed in 24-
48h. 
2.3.4 Ultra-low attachment plates 
Ultra-low attachment (ULA) 96-well round bottom plates are 
commercially available plates pre-coated with a hydrophilic polymer that 
prevents attachment and triggers the formation of a single spheroid per 
well.  Using these plates, spheroids of different size were formed in NSC 
media with both cell types using single-cell suspensions with a constant 
volume of 200 µL and concentrations ranging from 250 to 200 000 cells 
per ml. The plates were centrifuged lightly at 100g for 3 minutes after 
seeding to bring the cells closer together, minimize cell death and 
encourage the formation of a single spheroid [260], [261]. Old medium 
was carefully exchanged with fresh (150 µL) on days 3 and 5, taking care 
not to disturb the spheroids, and spheroids were cultured for 7 days 
before final analysis. 
Section 2.4  Tissue processing 
Prior to processing all tissues were fixed using paraformaldehyde solution 
(PFA, 4%) in PBS. Incubation time was 15 minutes for cell suspensions 
and 40 for spheroids followed by a wash with PBS. Spheroids for wax 
embedding were dispersed in a warm agarose solution (5 %, 500 μL, 
Type IA). The agarose was allowed to set and the excess gel that did not 
contain any spheroids was removed using a scalpel. The tissue was 
processed using a Leica TP1020 tissue processor on a 16h cycle with 
xylene. The wax embedded tissue was cut on a Microtome (Slee Cut 
4060) at 10 μm sections. Sections were mounted on 
Aminopropyltriethoxysilane coated slides with distyrene plasticizer in 
xylene. 
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Section 2.5  Spheroid viability assessment 
2.5.1 Spheroid volume determination – microscopy and 
image-analysis 
Images of all spheroids were taken daily for growth determination and on 
day 3, day 5 and day 7 in cytotoxicity experiments using an Olympus 
CKX41 microscope with a 10X objective and an attached Olympus E330 
camera. The scale of images was determined using a calibration slide. 
Images were analysed using the open-source software ImageJ (Fiji 
package) and a macro was written to automate the process (Supporting 
information macro S1). The macro works on whole folders of images, 
converts them to black and white, and uses the Yen thresholding 
algorithm [262]. It proceeds to clean any artefacts from the image, fills 
holes in the spheroid, separates it from debris and determines the area, 
maximum and minimum Feret diameter of the spheroid. The maximum 
Feret diameter, also known as calliper diameter, measures the longest 
distance between any two points of the spheroid boundary. The minimum 
Feret diameter measures the minimum distance between the boundaries 
of the spheroid. The macro also saves a copy of the file of each analysed 
image with a blue outline of the spheroids it has detected and an 
additional file with the numerical measurements for the whole folder. 
Variation in the area determination between the algorithm and manual 
measurement was found to be less than 5%. Data from the macro was 
analysed in Excel and the measured area (S) of the 2D projection of the 
spheroids was used to calculate the radius (
S
R

 ) and the volume (V=
34
3
R ) of an equivalent sphere [263]. 
2.5.2 Resazurin (Alamar Blue) assay 
A stock solution of resazurin (440 µM in PBS), was aliquotted and stored 
at -18°C. Frozen aliquots were thawed and kept in the fridge before use, 
protected from light. On the day of analysis a working solution of 60 µM 
resazurin was prepared in NSC medium. Medium in the wells was 
partially replaced with working solution (150 µL) and the plates were 
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placed back in the incubator. Fluorescence was measured with an 
excitation wavelength of 530 nm and emission 590 nm on a Galaxy 
Fluostar plate reader at 4h after dye addition. 
2.5.3 Acid phosphatase assay 
Acid phosphatase (APH) activity was determined using 4-nitrophenyl 
phosphate as described by Friedrich [264], [265]. The APH assay was 
performed on the same spheroids after the Resazurin assay.  Resazurin 
was removed using two washes with PBS to leave 100 µL, APH assay 
buffer (100 µL), containing para-nitrophenylphosphate (PNPP, 2 mg/mL), 
TritonX (0.1 % vol/vol) in Citrate buffer (0.1 M), was added and the 
plates incubated for 90 minutes at 37 °C. Afterwards NaOH (1 M, 10 µL,) 
was added to the wells and the absorbance was read at 405 nm with a 
reference wavelength of 630 nm on an Asys Expert 96-well plate reader. 
2.5.4 Cell number determination 
After volume and Resazurin assays, spheroids from the growth kinetics 
and cytotoxicity experiments were dissociated and counted. Dissociation 
was carried out after washing the spheroids twice with Ca2+ and Mg2+ 
free PBS (150 µL), removal of PBS, followed by 20 minute incubation with 
Accutase (50 µL) at 37 ˚C. Mechanical dissociation with a multichannel 
pipette was carried out to form a single cell suspension and all six wells 
representing the same conditions were pooled in a microcentrifuge tube 
and centrifuged at 300g for 5 minutes. The supernatant was taken off 
and the cells were resuspended in PBS (200 µL). Cell counts were 
performed using the Orflo Moxi Z automated thin-film sensor cell Coulter 
counter. The Moxi Z software has an internal curve-fitting algorithm 
which finds the healthy part of the cell population and expresses overall 
viability based on cell size reduction and debris content without the use 
of special reagents. 
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Section 2.6  Marking cells with tracer dyes 
 
Figure 2-4 Cell labelling strategy for tumour monolayers and foetal neurospheres. VCR 
and UW228-3 cell were stained in monolayer (top row), while neurospheres had to be 
dissociated and stained as a single cell suspension (bottom row). In initial experiments 
cell were cultured in non-adherent flasks forming spheroids of all sizes. Later ultra-low 
attachment plates were brought to increase reproducibility and facilitate analysis and 
quantification. 
Initial experiments included the VCR cells and were done in non-treated 
flasks. Varying labelling conditions (HBSS, PBS, media), concentrations 
(5-40 µM) and dye exposure times (5-30 minutes) were tested in effort 
to minimize staining toxicity while maintaining high cellular fluorescence.  
After the adoption of the ultra-low attachment plates and the substitution 
of the VCR cell line with UW, cell marking optimisation screening was 
performed with UW and NSC cells with both CellTrace Violet and 
CDCFDASE in concentrations ranging from 2.5 to 20 µM. 
UW228-3 (UW) cells were labelled in monolayers prior to culturing as 
spheroids. Cells, grown to 80% confluence in cell culture treated flasks, 
were washed twice with HBSS (with Ca2+ and Mg2+) and incubated with 
2.5-20 μM concentrations of CDCFDASE and CellTrace Violet in HBSS 
(with Ca2+ and Mg2+) for 30 minutes at 37 °C. Afterwards they were 
washed twice with HBSS and incubated for further 3-4 hours in FCM in 
order to remove any unconjugated dye. The labelled cells were 
dissociated using 0.025% Trypsin 
Human foetal neurospheres (NSC) were dissociated and the cell 
suspension was incubated with 2.5-20 μM concentrations of CDCFDASE 
and CellTrace in HBSS for 30 minutes at 37 °C. 
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Both cell types were seeded in ultra-low attachment plates (200µL, 7000 
cells per well). The plates were centrifuged lightly at 100g for 3 minutes 
after seeding and the cells organised into one single spheroid per well 
within 24h. Controls of unstained cells of each type were included in 
every plate. Old media were carefully exchanged with fresh media 
(150 µL) on days 3 and 5. Spheroids were cultured for 7 days before final 
analysis. 
The effect of both cell marker dyes on spheroid proliferation and 
metabolic activity were assessed by comparing marked spheroid volume 
and metabolic activity to unstained controls. Flow cytometry was used to 
assess dye retention in each condition. 
Section 2.7  Co-culture of human foetal neurospheres 
and tumours 
Co-culture spheroids were established by plating a homogenous mix of 
fluorescently labelled tumour and normal cells (200 µL, 3500 cells/well 
from each type) as a single-cell suspension in ULA plates at the same 
time. Co-culture spheroids formed in 24h and were cultured for 7 days, 
exchanging with fresh media (150 µL) on days 3 and 5.   
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Section 2.8  Poly (glycerol adipate) synthesis and 
substitution 
2.8.1 Backbone synthesis 
 
 
Figure 2-5 The synthesis of poly(glycerol adipate). Lipases are hydrolytic enzymes that 
can catalyse both hydrolysis and esterification. They can work in organic solvents and the 
reaction is driven to completion because acetaldehyde is released through the condenser. 
Their preference for primary hydroxyl groups determines the predominantly linear 
structure of the product. 
Equimolar quantities (0.05 mol) of Divinyl adipate (DVA, 9.91g) and 
glycerol (4.6 g) were added to a clean, dried three-neck 250 ml round 
bottom flask, followed by THF (15 ml). The flask was maintained at 50 °C 
and allowed to equilibrate for 10 minutes. A stirring rod fitted with a 
Teflon paddle was placed in the flask, with the stirrer paddle held just 
above the bottom of the flask (approximately 2-3 mm) to limit crushing 
of the enzyme support. A mechanical overhead stirrer (Heidolph RZRI 
stirrer) was secured over the water bath with the stirring rod held in 
place with a Quickfit thermometer adaptor. The system was also fitted 
with an open top condenser (to enable release of the acetaldehyde 
produced as a by-product of the reaction) and the free open neck of the 
flask stoppered. To such a set-up, 1 g of Novozyme 435 was added via 
the available flask neck and the residual resin washed from the sides of 
the glassware with an additional 5 ml THF (making the total volume of 
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THF used 20 ml). Stirring commenced at 2000 rpm and the reaction was 
allowed to proceed for 24 hours.  
Afterwards THF (100 ml) was added to the flask, washing any residual 
polymer off the stirring paddle. The contents of the flask were then 
vacuum-filtered by standard Buchner filtration through 2 layers of GF/A 
(Whatman) filters to remove the residual immobilised enzyme. The 
filtrate was poured into a round bottomed flask and the solvent removed 
via rotary evaporation at 80 °C (Laborota 4000, Heidolph Instruments 
attached to Rotavac plug and pump). The flask was then heated to 
100 °C for 30 minutes. The resultant viscous polymer sample was 
transferred into a jar and stored for 48h in the vacuum oven (60 °C) to 
remove any traces of solvent, then sealed and stored over silica gel in a 
desiccator. 
2.8.2 Polymer characterisation 
All synthesised polymers were analysed by gel permeation 
chromatography (GPC). Gel Permeation Chromatograph (GPC) results 
were obtained using a Polymer Labs GPC-120, run with HPLC THF at 40 
°C with a flow rate of 1 mL/min, using two PolarGel-M columns and 
calibrated with polystyrene standards. The polymer samples were 
prepared at 10 mg/mL in THF in a dry glass vial prior to filtration through 
a 2 μm syringe filter. 
The GPC results from this setup were compared after analysis in Liverpool 
where the setup included a Viscotek system, TDA Model 300 coupled to a 
gpcMAX integrated solvent and sample delivery module (degasser, pump 
and auto-sampler) ran by OmniSEC3 software and two ViscoGEL GMHHR-
N columns.  
The solutions were mixed for an hour on the roller-mixer (SRT1) to allow 
the polymers to fully dissolve. The samples were then filtered (0.2 m 
PTFE syringe filters, Whatman) into 2.0 mL glass vials. PTFE septa 
(Sigma) were used in the vial lids to avoid solvent evaporation and 
clogging up of the injecting needle. Control (THF) samples were run prior 
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to the other samples. The mean molecular weight Mw of the main peak 
was taken as the average molecular weight of the polymer batch. 
1H-NMR analysis of the PGA polymers (2mg) was performed using 
deuterated acetone ((CD3)2CO, δH=2.05ppm) as solvent (0.7ml) on a 
400Mhz Bruker spectrometer. The data was processed using MestReNova 
6.0.2 software. The NMR spectra were used to verify polymerisation of 
PGA and determine degree of substitution in the substituted 
polymers[266]. 
2.8.3 Acylation with C8 and C18 
Substitution of the secondary hydroxyl group in the backbone polymer 
was carried out using the relevant acyl chloride in THF with the addition 
of pyridine as a catalyst and acid scavenger (Figure 2-6)[176]. 
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Figure 2-6. Substitution of the pendant hydroxyl groups in poly(glycerol adipate) with 
40% Stearic acid as described by Kallinteri[176]. 
Poly(glycerol adipate) (2.10 g) was dissolved in dry THF (10 mL) and the 
mixture heated to reflux until the polymer was dissolved followed by the 
addition of acyl chloride (1.4 mL for stearoyl chloride). Afterwards, 
pyridine (0.4 mL) was added and the reaction refluxed (2 h) and then 
poured onto HCl (2 M, 100 mL) and followed by extracting three times 
using DCM (50 mL). The organic phase was collected and washed then 
with water (100 mL), dried over magnesium sulphate and the solvent 
removed by rotary evaporation to a white waxy solid. 
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Section 2.9  Nanoparticle preparation and 
characterisation 
2.9.1 Nanoprecipitation 
 
Figure 2-7. The nanoprecipitation method for nanoparticle production. A water-miscible 
solvent (acetone) is used to dissolve the polymer along with the drug or dye to be 
encapsulated. The organic phase is added to an aqueous solution (buffer or surfactant) 
under stirring. Nanoparticles are formed immediately and the solvent is left to evaporate 
Fluorescently-labelled nanoparticles were produced as described by 
Meng[179]. Briefly 100%-C18-substituted PGA (20 mg) were dissolved in 
acetone (2 mL) containing RBITC (125 µL, 2 mg/mL in methanol). The 
solution was added dropwise into HEPES buffer (10 mM, pH=7.4, 7 mL) 
under stirring. 
Etoposide-loaded nanoparticles were produced according to the method 
described by Puri[180]. Etoposide (2 mg) and 40%C8-PGA (10 mg) were 
dissolved in acetone (1 mL) and evaporated to dryness by blowing dry 
N2. After an hour the matrix was dissolved in acetone (1 mL) and quickly 
added to water (5 mL) under stirring. 
A different procedure was employed in the polymer library screening 
experiments in Chapter 6. Etoposide or teniposide (1.5 mg) and polymer 
(10 mg) dissolved in acetone (1 mL) were mixed with water (2 mL) using 
a chamber mixer (Pharmacia, 50-60 Hz, 5 MPa).  
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In all cases the vials were protected from light using aluminium foil and 
were left under magnetic stirring, in a fume hood overnight to remove 
residual acetone. The suspensions were filtered through a 0.45 µm 
syringe filter before separation of the free drug. 
2.9.2 Emulsification-solvent evaporation 
 
Figure 2-8 Solvent-emulsification method for nanoparticle production. The polymer and 
drug are dissolved in a solvent with very limited water-miscibility (DCM, CHCL3, Ethyl 
acetate or Benzyl alcohol). The mix is homogenized under high-shear forces to form a 
coarse emulsion. High-energy techniques such high-pressure homogenizing or 
ultrasonication are used to form nanoemulsion. The solvent is later removed either by 
dilution or more often through evaporation at reduced pressure. 
Etoposide or teniposide (3 mg) and polymer (17 mg) were dissolved in 
dichloromethane (DCM, 1 mL) and mixed with water (4 mL) with or 
without the addition of different surfactants using a high-shear mixer 
(Ultra-Turrax, IKA T25) for 1 minute at 24000 rpm. The resultant course 
emulsion was immediately sonicated with a probe sonicator (Bandelin 
UW2070, 60%power, 2 minutes). The Nanoemulsion was evaporated 
using a rotary evaporator at 30 ˚C. The resultant nanoparticles were 
filtered through a 0.45 µm syringe filter and rapidly transferred for 
separation of the free drug. 
2.9.3 Separation of free drug from nanoparticles 
The loaded nanoparticles were separated from the free dye or drug via 
Low pressure gel permeation chromatography using a SepharoseCL-4B 
column (2.5x25 cm, GE Healthcare) [267]. The setup was automated 
Experimental materials and methods 
 59   
  
with a peristaltic pump, a UV detector (280 nm) and autosampler that 
collected 2 mL fractions. As seen in Figure 2-9, the macromolecular 
nanoparticles would not enter the cross-linked gel and eluted first while 
the lower molecular weight drug/dye would enter the pores of the gel and 
had a longer retention time. Separation was verified using the UV 
detector by the separation between the nanoparticle and drug/dye peak. 
Later for the extensive polymer screening campaign when higher 
throughput was desired the Sephadex GH25 (PD-10, GE Healthcare) 
columns were employed. These columns can separate up to 2.5 mL of 
nanoparticle suspension. A control with a solution of the free drug 
without any polymer was included to verify separation of nanoparticles 
from unincorporated free drug. 
 
Figure 2-9. Schematic representation of gel-permeation chromatography. The columns 
are filled with cross-linked polymers comprised of gelled particles with multiple pores. 
Small molecules (black dots) enter the pores and are retained longer on the column while 
big particles (red dots) are excluded by the pores and are eluted first. Left panel shows 
columns with nanoparticles eluting while drug is retained. Right panel shows a 
magnification of a single gel bead and the size-exclusion mechanism. 
2.9.4 DLS and Zeta potential 
The main technique used to determine the size of the nanoparticles made 
in this work was dynamic light scattering (DLS). The term is synonymous 
with photon correlation spectroscopy (PCS) and quasi-elastic light 
scattering (QELS). DLS is used to determine sizes for particles dispersed 
in liquid. It is called dynamic light scattering because it measures the 
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variations in the intensity of scattered light over time, while static light 
scattering (SLS) gives a time-averaged value and is used to measure 
molecular weight and radius of gyration. 
In the typical DLS setup, a collimated monochromatic laser light is used 
to illuminate a dispersion of nanosized (0.5-1000nm) particles in solution. 
The fluctuations in the intensity of scattered light are measured over time 
at a set angle (90˚ for the Viscotek 802). These fluctuations are caused 
by the random Brownian motion of the submicron particles and depend 
on their size- smaller particles cause more rapid fluctuations in light 
intensity while bigger particles cause slower fluctuations. What is really 
determined in DLS experiments is not the size but the diffusivity of 
particles in the medium: 
𝐷 =
𝑘𝑇
6𝜋𝜂𝑟
 Equation 2-1.  
D-diffusion coefficient 
Η- viscosity of the media 
k-Boltzmann constant 
T-absolute temperature 
The radius (r), calculated using this Stokes-Einstein equation is the so-
called hydrodynamic radius in the solvent (water). The particle shape is 
assumed to be spherical and the concentration of particles should be low 
enough to prevent multiple scattering from different particles. 
A limitation of DLS arises when polydisperse mixtures of particles are 
analysed. The intensity of scattered light using the Rayleigh 
approximation is proportional to the sixth power of the radius (r6) which 
leads to overestimations in the percentage of large particles by intensity 
measurements. For Rayleigh scattering, particles with a diameter smaller 
than the laser wavelength by a factor of 10, mass and number 
distributions can be calculated by dividing to the d3 and d6 respectively. 
However, these computations are mainly valid for particles with 
diameters less than 50nm[268]. 
As a surrogate measure for particle charge, the zeta potential (ζ) of 
particles dispersed in buffer was determined via Laser Doppler 
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Electrophoresis. What is actually measured is the electrophoretic mobility 
of the particles under the influence of an applied electric field.  
When a charged particle is dispersed in water, a strongly associated layer 
of counter-ions attaches to its surface (Stern layer). A more loosely 
associated diffuse layer surrounds the Stern layer formed under the 
influence of electrical attraction and thermal motion. When an electrical 
current is applied, the particle along with the Stern layer and a certain 
part of the diffuse layer starts moving towards the oppositely charged 
electrode. The ‘slipping plane’, where this process occurs, separates the 
mobile fluid and ions associated with the particle from the fluid 
associated with the medium. Therefore the zeta potential is a measure of 
the difference in potential between the particle and medium at the 
slipping plane in the diffuse layer. 
The Zetasizer ZS, uses the shift in phase between a scattered and a 
reference beam to determine the electrophoretic mobility and the zeta 
potential of the particles. 
Zeta potential in buffered aqueous solutions depends on particle type, 
buffer concentration and pH. The surface electrical charge is important 
for colloid particle stability and zeta potential values up to ±30mV are 
generally expected to confer electrostatic stabilisation of dispersions. 
Values ±10mV are usually considered approximately neutral. 
Section 2.10  Flow cytometry 
Flow cytometry is a technique which analyses cells (or micron-sized 
particles) as they pass through a beam of light. It allows the analysis of 
multiple cellular parameters within heterogeneous populations with 
speeds of thousands of cells per second. 
In the classical setup a suspension of cells is delivered to the fluidics 
system of a flow cytometer, which focuses the cells into a thin jet stream. 
The cells are arranged by the use of hydrodynamic focusing- injecting 
them in a laminar stream of sheath fluid (buffered saline). The cells are 
delivered one by one in the fluid stream to one or multiple interrogation 
points. There is a laser at each interrogation point which illuminates the 
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cells and the scattered light is collected by detectors in front and to the 
side of the laser beam. The forward scatter, is the light that is detected in 
front of the laser beam and is a measure of cell size. The light scattered 
to the side is detected by the side scatter detector and the recorded 
signal gives an idea of the granularity and complexity of the cells. 
In addition, a carefully arranged optical system of mirrors, filters and 
detectors splits the scattered light from each laser to a number of 
different wavelength bands. For example, the scattered light from the 
most common blue, 488nm, Argon laser can be split into a number of 
channels spanning green, orange, yellow, and a number of shades of red 
(Figure 4-1). The information is digitized in the signal processing unit and 
can be displayed in a variety of ways.  
The simplest way of plotting the information is by using a histogram plot. 
The histogram plot maps the distribution of fluorescence intensity in a 
single channel for the cell population (Figure 2-10). 
 
Figure 2-10.Histogram plots of fluorescence intensity for two cell samples. A-control cells 
without green fluorescent dye. B- cells prestained with green fluorescent dye. X-axis 
intensity Y-axis number of events. 
As seen in Figure 2-10 the control sample has a low fluorescence in the 
green channel and the whole population is situated to the left of 100 
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relative units of fluorescence (RFU). In contrast, almost every cell from 
the stained sample has fluorescence intensity higher than 100 RFU. 
Histogram plots can be overlaid so that the control and stained samples 
are plotted on a single graph (Figure 2-11). This way of plotting the data 
allows the user to examine whether the intensities of the unstained and 
stained cells overlap. Here the control and the marked samples are very 
well separated into two populations.  
 
Figure 2-11. Overlaid histograms of non-marked cells and marked cells in the same plot. 
The lighter-green population to the left is the unstained control. The population to the 
right is the fluorescently labelled sample. 
Another way of presenting flow cytometry data is through the use of dot 
plots. Dot plots are made by combining two histograms in a single plot 
and each axis represents fluorescence intensity in the respective channel. 
Figure 2-12A shows a plot of the intensity in the forward scatter versus 
side scatter for a sample of unstained cells. In its essence, this is a figure 
where cell size is plotted on the x-axis and cell complexity is plotted on 
the y-axis. In the left corner of the plot the particles are very small and 
simple. Those particles represent the inevitable debris found in the 
majority of cell suspension samples. Figure 2-12B shows side versus 
forward scatter for the stained sample. There are no major differences 
between the two samples because the staining procedure has not 
affected the size or granularity of the cells. Figure 2-12C shows a plot of 
the intensity of fluorescence in the green and blue channels for unmarked 
control cells. As illustrated, the cells have very low fluorescence in each 
channel. The plot can be subdivided into four quadrant subplots. The 
lower left quadrant is defined by the unstained control and contains 
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unstained cells. The lower right quadrant in Figure 2-12C would be 
reserved for cells which are more fluorescent than the unstained control 
in the green channel. The upper left quadrant represents cells with blue 
fluorescence brighter than the control. The upper-right quadrant would 
be taken by cells brighter than the control in both the green and the blue 
channels. The utility of this quadrant splitting is seen in Figure 2-12D, 
where the fluorescence of the stained cells is visualised. It can be seen 
that around 88.5% of those cells exhibit blue fluorescence brighter than 
the unstained control. Nevertheless, close to 11% of the stained cells 
have the same fluorescence as the unmarked control and cannot be 
distinguished based on this staining procedure.   
 
Figure 2-12. Dot plots in flow cytometry. A-side vs forward scatter for unstained control 
B-side/forward scatter for fluorescently labelled cells; C-dot plot of green vs blue 
fluorescence in unstained control; D-dot plot of green vs blue fluorescence in cells stained 
with blue dye. 
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Figure 2-13. Regions and Gating in flow cytometry. The left dot plot plots the intensity in 
fluorescence in a mixed sample of tumours and normal (stem) cells marked with a violet 
and green fluorescent dye respectively. Regions of interest are drawn along the green 
(stem cell) and violet (tumour) populations. When these are applied as gates the top 
(tumour) and bottom (stem cell) dot plots can be created. In the separate tumour and 
stem cell dot plots the viability of each cell population is determined separately using 
viability markers 7-AAD (cell death) and Annexin-V-APC (apoptosis). 
A useful technique in flow cytometry is the ability to gate populations of 
interest by drawing regions which allow analysis of different cell 
populations in various ways. The single graph in the left part of Figure 
2-13 shows a dot plot of the fluorescence intensity in two channels- violet 
and green. There is a clear separation into two populations- one which is 
intensely fluorescent in the green channel, and a population that exhibits 
fluorescence solely in the violet channel. If one applies the prior 
knowledge that the normal (stem) cell populations have been marked 
with a green dye and that the tumours have been stained with a violet 
dye then a region can be drawn around each population. The flow 
cytometry software can then be used to gate on each population 
separately and analyse the tumour and neural progenitor cells for their 
viability status with a combination of viability dyes. More information 
regarding cell marking and viability dyes will be given in Chapter 4. This 
figure serves solely to illustrate the utility of gating in flow cytometry. 
Another important aspect in flow cytometry and fluorescence is spectral 
overlap. When a fluorophore is excited it emits light which is centred 
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around a single wavelength. However, the spectrum of emitted light can 
be quite broad, gradually tailing off towards the longer wavelengths. For 
example, when fluorescein is excited by the blue laser, its peak 
fluorescence is in the green wavelengths but it also spills into the orange 
and yellow wavelengths. The amount of this spectral overlap will be 
proportional to the intensity of fluorescence in the main channel and can 
be accounted for either during acquisition or in the post-processing of 
data. The process of correcting for the spillover of fluorophores into 
neighbouring channels is known as compensation. When this is done 
during data acquisition it is generally referred to as hardware 
compensation. Compensation can be done using a variety of different 
software tools as well. The general procedure involves subtracting a 
certain percentage of the intensity of the fluorophore from the adjacent 
channels. 
 
Figure 2-14. Compensation in flow cytometry. Histogram plots in fluorescence intensity in 
the green  channel and the red channel.. Unstained control populations are shown in blue. 
The stained populations are depicted in red. A shift in fluorescence between the two 
indicates that the cells are positive for the dye. A-sample stained with CDCFDASE before 
compensation; B-the sample after applying software compensation. 
The utility and limitations of compensation are shown in Figure 2-14. In 
these experiments cell samples were marked with a dye (CFDA SE) and 
the fluorescence intensity of the labelled cells (red on the histogram) was 
plotted against the unstained control (blue population on the histogram). 
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Figure 2-14A shows the intensity of fluorescence in the desired CFDA SE 
channel and the spectral overlap in the neighbouring red channel. The 
stained cells (red) had brighter fluorescence than the control (blue) in 
both channels. A software compensation algorithm was used to correct 
for this phenomenon Figure 2-14B. Although the fluorescence in the red 
channel was minimized, applying compensation did not lead to a simple 
shift towards the left but had a profound effect in the shape of the 
histogram of the marked cells. This shows that the spectral overlap was 
too great to be fixed through simple compensation. The combination of 
CFDASE and red dyes was deemed unsuitable for the purposes of this 
experiment. 
Section 2.11  Confocal and multiphoton microscopy 
Both confocal and multiphoton microscopy are subtypes of fluorescence 
microscopy. They use a laser to illuminate a single point in a sample 
labelled with specific fluorophores and produce an image based on the 
emitted fluorescence light. What distinguishes them from conventional 
wide-field fluorescence is the ability to eliminate out-of-focus light and 
optically section a thick specimen. This means they can produce three-
dimensional images in the x,y and z directions. Being able to also image 
specimens in the vertical axis is especially important for analysing 
spheroids as they are three-dimensional structures in which the periphery 
and inner parts of the spheroid often have very different properties. 
Confocal laser scanning microscopy[269] focuses laser light through a 
pinhole aperture to excite a single point in the object of interest. The 
fluorescence, emitted by the illuminated point, reaches the detector 
through another, emission pinhole, which serves to eliminate light coming 
from out-of-focus planes. The object is scanned point by point to produce 
an image of a single plane. Multiple planes can be sequentially scanned 
and combined to render a three-dimensional representation of the image. 
Although the laser light is focused in a single point, the beam illuminates 
the sample in its entire depth and can cause photobleaching and 
toxicity[270]. Another limitation of confocal microscopy is that the 
penetration depth is limited by the opacity of the tissue and the 
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excitation wavelength of the fluorophore. Spheroids are not transparent 
and light scattering, especially for the shorter wavelengths (UV, violet, 
blue) can significantly limit penetration notably in spheroids larger than 
100 µm in diameter. 
 
Figure 2-15. Jablonski diagrams comparing one-photon fluorescence and two-photon 
fluorescence. In one photon fluorescence a fluorophore receives energy from a single 
photon in order to transition from its ground state to an excited state. After a small non-
radiative energy dissipation, the excited fluorophore releases its energy as fluorescent 
light and returns to the ground state. The emitted photons normally carry less energy 
than the excitation ones (Stokes shift). In two photon fluorescence, two longer 
wavelength photons delivered by a femtosecond pulsed laser are used to convert the 
fluorophore to its excited state. 
In contrast to the single photon excitation used in confocal microscopy, 
multiphoton microscopy excites the fluorophore by delivering two longer 
wavelength photons in a single point[271]. An infrared pulsed laser is 
programmed to deliver two photons in a precise focal point in the 
specimen. This gives multiphoton microscopy a significant advantage 
over confocal because photobleaching is confined to a smaller area where 
the two photons coincide. Moreover, the near infrared wavelengths can 
penetrate deeper into the tissue making the visualisation of spheroids 
larger than 100 µm possible. Furthermore, since there is no need for a 
pinhole, more light can reach the detector and brighter images of thick 
specimens can be achieved[270]. 
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Chapter 3.  3-D monocultures of foetal neurospheres 
and medulloblastoma cell lines 
Section 3.1  Introduction  
This chapter shows the development of the prototypical in vitro model of 
medulloblastoma. The purpose was to culture both normal tissue (neural 
stem cells) and a medulloblastoma cell line separately as spheroids, 
expose them to different concentrations of etoposide and compare their 
relative drug sensitivity.  
As noted in Section 1.3.3, multicellular spheroids have been reported to 
match many aspects of the true behaviour of small avascular 
tumours [243]. Culturing cells in 3D accounts for the complex cell-cell, 
cell-extracellular matrix interactions, and the formation of nutrient and 
oxygen gradients which tumours exhibit in vivo [237]. 
Although the advantages of using spheroids in cancer research have been 
known since the 1970s [210], monolayer cultures are still the primary 
form of cell-based screening. That is because three-dimensional cultures 
have been notorious for their slow growth, expensive maintenance and the 
difficulties associated with viability determination in 3D. In order to match 
the ease and convenience of 2D assays the ideal 3D screen should be 
quick, reproducible and amenable to high-throughput using standard 
methods such as phase and fluorescent microscopy and standard plate 
readers.   
Two methods claim to have all of the above qualities and aim to replace 
monolayer cultures as the methods of choice for anticancer drug screens: 
hanging drop plates and overlay cultures. The hanging drop plates 
developed by InSphero [272] and 3D Biomatrix [257] utilise the 96 and 
384 well format and rely on growing the spheroid in a hanging drop. Their 
main drawback is the need to transfer the spheroid to a normal 96 or a 
384-well plate in order to probe viability and proliferation. The liquid 
overlay method overcomes these challenges and utilises either in-house 
prepared poly-hydroxyethyl methacrylate [260] and agarose [264] coated 
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plates or commercially available ultra-low attachment plates [261]. 
Spheroids grown using the liquid overlay method are scaffold free and the 
extracellular matrix that keeps them together is naturally secreted by the 
cells [273]. This is especially advantageous for testing the interaction 
between submicron delivery systems and tissues. In monolayer assays all 
cells are exposed to the nanoparticles. In contrast, the presence of 
extracellular matrix in spheroids mimics the obstacles to nanoparticle 
penetration in a more physiologically relevant way.  
Although both liquid overlay and the hanging drop methods can produce 
spheroids with diameters of 100 µm to over 1 mm, the preferred size for 
analysis is 300-500 µm. This ensures that the right pathophysiological 
gradients of oxygen and nutrients are present along with a core of hypoxic 
quiescent cells thought to be responsible for the increased chemo- and 
radioresistance of spheroids and solid tumours [216], [217], [264]. 
Another reason for choosing this size range was to match the size of 
avascular small metastases and leftover tumour tissue, which were 
identified as the primary target of the nanoparticle delivery system as 
discussed in 1.3.3.1. A preliminary search for the optimal platform to 
culture the normal foetal neurospheres and medulloblastoma cells was 
initiated. The priority was to establish a cell-based analytical platform with 
optimal levels of speed and reproducibility in order to faithfully determine 
dose-response relationships for a number of formulations. 
The replacement of monolayers by 3D cell culture will require validated, 
cost-effective, high-throughput compatible methods to assay spheroid 
growth, viability and the effects of treatment. Over 50 years of spheroid 
research has shown that the growth of cells in three dimensions is only 
advantageous in a practical sense if analysis is rapid and reliable in high 
throughput and with standard equipment. Since liquid overlay cultures are 
stationary and produce a single spheroid in the middle of each well, 
tracking growth can be easily accomplished with phase-contrast light 
microscopy. Images of the spheroids in each well can be collected and 
analysed using specialised equipment like the Celigo cytometer [261] or 
commercial software programmes [261], [264], [274]. However, the 
investment in new equipment or image editing software can be seen as a 
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hindrance to the mainstream implementation of spheroid research. 
Therefore, it was decided to work with the open-source software ImageJ 
and develop an in-house automated macro for spheroid analysis to 
facilitate image analysis within the scientific community.   
Apart from volume, cell viability within the spheroid can be assessed using 
metabolic assays like the reduction of Resazurin [275] or measuring ATP 
[261]. These assays are convenient and quick, however, they have not 
been properly validated for use in 3D cultures yet. Friedrich et al [265] 
have validated and encouraged the use of the acid phosphatase assay to 
determine viability and claimed that metabolic assays may not be equally 
suited for the task.  
This chapter describes the pathway for development of the simpler, 
separate culture version, of the two in vitro medulloblastoma models. In 
this instance, the neural stem cells and medulloblastoma tumours were 
cultured in separate wells apart from one another. The main focus was 
throughput plus reproducibility, and viability was chosen as the primary 
endpoint.  Spheroid volume, metabolism and acid phosphatase activity 
were employed as surrogate markers for viability. 
The brain tumour medulloblastoma cell lines DAOY and VCR were used in 
the initial experiments and later UW228-3 was chosen to represent the 
pharmacological target of treatment. Human foetal brain tissue spheroids 
cultured in neural stem cell media to enrich for neural progenitors were 
selected to determine possible off-target effects on the developing brain. 
Etoposide was used in those experiments as the initial plan was to 
compare the sensitivity of the cells to free etoposide at this stage and 
include etoposide-loaded nanoparticles later. 
Section 3.2  Materials and methods 
3.2.1 Cell lines and culture 
All experiments were performed in standard cell culture conditions at 
37 °C and 5% CO2 as described in Section 2.2 
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3.2.2  Doubling time determination for UW228-3 cells in 
monolayer 
Uw228-3 cells were dissociated, suspended in FCM and 400 000 cells were 
seeded in 75cm2 cell culture treated flasks. Cells were cultured for 60-80 
hours, dissociated and counted using a haemocytometer. Initial and final 
cell counts were fitted to an exponential growth equation using GraphPad 
Prism 6.0 and the doubling time was determined as an average from three 
independent experiments. 
3.2.3 Monolayer sensitivity to etoposide 
Adherent cultures of UW228-3 cells were exposed to etoposide in order to 
determine their intrinsic sensitivity to etoposide while actively growing in 
monolayer. UW228-3 were dissociated, suspended in full culture medium 
and seeded in tissue culture treated flat bottom 96-well plates (150µl, 
500cell/well). The initial seeding density was chosen to ensure exponential 
growth for the duration of the assay, after an optimisation screen with 
seeding densities from 500-10000 cells/well.  
Cells were left to attach for 24h, the old medium was replaced with half-
log10 dilutions of etoposide (1nM-100µM) in FCM (150µl) and the cells 
incubated with the drug for 48h. DMSO levels were kept constant at 0.2% 
for all wells, the untreated control was used to determine 100% viability 
and 25%DMSO was used as positive control for complete cell kill.  After 
drug treatment the old medium was replaced with fresh drug-free medium 
and the cells were incubated for further 48h. On the last day the viability 
of the cultures was determined using resazurin reduction (2h incubation) 
after complete medium renewal. There were six replicate wells for each 
condition and dose-response curves were plotted as the average of three 
independent experiments. 
3.2.4 Spheroid production using the 3D Biomatrix platform 
Spheroids were formed in the hanging-drop plates according to the 
manufacturer’s manual and the methods described in section 2.3.2  
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3.2.5 Production of spheroids using 3D Microtissues® agar 
moulds 
Spheroids were formed according to manufacturer’s protocol[258], [259] 
as described in Section 2.3.3  
3.2.6 Tissue processing for histology and Haematoxylin and 
eosin staining 
Tissue processing was done after fixation with 4% polyformaldehyde as 
per Section 2.4 
3.2.7 Spheroid production in ultra-low attachment plates 
Ultra-low attachment plates were used as shown in Section 2.3.4 
3.2.8 Phase microscopy and image analysis 
Image analysis and volume measurements were done with the specialty 
written ImageJ macro as described in in Section 2.5.1. 
3.2.9 Growth kinetics  
UW228-3 cells were seeded in ULA plates at concentration ranging from 
250 cells to 200 000 cells/mL and NSCs were seeded at 1000 to 
200 000 cells/mL. They formed spheroids which were photographed daily 
and analysed for metabolic and acid phosphatase activity on day 7. 
Spheroid volume growth was calculated by comparing spheroid volume on 
days 3 and 7 to that of day 1. (V growth=100 X Vday7/Vday1). 
3.2.10 Cytotoxicity experiments 
Single cell suspensions were seeded in ULA plates at concentrations 
determined by the growth kinetics to produce spheroids between 300-
500µm in size on day 3 (2.5x104 cells/mL for UW228-3 and 5x104 cells/mL 
for NSCs).  Old medium (150µl) was carefully removed on day 3 and 
replaced with medium containing etoposide ranging from 0.03 µM to 
300 µM from a 50 mM etoposide stock solution in DMSO. The drug 
exposure time was 48h (until day 5) when medium was exchanged twice 
with fresh etoposide-free medium (150 µL), reducing drug concentrations 
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to 1/16th of initial levels. Afterwards spheroids were incubated for a 
further 48h until day 7 when their viability was assessed using spheroid 
volume, resazurin metabolism and acid phosphatase activity. Negative 
control spheroids were cultured with 0.2% DMSO as vehicle and used to 
determine 100% viability while the positive control ones were exposed to 
25% DMSO and represented 0% viability. The 300 µM etoposide 
concentration contained a higher level of DMSO (0.6%) and was used 
along with the positive control to elicit complete cell death and represent 
the bottom of the dose-response curve. A row of wells with media only 
and no cells was included to exclude contamination and verify that the 
positive control is functioning properly. Six replicate spheroids per 
condition were exposed to a total of 9 levels of etoposide in each 
experiment and the displayed results are the average of at least three 
independent experiments. In the case of neural stem cells, tissue from 
three different foetuses was used in the different experiments. 
     
3.2.11 Resazurin, Acid phosphatase and Cell counting 
Cell metabolism, enzymatic activity and absolute cell counts after spheroid 
dissociation were assessed as per the methodology described in Section 
2.5 
3.2.12 Assay Validation 
Resazurin, Acid phosphatase and Volume determination assays were 
optimised and evaluated based on their Z-factor [276], Signal window 
[277] and Coefficient of Variation. 
Z-factors were calculated using the equation: 
controlsample
controlsample
MeanMean
SDSD
Z



)(*3
1  
In growth experiments, the standard deviation and mean of the readings 
for medium-only wells were used as control. Z’-factors, reported in 
cytotoxicity assays, have been calculated by substituting the values for 
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positive and negative control in the above equation. Signal window (SW) 
was defined as: 
sample
controlsamplecontrolsample
SD
SDSDMeanMean
SW
)(*3 
  
Coefficient of variation was calculated as  100% x
Mean
SD
CV   
Acceptance criteria [278] were set at Z-factor>0.4, SW>2 and 
CV%<20%. They were used along with the biological considerations to 
optimise the cell density needed for the cytotoxicity screens. Plate 
uniformity was assessed on whole plates seeded with 2.5x104 cells/mL 
UW228-3 and 5x104 cells/mL NSCs. Phase contrast photographs were 
taken on day 3 after seeding and the variation in volume of the resultant 
spheroids was examined (acceptance criteria CV<20%). Signal variability 
validation was carried out on the 7th day of the etoposide exposure 
experiments. Non-normalised (raw) assay readouts at each etoposide 
concentration were compared to the 25% DMSO positive control and Z-
factor, SW and CV were calculated for each condition.  
3.2.13 Data analysis 
Results from volume, Resazurin reduction, APH activity and cell number 
measurements were analysed in MS Excel and GraphPad Prism 6. In assay 
validation experiments, readings for each assay were normalised so that 
the highest reading represents 100% and the reading for cell-free media 
0%. Data was fitted to a straight line using Prism’s least squares 
algorithm. In cytotoxicity experiments, readings were normalized so that 
untreated control has 100% viability and the readings for the positive 
control were taken as 0% viability. Dose response curves were fitted using 
either the four-parameter logistic equation for monophasic dose response 
(UW228-3) or the biphasic dose-response equation (NSCs) in Prism. 
Results are displayed as mean ± SD. Combined IC50 values from several 
experiments were derived by pooling the data together and analysing all 
runs from a single assay as one, using the logIC50 means (geometric 
means of IC50s) or by employing Prism’s extra-sum-of-squares F-test to 
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fit a curve with a common logIC50 between experimental runs as 
described in [279]. There were n=6 replicates for each condition in each 
individual experiment and displayed data represent the mean of at least 
three independent experiments 
Section 3.3  Monolayer experiments in UW228-3 
Some preliminary work was done on the UW 228-3 cell line in order to 
determine doubling time and sensitivity to etoposide. The UW228-3 cell 
line was found to have a doubling time of 29h (SD=5h, n=3) in monolayer 
which is similar to the doubling time reported in the original studies on the 
cell line[226].  
When seeded in 96-well plates and cultured for 48h with etoposide, 
followed by a 48h drug-free period, the exponentially dividing UW228-3 
cells were killed by etoposide treatment in a dose-dependent manner. 
Using resazurin reduction as a surrogate viability measure, the IC50 for 
etoposide was determined to be 0.36 µM (Figure 3-1) which is in 
agreement with the studies by Othman et al [228].  These preliminary 
data were used to define the range of concentrations to be used in the 3D 
and confirm the sensitivity of the cell line to the drug. 
 
Figure 3-1. Etoposide dose-response curve for exponentially growing UW228-3 
medulloblastoma cells in monolayer. IC50 was 0.36 µM (95%CI=0.29-0.44µM, n=3 
experiments with 6 replicates for each condition). 
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Section 3.4  Initial search for a suitable 3D cell culture 
growth platform 
3.4.1 Non-adherent cell culture flasks 
Neural stem cell enriched neurospheres were routinely cultured as 
neurospheres in non-treated flasks as described in 3.2.2. 
 
Figure 3-2 Phase microscope image of normal neurospheres cultured in serum-free media 
in non-adherent flasks. Foetal neurospheres were cultured for 6 days in non-adherent 
flasks. Spheroids with diameter ranging from 80 μm to 250 μm are visible. Scale bar 
100 µm 
Figure 3-2 shows the broad distribution of sizes that is characteristic for 
spheroids cultured using this simple method. Although this technique was 
suitable for neurosphere expansion, the poor reproducibility and the 
variety of spheroid sizes makes it unfit for medium and high-throughput 
analysis. Some researchers have relied on manual sorting[204] while 
others have opted for large particle sorters like the COPAS system[280]. 
3.4.1 3D Microtissues® agar moulds: 
The 3D Petri DishTM micromoulds are filled with molten agarose solution, 
which is allowed to set in the fridge and afterwards separate from the 
plastic. The numerous micro-wells in the agarose 3D Petri dish® are used 
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as a non-adherent hydrogel growth surface and spheroids are grown in 
overlay culture (Figure 3-3)[259].  
 
Figure 3-3. Spheroids in the 3D microtissues micromoulds. A-loading the agarose 
micromould (image taken from the 3D Petri DishTM manual); B-VCR spheroids 48h after 
seeding; C-VCR spheroid 72h after seeding 
 
Figure 3-4. Phase-contrast images of the spheroids produced by VCR cells using two sizes 
of the 3D Petri Dish-small with 256 wells and large with 81 wells. Cells were seeded with 
190μl of medium at three different concentrations. The spheroids formed in the first 24h 
had a higher number of single cells in the periphery without a well-defined border. By day 
4 most spheroids had a dense well-pronounced border. Most spheroids grew to roughly the 
same diameter which was probably determined by the size of the wells 
The VCR cells formed spheroids within 24h using the 3D Petri dish. The 
spheroids were initially loosely packed with many single cells in the 
periphery. Although with prolonged culturing time the border of the 
spheroids became denser, they did not grow much in diameter (Figure 
3-4). 
The main advantage of the micromoulds is that a large number of 
spheroids with a narrow size distribution could be formed in a single 
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seeding step. However, those spheroids would later need to be sorted and 
transferred to a standard 96- or 384-well plate if the spheroids are to be 
assayed in a larger set of experiments. Alternatively, each agarose mould 
can represent one condition, with as many as 256 replicate measures in 
the mould, but the limiting factor here will be the number of moulds that 
can be produced at one go. Moreover the plastic used to mould the 
agarose loses its flexibility with multiple autoclave cycles which may 
increase costs in big screens.   
3.4.2 3D Biomatrix hanging drop plates 
The hanging-drop plates have been hailed as the state-of-the-art in 
matrix-free spheroid technology. In theory they offer high-throughput 
formats, reproducible sizes and promise compatibility with standard 
assays and plate readers. The most popular manufacturers are InSphero 
[272] and 3D Biomatrix [257]. 
Both DAOY and VCR cells formed spheroids when seeded at various cell 
densities and the size of the spheroid was controlled by the number of 
cells seeded Figure 3-5 and Figure 3-6. 
  
Figure 3-5 Phase-contrast images of DAOY spheroids formed in hanging drops after 48h of 
culturing in hanging drops at different seeding cell densities. Left to right- 60 000 cells 
(800 μm); 30 000 cells (700 μm); 7 500 cells (400 μm), 3 750 cells (300 μm); Scale bar 
100 µm 
 
Figure 3-6 Microscope phase-contrast images of spheroids formed in hanging drops by the 
VCR cell line at two different concentrations. A-C (7 500 cells per well), D,E (3 750 cells 
per well). A- after 24h-numerous small spheroids, B- after 48h the spheroids are coming 
together and forming a 500 μm aggregate, C- After72h the aggregate is becoming more 
compact with well-defined edges; D- after 48h the cells have formed a single 240 μm 
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spheroid, E- after 72h the spheroid is compacting but size has remained the same; scale 
bars 100 µm 
The number of cells needed to form a spheroid with a diameter of about 
300-500 μm that has been reported to exhibit a hypoxic core deprived 
from nutrients was 3750 to 7500 cells per well [264]. In the first 24 hours 
cells formed multiple smaller spheroids (VCR) or loose aggregates (DAOY) 
which gradually rounded and united in a single spheroid by the second 
day. Further compaction of the spheroids and the formation of a well-
defined border were observed by 72h. The spheroids were harvested by 
purging the hanging drops with additional HBSS from the top of the plate, 
fixed, embedded in paraffin, sectioned and stained with haematoxylin and 
eosin H&E 
 
Figure 3-7 H&E stained sections of spheroids formed by VCR cells after 4 days of culture in 
hanging drop plates. A- Spheroid 300μm with lots of loosely packed cells in the periphery, 
scale bar 100µm. B- Spheroid (500μm) with a well-formed border and uniform packing 
throughout, scale bar 100µm. C- Spheroid (1500μm) with a very dense border and loosely 
packed core, scale bar 500µm. 
The H&E staining reveals that smaller spheroids (300 μm) in the initial 48h 
of culture have a higher number of loose cells in the periphery. These 
“free cells” could play an important part in metastasis by invading 
neighbouring tissues. With longer culturing periods the cells pack in a 
tighter formation and eventually develop a dense border which is an 
indication of a vital mechanism explaining the higher chemoresistance of 
cells in the core of the spheroid. That could be an additional mechanism of 
tumour cell survival apart from the resting phase hypothesis[257], [281]. 
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The encouraging results for the tumour cell lines led to attempts to culture 
the foetal neurospheres in the hanging drop plates as well. The normal 
cells did not merge together to form a single spheroid but produced a 
number of small spheroids instead. Although at higher concentrations 
some of the smaller spheroids united in a big one in the centre of the 
drop, there was still a number of small ones floating around the main 
spheroid. 
 
Figure 3-8 Phase-contrast microscope photo of foetal neurospheres seeded in the hanging 
drop plate. Despite the formation of a single (300μm) spheroid there were still a number of 
smaller spheroids within the same drop that did not merge with the main one. 
The mechanism of spheroid formation for the tumour and the normal cells 
appears to be different. The tumours form spheroids when their cells are 
close to each other by flocculating and secreting their own extracellular 
matrix. In contrast, the foetal brain cells form spheroids derived from a 
single mother cell and do not flocculate as readily. Even though 
neurospheres can merge, as exemplified by the big spheroid formed in the 
hanging drop, this happens much slower than it does in medulloblastoma 
cell lines. 
The failure of normal brain cells to form a single spheroid per well 
combined with the need for spheroid transfer to a normal plate-reader-
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compatible 96 or 384-well plate precluded to use of the hanging drop 
platforms for this project. 
3.4.3 Ultra-low attachment plates 
The landmark paper by Vinci et al[261] recommended the use of ultra-low 
attachment plates to grow spheroids in a reproducible medium- to high-
throughput manner.  
At the time of receiving the plates the VCR medulloblastoma cell line was 
deemed unsuitable for further development due to issues with etoposide 
sensitivity (see Sections 1.3.3.2 & 4.4) and doubts about origin raised in 
the literature[225]. The DAOY cell line was excluded because of its 
tetraploidy and number of genetic aberrations falling outside that of in 
vivo medulloblastoma[221]. The UW228-3 cell line was confirmed to be 
human and sensitive to etoposide[228] and was therefore taken forward 
in the next experiments. It was used as a model of the parent tumour in 
order to establish assay methodology and proof of principle. 
Both normal brain progenitor cells and UW-228-3 tumour cell lines formed 
one centrally positioned spheroid in each well of the round bottom 96-well 
plates. Single spheroid formation and cell survival were encouraged with a 
light centrifugation which brought the cells together. Centrifugation 
reduced cell loss and yielded viable spheroids within 24h with as few as 50 
and up to 40000 cells. Centrifugation is reported to encourage paracrine 
signalling and suppress apoptosis in the early stages of spheroid formation 
[282]. The spheroids were cultured for 72h before the first media change 
to allow for the formation of extracellular matrix and spheroid compaction.  
UW 228-3 medulloblastoma cells formed spheroids ranging from 92 µm 
(50 cells) to 840 µm (40 x 103 cells) in diameter and coefficient of 
variation CVdiameter ≤5% (n=6). The spheroids formed by NSCs were 
150 µm (200 cells) to 730 µm (40x103 cells) in diameter and CVdiameter 
≤4% (n=6).  The culture in ULA plates was quick and reproducible and did 
not differ much from a regular monolayer screen except for the fact that 
the spheroids were left for 3 days before drug addition. 
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Brain progenitor cells and tumours exhibited different size increases over 
the 7 day duration of the experiment (Figure 3-9Error! Reference source 
not found.A and B). Both cell types showed a similar relationship between 
seeding concentration and proliferation capacity. Very low seeding 
densities (50-100 cells/well) resulted in little growth, intermediate ones 
(1000 and 5000 cells/well for NSCs and UWs respectively) proliferated the 
most, while seeding high cell numbers yielded big spheroids whose growth 
was hindered by the constant volume of media and the geometry of the 
well. Similar findings have been reported by Mori et al. [282], who argued 
that paracrine enhancement of Notch signalling in intermediate sized 
spheroids is one of the reasons for their enhanced growth.    
The neural progenitors had grew faster at the conditions of the assay 
(Figure 3-9A). This can be explained by the composition of the NSC media 
containing EGF and bFGF, which stimulate the division of stem cells. The 
decreased proliferation of the tumour cell line can be a consequence of 
having a lower percentage of stem-like cells responsive to EGF and FGF 
within the tumour spheroids and lack of interactions with normal tissue, 
which could enhance tumour growth [248]. Nevertheless, tumour 
spheroids increased their volume to 270% of the spheroid volume at day 
1, showing a slow and steady growth pattern similar to the behaviour of 
tumours in-vivo which grow slowly rather than exponentially. 
Seeding densities of 10000 cells per well for the NSCs and 5000 cells per 
well for the UW228-3 cell line were seen as a good compromise in order to 
minimize the difference in growth rate (Figure 3-9C) between the two cell 
types, and yield similar spheroid size at day 3 (Figure 3-9D).  
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Figure 3-9. Growth curves for spheroids of normal progenitor and UW228-3 medulloblastoma cells. A and B- Spheroid volumes compared to day 1 in % 
for NSCs (A) and UW228-3 (B)  seeded at different cell densities per well. C-Increase in volume of NSC and UW spheroids seeded at 10 and 5 thousand 
cells per well respectively. C-representative light microscopy images of the spheroids formed by each cell type. Scale bar 100µm  
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Section 3.5  Assay validation in healthy spheroids 
Apart from investigating growth patterns, these initial experiments were 
used to probe the suitability of spheroid volume, metabolic activity and 
acid phosphatase activity to predict numbers of viable cells within 
spheroids of various sizes of both cell types. Spheroids were grown for 7 
days and their ability to reduce resazurin, acid phosphatase activity 
(performed on a second twin plate) and volume were determined as 
described above. Spheroids were dissociated and the resultant cell counts 
were plotted against assay response (Figure 3-10). 
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Figure 3-10. Volume, resazurin and acid phosphatase as methods to determine viability in 
NSC and UW228-3 spheroids. A. NSCs spheroids, diameter 200-800µm. B. UW228-3 
tumour spheroids, diameter of 160-700µm. Both cell types were grown as spheroids for a 
week and then probed for volume, metabolic and acid phosphatase activity. Spheroids 
were enzymatically dissociated and normalised assay response plotted against the number 
of cells per spheroid in order to compare the three assays. Normalised assay responses 
from three independent experiments were pooled together, plotted and the linearity of 
each method was examined 
3-D monocultures of foetal neurospheres and medulloblastoma cell lines 
 87   
  
 The graphs clearly show that for healthy spheroids, over the range of 
160-800 µm in diameter, volume correlates best with the number of 
healthy cells within a spheroid. As spheroids grow in size the cells in the 
core have less access to nutrients and oxygen, become firstly hypoxic and 
afterwards necrotic. Although the core of the spheroid becomes less 
populated the opposite is true for the periphery where a layer of densely 
packed cells is established [265], [283], [284]. This phenomenon can 
explain the relatively constant relationship between volume and cell 
number of the spheroids in this experiment. However this relationship will 
need to be confirmed and validated for every new cell type used and the 
relevant spheroid size as spheroids of >500 µm in diameter will have a 
more pronounced necrotic core and deviate from linearity [274], [285]. 
With the use of our specially written ImageJ macro (Supporting 
information macro S1) we were able to increase greatly the speed of 
image processing and facilitate the use of spheroid volume in rapid 
automated screens. The algorithm estimates spheroid volume using the 
area of the spheroid and fits the radius to that of an equivalent sphere. 
The spheroids do not need to be perfect spheres as the estimation is 
roughly valid for ellipsoids of width/length ratio up to 1.5 [263]. Moreover 
initial studies utilising the maximum and minimum Feret diameter and 
estimating the volume of an ellipsoid (data not shown) exhibited greater 
variation due to thresholding artefacts affecting automatic measurements. 
The macro is optimised for phase-contrast images and requires manual 
magnification calibration at line 6. However the code can be easily adapted 
to suit applications like fluorescence imaging by altering the thresholding 
mechanism and using additional macros distributed with the free Fiji 
version of ImageJ [286], [287]. 
Acid phosphatase activity correlated almost linearly with cell number and 
volume for UW228-3 and NSCs. As evident from Figure 3-10A, in healthy 
NSC cells volume and acid phosphatase can be used interchangeably as 
markers of viability. Moreover, the correlation coefficient was above 0.9 
for spheroids of both cell types indicating an excellent linear relationship. 
Although the APH method is faster and easier than photographing and 
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computing spheroid volume it requires lysing the cells and has to be the 
final assay in a high-content analysis program. 
The reduction of Resazurin, also known as Alamar Blue, by metabolically 
active cells was the final method for viability determination. Resazurin 
reduction was proportional to the number of cells within NSC and UW 
spheroids. However this method had a higher variability than volume and 
APH activity and the r2 values for Resazurin were the lowest of the three 
methods tested. Nevertheless, the Resazurin assay has the advantages of 
being non-toxic to the cells at the concentrations and time of exposure, 
can be used many times on the same cells and can also be multiplexed 
with other assays. Our initial concern with using Resazurin was that it may 
only detect metabolically active cells and miss hypoxic quiescent cells in 
the core of the spheroid. Cells in the periphery of the spheroid have good 
access to oxygen and nutrients and are actively dividing. Therefore their 
metabolism is much more rapid than the cells in the core of the spheroid 
where ATP levels have dropped to the minimum and metabolism is much 
slower [213], [288], [289]. In this way smaller spheroids were expected 
to be more metabolically active and appear more ‘alive’ than bigger 
spheroids which have a significant quiescent population [265]. This effect 
was observed in the NSC population (Figure 3-10A) and led to minor 
overestimation of viability for smaller spheroids.   
Apart from viability validation the growth studies were also used to select 
the seeding concentration for both cell types that resulted in spheroid 
diameter at day 3 of around 400-500 µm, namely 5000 and 
10000 cells/well for UW228-3 and NSCs respectively. The size was chosen 
because it fits the requirements for gradients of oxygen, nutrients and 
proliferation rate that are essential for a biorelevant spheroid screen 
[264].  
Additionally, Z-factor, Signal window and Coefficient of variation were 
compared for the assays in both cell types at each seeding cell density 
after 7 days of culture in order to determine their suitability for high 
throughput screening. Both the Z-factor and Signal window take into 
account the variability of empty (media-only) control wells as well as the 
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sample wells and provide a useful benchmark for hit-detection fitness in 
high-throughput screening (HTS). The coefficient of variation provides 
information on assay variability and can uncover pipetting problems 
especially at low seeding densities. 
 
Figure 3-11 Assay characterisation using Z-factors, Signal Window (SW) and Coefficient of 
variation (CV) for UW228-3 cells. Z-factors (A-C), Signal window (D-F) and Coefficient of 
variation (G-I). Acceptance criteria Z-factor>0.4, SW>2 and CV<20% were colour coded 
so that values above the green lines meet quality criteria whereas values above the red 
line fail. Dotted line at 5000 cells represents chosen seeding density for spheroid 
cytotoxicity screening 
In UW228-3 cells (Figure 3-11) spheroid volume determination provided a 
sufficient working range for HTS when spheroids were seeded at density 
higher than 1000 cells/well. This high sensitivity is due to the ability of the 
thresholding macro algorithm to recognise empty wells and report them as 
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such. Although the APH and Resazurin assays were also able to detect 
spheroids at the 1000cells/well, they excelled in all indicators at seeding 
concentration of more than 5000 UW228-3 cells/well. This along with the 
biorelevance arguments discussed above showed that seeding density of 
5000 cells/well or more is optimal for cytotoxicity screening. 
 
Figure 3-12. Assay characterisation using Z-factors, Signal Window (SW) and Coefficient of 
variation (CV) for NSCs. Z-factors (A-C), Signal window (D-F) and Coefficient of variation 
(G-I). Acceptance criteria Z-factor>0.4, SW>2 and CV<20% were colour coded so that 
values above the green lines meet quality criteria whereas values above the red line fail. 
Dotted line at 10000 cells represents chosen seeding density for spheroid cytotoxicity 
screening 
Neural stem cells produced spheroids with narrower size distribution and 
could be used in screens at even lower seeding densities (Figure 3-12). 
Volume and APH had generally higher Z-factor and SW than Resazurin as 
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their signals had lower variability. All parameters were within specification 
for spheroids initially made up of more than 2000 cells. Nevertheless a 
seeding density of 10000 cells/well was chosen as it produced 
neurospheres of similar size to the tumour spheroids at the day of drug 
application. 
 
Section 3.6  Assay validation in spheroids treated with 
etoposide 
Plate uniformity was assessed prior to etoposide addition at day 3. 
Spheroid uniformity was evaluated by the variability of spheroid diameter 
and volume along the whole plate in at least three plates on different 
dates (Figure 3-13). 
 
Figure 3-13 Plate uniformity assessment for volume and diameter of spheroids before and 
after outlier removal. NSC and UW populations are marked according to experiment 
number. All populations, with the exception of UW1, had a normal distribution according to 
the D’Agostino-Pearson omnibus K2 test after outlier elimination using Prism’s ROUT 
algorithm. 
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The mean diameter for UW spheroids was 422 µm with a coefficient of 
variation of 4-7% between 7 plates of 33 to 66 spheroids each. NSC 
spheroids had a mean diameter of 463 µm and CV of 3% between 3 plates 
containing 66 spheroids each.  The coefficient of variation for volume 
measurements was around 9% for NSC and ranged from 6 to 22% for 
UW228-3 cells with only one plate exceeding the 20% limit. Several 
outliers were identified and were attributed to deficiencies in pipetting 
technique and equipment. Therefore the GraphPad Prism ROUT method 
was used to eliminate outliers before testing for normality of volume 
distribution. The D’Agostino-Pearson omnibus K2 test showed a normal 
distribution of the cleaned volume data in all but one case. Even without 
outlier elimination a one-tailed t-test, for a sample of 6 replicates from the 
plate population, with α=0.05 will have 1-β=74% power to detect a 20% 
viability drop in UW228-3 cells (CV 15%) and 99% power to detect the 
same viability drop in NSC cells (CV 9%) [290]. 
After the plate uniformity assessment, the tissues were exposed to 
etoposide for 48h, followed by a 48h period in plain media for the drug 
effects to fully manifest. The dosing scheme was chosen with the intention 
to model the delivery of a single dose of nanoparticles after surgery. Since 
the incision is closed after surgery, redosing of nanoparticles would not be 
possible in the absence of additional surgical interventions. Moreover, 
submicron drug delivery systems have high surface-to-volume ratio and 
often exhibit rapid drug release. That is why drug exposure was limited to 
48h to model the predicted optimal timeframe for drug release from the 
nanoparticles. Additionally, other researchers have determined the 
stability of etoposide in cell culture media to be 48h, maintaining levels 
above 90% of the nominal etoposide concentration[291]. The second 48h 
drug-free period was chosen because the toxic effects of topoisomerase 
inhibitors do not normally manifest immediately. The affected cells need to 
accumulate a critical number of single and double strand breaks before 
they go into apoptosis and die. The total duration time of the screen was 7 
days and spheroid viability was determined using volume, acid 
phosphatase, metabolic activity and dissociated spheroid cell counts 
(Figure 3-14). 
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Figure 3-14 . Dose-response curves for UW228-3 (5000cells/well) and NSCs 
(10000cells/well) spheroids exposed to increasing concentrations of etoposide. Normalized 
viability is expressed as volume, resazurin reduction, acid phosphatase activity and cell 
number. Data is pooled from at least three separate experiments. 
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Figure 3-15 Phase-contrast image of a representative plate of UW spheroids treated with 
etoposide. Each column represents 6 replicate spheroids at the same condition. Left to 
right untreated control, and half-decimal-log concentrations of etoposide 0.03-300µM.  
The dose-response curves for UW228-3 (Figure 3-14A) spheroids 
produced by reduction in volume (Figure 3-15), metabolism or acid 
phosphatase activity were very similar and the three assays appeared to 
be equally suited for a spheroid screen in this cell line. Viability 
determined by cell counts for dissociated spheroids was comparable to 
that calculated using the other assays up to drug concentrations affecting 
spheroid health. At pharmacologically active concentrations there appears 
to be an overestimation of cell death after subjecting the spheroids to 
enzymatic and mechanical dissociation. Apoptotic and stressed cells may 
be more sensitive to the dissociation process and that could be the reason 
behind the fast drop in viability estimated using cell numbers. Regarding 
phosphatase activity it is worth noting that at high drug concentrations the 
APH assay fails to detect any enzymatic activity in UW228-3 cells, whereas 
there was still some signal present from the Resazurin assay.  
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Figure 3-16.Phase-contrast microscope image of UW228-3 spheroids exposed to increasing 
concentrations of etoposide. Panels A-C show intact UW228-3 spheroids with a halo of 
debris and dead cells at high drug doses impeding image analysis. Panels A’-C’ capture the 
same UW228-3 spheroids after PBS rinse. Controls were cultured in plain media, 
concentration of etoposide is given in µM and scale bar applies for all images. 
Initially the volume measurements for the tumour cell line at high drug 
doses were thought to be less reliable because the spheroids were 
surrounded by a cloud of debris and dying cells and it was not possible to 
distinguish the dead cells from the living ones without bias (Figure 3-16, 
panels A-C). Similar observations about the difficulties in volume 
measurements have also been reported by Friedrich [265]. However it 
was soon apparent that the debris and apoptotic cells can easily be 
washed out by exchanging the media twice with PBS (Figure 3-16, panels 
A’-C’). This greatly facilitated automated image analysis by improving the 
speed and accuracy of spheroid size measurements.  
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Figure 3-17 Phase-contrast image of a representative plate of NSC spheroids treated with 
etoposide. Each column includes 6 replicate spheroids at the same condition. Left to right 
untreated control, and half-decimal-log concentrations of etoposide 0.03-300µM. 
 
Contrary to the UW228-3 monophasic response, foetal brain tissue-
derived NSCs (Figure 3-14B, Figure 3-17) had a biphasic etoposide dose-
response curve. Initially there was a very sharp decrease in viability down 
to 50% at concentrations approaching 0.3 µM. Beyond this concentration 
point the viable cell fraction decreased only slightly when etoposide 
concentrations were increased from 0.3 to 3 µM. This was followed by a 
moderate decrease in viability down to around 5% at the highest drug 
concentrations. The biphasic behaviour of the NSC spheroids is a sign that 
there are at least two distinct cell populations within the microtissues. The 
gradients of nutrients and oxygen can trigger differentiation into glia and 
neurons which would have a different sensitivity to the parent stem cells. 
Moreover, there could be an indigenous population of partially-
differentiated progenitor cells in the foetal brain tissue which have a 
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limited division potential and differ from the true stem cell phenotype 
[231], [284].  
Viability estimates for NSC spheroids using the suite of four methods 
varied more than those for the UW228-3 cell line. That was probably due 
to the heterogeneous character of the tissue derived from foetal brains. 
Viability estimates using cell number and volume were of similar 
magnitude and were both generally lower compared to the values 
determined by resazurin and APH. Despite the fast drop in spheroid 
volume and cell counts, the metabolic activity as determined by resazurin 
reduction, dropped more slowly. The innate features of apoptosis, which 
starts with cell shrinkage while metabolic activity is not impaired, can give 
a possible explanation to these differences. Treatment with increasing 
concentrations of etoposide would push some of the cells in the spheroid 
towards apoptosis, leading to cell shrinkage and reduction in spheroid 
volume. It could also make the affected cells more sensitive to enzymatic 
digestion and the effects of mechanical agitation, leading to cell loss upon 
spheroid dissociation. However the apoptotic cells within intact spheroids 
would remain metabolically active, continue to reduce Resazurin and 
register as alive in the assay. Similarly to our findings, Chan et al [292] 
noted a difference in viability estimation between various cytotoxicity 
assays being developed for high throughput screening in 2-D assays. In 
some experiments using etoposide they showed that ATP and metabolism-
based assays underestimated cytotoxicity compared to cell number. They 
have attributed this to increase in cell volume and mitochondrial mass 
relative to cell number. Other studies have also demonstrated increased 
ATP content and mitochondrial activity during etoposide treatment and 
have linked this with apoptosis [293], autophagy [294] or AMPK activation 
[295]. The viability measurements using acid phosphatase enzymatic 
activity against PNPP were the highest of all four assays. That was most 
pronounced for high etoposide concentrations between 10 and 100µM 
where the fraction of apoptotic cells was the highest. Acid phosphatase is 
a digestive enzyme and has a role in cell death, apoptosis and autophagy 
[296]. The extensive cell kill induced at high etoposide concentrations 
could be triggering an increase of specific and non-specific phosphatase 
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activity in stem cells. The biphasic curve also hints at the possibility that 
there are two cell populations with different drug sensitivity and enzymatic 
activity. The first population which is very sensitive to etoposide has a 
relatively low phosphatase expression and a more resistant second 
population which expresses higher APH activity.  
 
Figure 3-18 Confidence intervals for etoposide IC50 determinations for different assays in 
UW228-3 cells. The 95% confidence intervals (CI) for each experiment were plotted 
against the geometric mean (black dotted line) and 95% CIs (green dotted lines) for all 
individual experiments for each assay. 
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Figure 3-19. Methods of combining different IC50 determinations between experiments for 
UW228-3 cells. Data was subjected to an F-test to find a common curve that described all 
runs (Prism’s F-test); The mean of logIC50 values was used in the geometric mean method 
and combining all normalised readings from different runs together was employed in the 
pooling method. Error bars are 95% Confidence intervals. The * in Volume F-testing means 
that the calculated IC50 values were statistically different between runs according to the 
extra-sum-of-squares F-test. 
The precision of the four assays for UW228-3 cells Figure 3-18) was 
assessed by comparing the 95% confidence intervals (CIs) for each 
experimental IC50 determination to the geometric mean values for all 
IC50 determinations along with the associated 95% confidence interval of 
the mean. The geometric mean of all experiments was calculated using 
the logIC50 values which have a distribution closer to normal as opposed 
to IC50 results which tend to be skewed [297]. This approach was chosen 
after comparing it to the methods of pooling the data into one or using 
Prism’s extra-sum-of-squares F-test to compare IC50 values of dose-
response curve fits [279] (Figure 3-19). It was deemed useful as a 
graphical aid to assess between-run variability and gave slightly broader 
CIs as seen in the case for Cell counting for example. Overall, resazurin 
and volume assays were superior to APH and direct cell counting. Although 
estimating viability using volume exhibited the smallest confidence 
intervals for the individual measurements, the IC50 values between runs 
varied more than those for resazurin. Moreover resazurin had the 
narrowest 95% confidence interval for the mean of the five separate runs. 
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Figure 3-20. Confidence intervals for etoposide IC50 determinations for resazurin and 
Volume in neural stem cells. The 95% confidence intervals (CI) for each experiment were 
plotted against the geometric mean (black dotted line) and 95% CIs (green dotted lines) 
for all individual experiments for resazurin and Volume determinations. 
For assay precision in neurospheres, only Resazurin and Volume gave 
IC50 values that were reproducible and had reasonable 95% confidence 
intervals varying less than one order of magnitude (Figure 3-20). Volume 
determinations yielded the tightest CIs with the highest level of precision 
out of the four assays. The determinations of IC50_1 and IC50_2 from 
APH and Cell counting varied over two orders of magnitude and were not 
included in the graph. The high level of variability in cell number 
estimation is due to the extra number of steps required to dissociate the 
spheroids and the possibility for cell loss during the process of mechanical 
and enzymatic cell separation. The APH assay, on the other hand, may 
have been affected by non-specific substrate cleavage at high etoposide 
concentrations leading to overestimation of viability and poor non-linear 
regression fits.  
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Figure 3-21. Z-factors in cytotoxicity tests for Volume- A and B; Acid phosphatase- C and 
D; and Resazurin- E and F. 
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Figure 3-22 Coefficient of variation for different assays of etoposide treated plates. A and 
B- Volume; C and D-APH; E and F-Resazurin. 
Additionally, signal uniformity assessment was performed on all etoposide 
treated plates to determine variability at each concentration. This test is 
similar to the signal variability assessment in the NCAT’s Assay guidance 
manual [278] but instead of only using high, medium and low signal 
points we have used the whole dose-response curve to determine Z-
factors (Figure 3-21) and Coefficient of Variation (Figure 3-22). The Z’-
factors of all three assays were higher than 0.5 for the medium-only 
control wells and remained above the threshold of 0.4 even up to the IC50 
concentration of 3 µM. This shows that the assays are well within their 
optimal working range for high-throughput screening at viabilities down to 
50%. Although normalising the data did not affect the results of non-linear 
regression as described by Motulsky and Christopoulos [279], it was found 
to change the CV of the measurements and therefore CV calculations were 
done on the raw data before normalisation. CV was below 15% for most of 
the spheroids on the dose-response curve for APH and Resazurin assays. 
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Volume had the lowest variability at low concentrations of etoposide, 
closely followed by the APH assay. However, the variability of volume 
measurements increased significantly in the wells where cell death was 
predominant (30-300 µM) making volume measurements less reliable at 
high etoposide concentrations despite the washing procedure. It is worth 
noting that despite the low CV% of the APH assay compared to Volume 
determinations and Resazurin, the precision of the APH IC50 fits was 
generally lower. 
Overall, volume measurements were the best method to study etoposide 
activity in foetal brain tissue closely followed by Resazurin reduction. 
Volume measurement sensitivity was greatly improved by washing off 
debris and dead cells with PBS similarly to the UW228-3 cells (Figure 
3-23).  
 
Figure 3-23.Phase-contrast microscope images of NSC exposed to increasing 
concentrations of etoposide. A-C spheroids before PBS wash. A’-C’- the same spheroids 
after PBS wash. Control is grown in plain media, concentrations of etoposide on drug 
treated spheroids shown in µM, scale bar applies to all panels. 
Spheroid size reduction and metabolic activity determination complement 
each other as they use different mechanisms to estimate viability and can 
paint a fuller picture of spheroid health. When the rate of volume decrease 
is slower than the change in metabolic activity it would suggest that the 
proportion of dead cells, within the spheroid, is influencing the volume 
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reading or that cells increase their volume due to treatment. However, a 
faster rate of volume decrease compared to resazurin reduction would 
indicate stress-induced cell shrinkage without loss of metabolic activity. 
This is even more important in the context of impaired functionality of 
normal tissue. Often changes in cell volume will precede any other marker 
of viability indicating a nonspecific insult to baseline cell performance. 
On the other hand, a proportion of larger cells with increased metabolic 
activity at intermediate levels of etoposide, as described by Chan et al 
[292] may be present in our neurospheres assay causing an 
underestimation of cytotoxicity in the case of volume and resazurin. 
Nevertheless viability estimates for volume and cell numbers were not 
statistically different for the most part of the dose-response curve. While 
some cells in the spheroids could increase in volume, others may shrink 
due to apoptosis and yet another group would detach from the spheroid 
bringing volume estimates for viability closer to cell numbers. 
Although live cell counts can be viewed as the “gold standard” for viability 
determinations in 2D, the extensive procedure for spheroid dissociation 
introduces variability outweighing  the benefits of accuracy. Therefore, 
based on the lower variability of IC50 measurements and the similarities 
with actual cell numbers, in cases dealing with a new drug delivery 
strategy for a particular drug, volume would be a superior assay able to 
distinguish smaller differences in IC50s. 
Section 3.7  Conclusions 
Three-dimensional human cell culture is a useful tool that can help narrow 
the gap between preliminary in vitro studies and in vivo experiments 
required for drug development. Spheroids were cultured just as easily as 
monolayers in 96-well ultra-low attachment plates and a suite of assays 
was employed to probe their viability.  
The open source ImageJ macro can automatically measure whole batches 
of spheroids and record the results both numerically and as an image. 
Spheroid volume was shown to be an excellent predictor for the number of 
viable cells in healthy spheroids. It can also be used as a reference 
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method for cytotoxicity assays where the normalized volume readings are 
compared to other ways of estimating cell health.  
In this respect, the acid phosphatase assay was tested and its linear 
response to cell number in medulloblastoma spheroids of 160-700µm 
validated. It is a simple, quick method for viability determination that does 
not require any expensive ingredients and is high-throughput compatible. 
However, it relies on lysing the cells in question and needs to be the final 
assay in a high-content screening chain.  
The third assay tested, resazurin reduction, does not have these 
shortcomings because it is not toxic to the cells in the concentrations and 
exposure times used. Additionally, it can be performed multiple times and 
coupled with other studies. The difference in metabolic rate between the 
cells in the periphery and the middle of the spheroid can account for the 
lower r squared values of resazurin data fit compared to the other two 
methods. Although it appears inferior to volume determination and APH, 
we have demonstrated that metabolic activity can reliably be used in 
cytotoxicity screens despite its perceived limitations. An interesting recent 
study has shown some of the constraints of resazurin diffusion into colon 
cancer spheroids forming tight junctions[298]. While Walzl et al. have 
concluded that the resazurin assay is unsuitable for viability 
determinations in these cases, they have found an easy way to circumvent 
that problem by incubating the spheroids with ethylene glycol tetraacetic 
acid. Intriguingly, the authors have reported that cytostatic compounds 
could be distinguished from cytotoxics in colon cancer models using 
resazurin. This differentiation was accomplished by combining spheroid 
morphology and resorufin fluorescence in the absence of tight junction 
disruption. 
The optimal seeding densities for both cell types were determined by 
biological considerations for spheroid size and gradients and were also 
benchmarked for Z-factor>0.4, Signal window>2 and Coefficients of 
variation<20%. The suite of assays was performed on the same spheroids 
and the results compared and validated against the number of cells in a 
spheroid using both healthy tissue and spheroids exposed to a cytotoxic 
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drug. Plate uniformity was examined for spheroid volume at day 3 and 
signal variability was assessed for volume, resazurin and APH assays 
during the cytotoxicity screen. After comparing the precision of IC50 
determinations for all assays, cell volume and resazurin were found to 
perform better than APH and cell counts for both cell types. As volume, 
metabolism and acid phosphatase activity can all be influenced by 
cytotoxic drugs in a different manner, multiplexing those assays is the 
best way to get the true picture of cellular response.  
Etoposide sensitivity of the UW228-3 medulloblastoma cell line was carried 
out in parallel with human foetal brain tissue derived stem cells (NSC) in 
order to have a comparison with cells representing human brain tissue. 
While the tumours exhibited a normal four parameter logistic dose-
response curve, the NSCs had a biphasic response. The most likely 
explanation for this data is the presence of two sub-populations of cells 
within the neurospheres with a different sensitivity towards etoposide. The 
first sub-population had a low acid phosphatase activity and was more 
susceptible towards cytotoxic action, whereas the second one had a higher 
APH activity and was more resistant to topoisomerase inhibitors. The 
foetal NSC cells would be expected to have a relatively high proportion of 
stem cells[204]. Under 3D culture conditions and the associated gradients 
of oxygen and nutrients the population of early progenitor cells can 
differentiate into late progenitors, neurons and glia which would have 
different rates of division and different sensitivity to etoposide. The faster 
dividing and more sensitive cell population is probably the less-
differentiated one. Those undifferentiated cells are responsible for the 
growth, development and repair in vivo. While they make up a higher 
proportion of the brain in childhood when the brain is still growing and 
developing, they are confined to specific locations in the adult brain and 
have a supportive role. Establishing the proportions of stem-like, neural 
and glial cells that make up the neurospheres and how those change 
during etoposide exposure would bring greater insight into the off-target 
effects of topoisomerase II inhibitors. Furthermore, the relative cell type 
proportions in the neurospheres could be influenced by changes in the 
media, such as EGF and FGF withdrawal that would promote progenitor 
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differentiation into neurons and glia. Nevertheless, foetal brain tissue as a 
whole was more sensitive to etoposide up to concentrations of 5-10 µM 
when the neurospheres’ slow decrease in viability was surpassed by the 
sharp decline in tumour cell survival. This is a biorelevant concentration 
that has been established to be tolerable in humans thereby inferring 
some limited selectivity of free etoposide [299].  
Although etoposide is not generally regarded as a neurotoxic drug [121] 
there are reports which have demonstrated neurotoxicity in mice after 
blood-brain barrier disruption [300]–[302]. The heightened sensitivity of a 
sub-population of the neurosphere cells to etoposide can be explained by 
the presence of growth factors in the media which limit differentiation and 
stimulate division. In the normal human brain in vivo, only a small 
percentage of the available neural stem cells proliferate whereas the 
others are quiescent and may be spared from the effects of the cytotoxic 
drugs [303], [304]. Nevertheless this study suggests that free etoposide is 
not discriminating between actively dividing tumour and normal cells. 
This Chapter has established a quick and reliable way to culture and 
analyse neural progenitors and tumour cells in 3D allowing to probe their 
relative sensitivity to chemotherapy. The next step was to bring both 
tissues together in a single co-culture model of medulloblastoma and 
analyse the viability of each cell type separately.  
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Chapter 4.  Co-culture model of medulloblastoma 
Section 4.1  Introduction 
This chapter presents the development of an advanced co-culture model 
of medulloblastoma. Employing cultures of both normal and tumour 
tissue provides information for the relative safety and efficacy of 
treatment and can be used to rank formulations according to their 
therapeutic safety ratio. 
It builds on the model from the previous chapter by including the 
interaction between normal and tumour cells. This tumour-host 
interaction  has been reported to influence tumour gene expression, 
growth, enhance vascularisation and modulate tumour sensitivity to 
chemotherapy[246]–[248]. Including a normal tissue component was 
proven to be vital in the successful development of a lung cancer 
model[305]. Moreover, spheroid co-cultures have been used to 
demonstrate differential response to local intravesical treatment in 
bladder cancer [306], [307]. The medulloblastoma model described here 
was created with the intention to evaluate the relative uptake and 
cytotoxicity of drug-loaded nanoparticles compared to free drug in future 
experiments. In order to accomplish this aim, a reliable method to tell 
apart and quantify each population separately had to be established. 
There are a number of methods that can be used to distinguish between 
different populations of cells cultured together in co-cultures. Specific 
antigens can be employed [307], [308], cells can be genetically modified 
to express fluorescent proteins [309], [310] and fluorescent dyes can be 
utilised for medium-term cell monitoring [311]. This method was 
developed with primary tissues in mind where the increased 
heterogeneity is thought to better reflect the true nature of tumours. 
However, the diversity can also hinder the discrimination between the 
normal and tumour population.   
Medulloblastoma is an embryonal tumour that shares many antigens with 
developing neural progenitor cells [251], [312]–[315]. Moreover, 
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medulloblastoma is made up of least four clinically and molecularly 
distinct types of tumours [13]. There appear to be further differences 
within subgroups [17], [22] as well as intratumoral heterogeneity 
especially after treatment with radiation and chemotherapy [23]. The 
combination of common antigen presentation and disease heterogeneity 
precluded the use of specific antibodies to distinguish between developing 
brain tissue and the tumour cells 
Another option was to use genetic manipulation to stably express a 
fluorescent protein into each of the cell populations[309], [310]. This 
usually involves introducing foreign genetic material into the cells and 
then selecting for the clones with favourable expression of the product of 
interest. A possible complication could arise if certain viruses 
(e.g. lentivirus) were to insert their sequence next to important genes 
and change cell behaviour. However, the main concern was that by 
artificially selecting the most highly fluorescent clones, the heterogeneity 
of primary tissues would be lost. 
Therefore, a procedure of temporarily marking the cells with fluorescent 
dyes, which would not affect their viability was chosen as the most 
suitable method. Supravital dyes are compatible with primary tissues and 
can be used to stain heterogeneous populations of cells. They employ a 
simple, universally applicable marking procedure and have no 
requirement for the presence of specific cellular antigens. The most 
common strategies for long-term supravital fluorescent cell labelling 
involve either marking the cell membrane with lipophilic carbocyanine 
dyes [316], or preferential cytosolic protein marking with amine-reactive 
compounds [317]. Nuclear staining dyes like Hoechst 33342 were not 
considered because of their reported DNA interaction and short-lived 
labelling [318]. 
Although the membrane-incorporating carbocyanine dyes, like DiI, have a 
proven track record of in neuron labelling their fluorescence staining can 
often diminish before analysis [319] and dye transfer to the nearby cells 
has been reported [320]–[322]. CM-DiI is a second generation 
carbocyanine dye which claims better retention due to the chloromethyl 
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group. The halogen reacts with thiol groups on membrane proteins and 
peptides and ensures prolonged stability and aldehyde fixability of 
stained cells. CellTracker Violet (BMQC) is also thiol-reactive but targets 
mainly the sulfhydryl groups of cytoplasmic glutathione.  
The amine-reactive dyes have been reported to be superior in peak 
resolution and non-specific dye transfer compared to the membrane-
staining dyes [323]  CDCFDASE is the 2,7-dichloro derivative of CFDA SE 
[324] which is less susceptible to photobleaching and pH fluctuations. 
Both CDCFDASE and CellTrace Violet share the same mechanism for 
marking the cells- acetate groups allow the molecules to cross the cell 
membrane and are subsequently cleaved in the cytoplasm. Afterwards 
the succinimidyl moiety reacts with amino groups of cytosolic proteins 
and labels the cells for about 5-8 cell divisions [325]. 
A number of imaging and analytical techniques can be used to 
characterise the co-cultures and quantify the number and health status of 
the labelled cells. Microscopy techniques offer the opportunity to image 
the intact spheroids and reveal the spatial distribution and interaction 
between both cell types. However, confocal microscopy is limited by the 
penetration depth of short wavelength photons and can cause 
considerable tissue photobleaching. For example, it has been reported 
that confocal microscopy can only achieve 50-100 µm penetration in 
tissues [326]. In contrast, multiphoton microscopy uses longer 
wavelength photons which can penetrate deeper into the spheroids. 
Moreover, multiphoton microscopy focuses the energy of both photons at 
a single focal point limiting integral tissue exposure and 
photobleaching[327]. Both microscopy techniques are limited in the 
number of fluorophores they can analyse and spectral overlap can be a 
significant problem. 
Flow cytometry circumvents the abovementioned obstacles by 
illuminating the cells with light from different lasers and detecting the 
emitted fluorescence in a number of separate channels. In multicolour 
flow cytometry experiments the cells pass sequentially in front of 
different lasers, the fluorophores are excited and the emitted light is 
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detected by a set of detectors for the laser. Afterwards they move on to 
the next laser, where the process is repeated without overlap between 
the two lasers. Notable shortcomings of flow cytometry are that it does 
not show the organisation and distribution of cells within the spheroid 
and can suffer from dissociation-related cell loss especially after drug 
treatment. However, flow cytometry has a larger dynamic range and is 
less susceptible to fluorescence interference. It also allows the use of 
more colours and provides superior data handling tools compared to the 
analysis of multiphoton images. Hence it was the preferred mode for 
normal brain and tumour population quantification and determination of 
cellular health status.   
Section 4.2  Materials and methods 
4.2.1 Materials: 
CellTrace Violet, the chloromethyl derivative of DiI (CM-DiI)- 1,1'-
dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine, CellTracker Violet 
(BMQC- 2,3,6,7-tetrahydro-9-bromomethyl-1H,5H-quinolizino(9,1-
gh)coumarin), CellTracker CMPTX  and 5-(and-6)-carboxy-2´,7´-
dichlorofluorescein diacetate succinimidyl ester (CDCFDASE) were 
supplied by Invitrogen (Paisley, UK). 
Annexin V-Allophycocyanin (Annexin-APC, 20X solution), propidium 
iodide (PI) and 7-Aminoactinomycin D (7-AAD, 50µg/mL) were purchased 
from Ebioscience (Hatfield, UK). 
4.2.2 Cell lines and culture 
UW228-3, VCR and NSC cells were cultured as described in Chapter 3  
4.2.3 Cell label optimisation experiments 
Cell marking optimisation and label selection was done as described in 
Section 2.6. Initial experiments, before the introduction of ultra-low 
attachment plates were performed in non-adherent flasks.   
4.2.4 Co-culture formation 
Co-culture model of medulloblastoma 
 112   
  
Co-culture spheroids were established by plating a homogenous mix of 
fluorescently labelled tumour and normal brain cells (200 µL, 3500 
cells/well from each type) as a single-cell suspension in ULA plates at the 
same time. Co-culture spheroids formed in 24h and were cultured for 7 
days, exchanging with fresh media (150 µL) on days 3 and 5.   
4.2.5 Spheroid viability monitoring 
Spheroid growth and metabolic activity were monitored as described in 
Section 2.5 with the omission of the acid phosphatase assay. 
4.2.6 Multiphoton confocal microscopy 
Spheroids were fixed using paraformaldehyde solution (4%) after 
washing twice with PBS (150 µL). The spheroids were stored in the plates 
at 4˚C in PBS protected from light. Imaging was done by placing the 
spheroids on top of a glass slide along with 20 µL of PBS. Zeiss 
LSM510NLO confocal multiphoton microscope was used with a Plan-
apochromat 20x/0.8 objective and 800nm excitation wavelength. Images 
were later processed using ImageJ by auto-adjustment of brightness and 
contrast, followed by creating an average intensity Z-projection. 
4.2.7 Cytotoxicity screen 
Labelled spheroid co-cultures were seeded in ULA plates and exposed to 
increasing concentrations (0.3-100 µM) etoposide on day 3. Etoposide 
was replaced with fresh media on day 5 and analysed on day 7. Controls 
included in the screen were unstained single cultures of UW and NSC 
cells, unstained co-culture, single colour controls and labelled co-culture 
control with media and DMSO (0.2%). Six spheroids per condition were 
analysed on each plate. Brightfield images of the cultures were used to 
determine the volume of the spheroids compared to untreated controls. 
The percentage of each population was estimated using flow cytometry.  
4.2.8 Flow-cytometry 
Spheroids were washed twice with PBS (150 µL/well), dissociated using 
Accutase (double concentrated, 50 µL/well) for 30minutes at 37 ˚C 
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followed by mechanical dissociation by repeated pipetting. The resultant 
single cell suspensions from six wells per condition were pooled together 
in a microcentrifuge tube, centrifuged (300g, 5min) and resuspended in 
Annexin binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl2 
pH=7.4; 50 µL). Dead and apoptotic cells were stained using 7-AAD 
(5 µL, 50 µg/mL) as per [328]. Early apoptotic cells were detected using 
Annexin V-APC (2.5 µL). After incubation for 15 minutes in the dark, 
further Annexin binding buffer (200 µL) was added and the cells stored 
on ice, protected from light were analysed within 2h. Flow cytometry 
experiments were done using a 14 channel MoFlo XDP cell sorter 
(Beckman Coulter) equipped with a three laser system (405, 488 and 
630 nm). CDCFDASE and 7-AAD positive cells were detected using the 
blue 488 nm laser and the 529/28 and 670/30 channels respectively. 
CellTrace Violet positive cells were excited with the violet 405nm laser 
and detected with a 450/65 filter. The Annexin V-APC positive apoptotic 
cells were excited by the red 630 nm laser and detected in the 670/30 
channel. Non-stained and single colour controls were included in each 
experiment. Data were analysed using the Weasel software package. 
Debris were identified and subsequently excluded by gating the Annexin 
V-APC and 7-AAD negative population on the Forward/side scatter dot 
plot and selecting for the particles with the lowest forward scatter values 
[329]. The MoFlo channel configuration (Figure 4-1) and dye emission 
and excitation maxima (Table 4-1) are summarised below: 
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Figure 4-1. MoFlo laser and filter setup. Please note that the cells pass in front of each 
laser separately 
Dye Excitation Emission Fluorescent Channel 
CellTrace   Violet 405 450 FL7 
CellTracker Violet 405 526 FL8 
CDCFDA SE 492 517 FL1 
CM-DiI 553 575 FL2 
CMPTX 577 602 FL3-4 
Cellular              viability                stains 
PI 488 647 FL3-4 
7AAD 488 670 FL4 
Annexin-APC 630 670 FL12 
Table 4-1. Excitation and emission maxima of the fluorescent labels employed in the 
experiments 
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4.2.9 Imaging flow cytometry 
Imaging flow cytometry using the Amnis Flowsight system was used to 
visualise the dissociated cells from the spheroid co-cultures. The following 
combination of lasers and detectors was employed (Table 4-2): 
Dye Function Excitation, nm Emission, nm 
CellTrace Violet Cell label (UW228-3) 405 Channel 7  (430-505) 
CDCFDASE Cell label (NSC) 488 Channel 2  (505-560) 
7-AAD Dead and apoptotic cells 488 Channel 5  (642-740) 
Annexin-V Early apoptotic cells 642 Channel 11 (642-740) 
Table 4-2. Dye combination and detection configuration used in the Flowsight imaging 
flow cytometer 
Non-stained and single colour controls were used to calibrate the 
channels and data were analysed on the AMNIS IDEAS Software.  
4.2.10 Data analysis and statistics: 
Raw data from volume determination, Resazurin reduction, and flow 
cytometry software were exported and analysed in MS Excel and 
GraphPad Prism 6. In label optimisation experiments, readings were 
normalised to the relevant unstained control (100%) and spheroid-free 
wells (0%). In cytotoxicity experiments, volume measurements were 
normalized so that untreated co-culture controls were assigned to 100% 
viability and media-only wells- 0% viability. Flow cytometry results for 
the proportion of normal brain cells and tumours were multiplied by the 
volume of each spheroid to estimate the surviving fraction of each cell 
type. Dose response curves were fitted using the four-parameter logistic 
equation in Prism, the top was constrained to 100% and the bottom to 
5%. Results are displayed as mean ± SD unless stated otherwise. There 
were n=6 replicates for each condition in each individual experiment and 
displayed data represent the mean of at least three independent 
experiments. 
Section 4.3  Stain selection considerations and 
experiments 
The cell labels included in the primary screens were CDCFDASE, CM-DiI, 
CellTracker Red-CMPTX, CellTracker Violet-BMQC and CellTrace Violet. 
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VCR and NSC cells were labelled with each stain and analysed after 
different number of days of culture in NSC-media in non-treated flasks. 
The initial dye selection experiments were done in the early days of the 
project when the ultra-low attachment plates were not yet employed and 
the medulloblastoma working cell line was still the etoposide-resistant 
VC312R. After marking and culturing the spheroids they needed to be 
dissociated in order to be analysed by flow cytometry. The initial 
experiments with Trypsin required a large number of mechanical 
dissociation steps (pumping up and down). The procedure had to be 
especially harsh to dissociate the tumour tissues with Trypsin 
concentrations reaching 1%, while foetal neurospheres required only 
0.1% of the digestive enzyme. Later experiments were performed using 
the marine-origin protease mixture Accutase. The process was much 
gentler when using Accutase, required less mechanical intervention and 
led to increased viability (data not shown). Nevertheless, the first 
experiments highlighted the importance of fluorescence signal overlap 
and demonstrated the toxicity of some stains. 
The data for the initial experiments with CDCFDASE, CellTracker Violet 
and CM-DiI for VCRs and NSCs are summarised in Table 4-3 and Table 
4-4. 
Dye 
CDCFDA 
SE 
CDCFDA 
SE 
CM-DiI CTV CTV CTV CTV 
Dye Concentration μM 5 5 5 10 20 30 40 
Dye media HBSS HBSS HBSS HBSS HBSS HBSS Media 
Seeded cells x106 0.2 1 0.5 1 1 1 1 
Time of culture, days 6 4 2 2 3 3 3 
Trypsin conc, % 1 1 1 1 1 1 1 
Formation of spheroids ++ +++ +++ +++ +++ +++ +++ 
Percentage of marked cells 86 94 99 71 73 85 71 
Table 4-3. Optimisation of cell staining for VCR cells labelled as monolayer and cultured 
as spheroid in non-treated flasks. The last row- percentage of cells brighter than control 
was the most important indicator of marking efficiency. The formation of spheroids was 
coded from none (---) to equal to control (+++). 
Table 4-3 shows that the percentage of labelled tumour cells was above 
85% for CDCFDASE and CM-DiI at levels as low as 5 µM. In contrast, 
CellTracker Violet (CTV) was not retained in the tumour population unless 
used at very high concentrations (30 µM), well above those 
recommended by the manufacturer (2.5-10 µM). The cell viability was 
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not affected by the marking procedure and was above 75% in all 
experiments. 
As seen by Table 4-4 CDCFDASE was the only label retained in the foetal 
neurospheres with percentage of cells brighter than the unstained control 
surpassing 95%. CM-DiI was not as effective, being retained in only 76% 
of cells, while CellTracker Violet (CTV) showed toxicity towards stem cells 
above 5μM concentrations. The toxicity was seen either as inhibition of 
spheroid formation or the induction of delayed apoptosis and cell death. 
Addition of media during staining, in order to mitigate the toxic effect of 
CTV, was attempted but this led to a decreased marking efficiency due to 
a possible reaction of the dye and thiol-containing ingredients of the 
media. 
Dye 
CDCFDA 
SE 
CM-
DiI 
CTV CTV CTV CTV CTV 
Dye Concentration μM 5 4 5 10 10 20 40 
Dye media PBS PBS PBS PBS media media media 
Seeded cells x106 2 2 2 2 2 0.6 1 
Time of culture, days 6 3 6 5 6 X X 
Trypsin conc, % 0.1 0.1 0.1 X 0.1 X X 
Formation of spheroids +++ +++ +/- --- +++  --- 
Percentage of marked cells 97% 76% 73% X 60% X X 
Table 4-4. Optimisation of cell staining for foetal neurospheres dyed as a single cell 
suspension and cultured as spheroids in non-treated flasks. The percentage of labelled 
cells and the formation of healthy spheroids were used to prioritise stains. X-indicates cell 
death. Spheroid formation compared to unstained control was coded from none (---) to 
equal to control (+++). 
The results shown in the tabular data suggested that tumours stained 
with CM-DiI and normal cells with CDCFDASE may constitute a possible 
combination. However, a careful examination of the spectral properties of 
both dyes revealed significant spectral overlap between the stains. 
Figure 4-2A shows a series of histograms plotting the distribution of 
fluorescence intensity of the unstained (control- blue) and stained (red) 
NSC cells. The unlabelled cells had a low basal fluorescence centred 
towards the left part of the graph. Marking the cells with CDCFDASE 
increased the fluorescence of the cells not only in the CDCFDASE channel 
but also in all channels of the blue laser (CM-DiI, PI and to a certain 
extent those for 7AAD) and even the CellTracker Violet channel. The 
CellTrace Violet channel and the AnnexinV-APC channels were the only 
ones not affected by the spectral spillover. The fluorescence interference 
could be mitigated using Weasel’s software compensation algorithms. As 
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seen in Figure 4-2B subtraction of 38% of the CDCFDASE signal from the 
CM-DiI channel was needed to decrease the spillover. 
The labelling of VCR cells with CM-DiI is shown in Figure 4-3. When 
compared to the unmarked cells- (A2) over 90% of the CM-DiI labelled 
cells- (B2) exhibit fluorescence brighter than the controls.  Subplot C 
shows the histograms of labelled (red) versus unlabelled (blue) cells. The 
fluorescence shift in the PI and 7AAD channels excludes the use of those 
viability markers with CM-DiI. A similar shift in fluorescence was not seen 
in the other channels of interest. 
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Figure 4-2. Histogram plots of control (blue) and CDCFDA SE (5µM) stained normal brain cells NSCs (red) before and after 35%software compensation in 
the CM-DiI channel. Fluorescent channels are named after dyes of interest that can be detected in them. A- before compensation. CDCFDA SE is spilling 
over in the CM-DiI, PI, and CellTracker Violet Channels. The spillover is less pronounced in the 7AAD channel and there was no channel cross-talk in the 
CellTrace Violet channel B-after 35% software compensation, the fluorescence in the CM-DiI channel is reduced 
A-before compensation B-after compensation 
NSC-CDCFDASE 
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Figure 4-3 Dot plots and histograms of control and CM-DiI (5µM) dyed samples of tumour VCR cells. A1- forward and side scatter plots for control tumour 
cells (VCR) A2- normal autofluorescence intensity of the control cell population in the CDCFDA SE (FL1) and CM-DiI (FL2) channels and statistical 
markers defining four quadrants-control cells (I), CDCFDASE (II), CM-DiI (III) and spillover (IV). B1- forward and side scatter plots for VCRs dyed with 
CM-DiI. B2- fluorescence of dyed VCR cells. All cells have been successfully dyed with CM-DiI and there is no spillover in the CDCFDA SE channel. C- 
histogram plots of control (blue) and CM-DiI dyed tumour VCR cells (red). Fluorescent channels are named after dyes of interest that can be detected in 
them. The CM-DiI fluorescence appears to spread over the 7AAD/PI channels and makes viability determination with these two dyes undesirable. CM-DiI 
does not interfere with the Sytox Blue, CellTracker Violet or the Annexin APC channels.  
I II 
III IV 
A1 B1 
A2 B2 
C 
Fluorescence intensity 
VCR -CM-DiI 
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The immediate conclusions from these initial experiments were that 
CellTracker Violet (BMQC) was toxic to the normal progenitor cells, CM-
DiI and CDCFDASE could not be used together and that CM-DiI had a 
pronounced fluorescence tailing in the red channels eliminating the 
options to use PI or 7-AAD. Based on these findings CMPTX was excluded 
from the screen due to its unfavourable fluorescence characteristics, 
namely being excited by green light and fluorescence in the red spectrum 
(Table 4-1). 
The combination of dyes chose for further testing and the respective 
fluorescent channels are given in Table 4-5: 
Component Dye Laser & Bandpass nm Excitation/Emission Max nm 
Cell type I Cell Trace Violet 405 (450/50) FL7 405/450 
Cell type II CFDA SE 488(530/30) FL1 492/517 
Necrotic 
7AAD 
PI 
488 (670/30)FL4 
488 (630/30)FL3 
546/647 7AAD 
535/617 PI 
Apoptotic Annexin- APC 633(670/30)FL12 650/660 
Table 4-5. Combination of dyes chosen for further development in labelling and analysing 
co-culture spheroids. 
Figure 4-4 shows the labelling of VCR tumour cells with CDCFDASE and 
CellTrace Violet and the determination of live and dead cells using PI. The 
first pair of dot plots in the left panel displays the unstained control 
before and after the addition of PI. A very small number of dead cells are 
seen as a separate fraction with higher fluorescence intensity in the PI 
channel in the second graph of the first pair. In contrast to the unstained 
controls, the CDCFDASE labelled cells in the second pair of dot plots had 
higher fluorescence in the CDECFDASE channel. Similarly to the control 
graphs, upon PI addition, a population of PI-positive cells was easily 
distinguishable. Likewise, the third pair of dot plots illustrates the 
marking with CellTrace Violet. Samples without PI had no cells positive in 
the PI channel which indicated lack of interference. The appearance of a 
PI positive population shows the baseline proportion of dead cells within 
the population. The right panel of Figure 4-4 demonstrates the feasibility 
of distinguishing a mix of VCR cells marked with CDCFDASE and CellTrace 
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Violet. Two separate populations are visible on the first dot plot without 
the addition of PI. The second dot plot with PI addition illustrates the 
health status for each cell population separately. Although the application 
of 15% software compensation in the PI, channel minimized the 
interference between CDCFDASE and PI, it was decided that the longer 
emission wavelength of 7-AAD would be more advantageous as it would 
require little post-processing compensation. 
The experiment illustrated in Figure 4-5 aimed to determine the 
prospects of combining CDCFDASE, CellTrace Violet and the viability 
markers 7-AAD and Annexin-V-APC together. The first row shows a series 
of unstained control samples before and after the addition of 7-AAD and 
Annexin-APC. Dead cells were identified as the 7-AAD positive population 
that appears after addition of the dye when compared to the control 
before dye addition. Similarly the Annexin-APC positive population after 
reagent addition was determined to be apoptotic. When both Annexin-
APC and 7-AAD were added to the unstained control, as seen in the last 
dot plot of the first row, both apoptotic (7-AAD- intermediate, Annexin-
high) and dead (7-AAD high, Annexin-high) could be distinguished from 
healthy cells (Annexin-low, 7-AAD-low). These results are in agreement 
with the findings of Zembruski[328] who reported that healthy cells 
exhibit low 7-AAD internalisation, apoptotic intermediate, while dead cells 
are very permeable to the dye. The second row shows the same 
progression of reagent addition for the CDCFDASE labelled cells. Similarly 
to the unstained control, cell viability could be determined using the 
viability stains and the 7-AAD and Annexin populations were not affected 
by the labelling. The same was true for the CellTrace Violet marked cells 
shown on the third row of the figure before and after the addition of 7-
AAD and Annexin. The middle panel of the third row shows the forward 
and side scatter characteristics of the cells and the gate used to exclude 
the debris from the samples.  In conclusion the use of 7-AAD and 
Annexin-APC to determine membrane permeability (death) and 
phosphatidylserine externalisation (apoptosis) was compatible with the 
marking procedure with CellTrace Violet and CDCFDASE. The cell labelling 
did not interfere with the fluorescent channels of the viability dyes and 
the combination was deemed successful. 
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Figure 4-4. Flow cytometry dot plots of VCR cells stained with CDCFDASE or CellTrace Violet (48h after staining) and their membrane permeability status 
determined by propidium iodide (PI). Fluorescent intensity axes are named after the stain of interest, sample names and reagents are stated inside the 
dot plot squares. Top row pair of plots in the left panel shows the distribution of intrinsic cellular fluorescence of unstained VCR cells before (left) and 
after (right) addition of (PI). Middle row shows cells marked with CDCFDASE. The left panel (without PI) shows that there was interference between 
CDCFDASE and PI (diagonal tailing of the population) that required the use of 15% software compensation. The right panel shows that it was still 
possible to distinguish dead (PI- positive) from living cells (PI-negative) despite the spillover. Bottom panel (CellTrace Violet marked cells) shows no 
interference with PI. Right part of the graph illustrates the separation of a mixed sample containing VCR cells marked with CDCFDASE and CellTrace 
Violet    
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Figure 4-5. Flow cytometry dot plots showing the compatibility of cell labelling and health status determination for VCR cells (48h after marking). Top row 
represents the fluorescence intensity distribution of unstained control samples in the CFCFDASE, CellTrace Violet, 7-AAD and Annexin-APC channels. 
Sample names and the addition of 7-AAD and/or Annexin-APC are indicated within the dot plot squares. 7-AAD positive cells are identified as D-Dead, 
while Annexin-APC positive cells are identified as A-Apoptotic. Samples stained with CDCFDASE and CellTrace Violet exhibited fluorescence brighter than 
controls. Staining with CDCFDASE or CellTrace violet did not interfere with viability determination. The bottom row, middle column Forward/Side scatter 
(FSC/SSC) panel shows the gating strategy for the experiments- particles with low 7-AAD/Annexin-APC fluorescence and low FSC/SSC were excluded as 
debris as per [329].  
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Figure 4-6. Dot plots showing the analysis of a mixture containing VCR cells marked with 
CDCFDASE and CellTrace Violet (48h after marking). A-fluorescence intensity dot plot of 
the green and violet channels. Both populations are very well separated from each other 
after 48h of culture and dissociation. B and C-dot plots showing fluorescence intensity in 
the labelling channels against Annexin-V-APC stain for apoptosis. D and E- analysis of 
apoptotic and dead cells for each population separately. 
The principal suitability of the combination of dyes for labelling and 
viability was established in a proof-of-concept experiment illustrated on 
Figure 4-6. VCR cells were labelled with CDCFDASE and CellTrace Violet 
and cultured separately for 48h as spheroids in non-adherent flasks. After 
dissociation the two cell suspensions were mixed and analysed using flow 
cytometry. When a dot plot was drawn by plotting the intensity of 
fluorescence in the CDCFDASE and CellTrace Violet channel (Figure 
4-6A), two separate populations of cells were easily distinguished. One 
exhibited strong fluorescence in the green (fluorescein) channel and the 
second one was highly fluorescent in the violet-blue (CellTrace Violet) 
channel. The health status of the separate populations could be 
determined by using a dot plot of Annexin-APC fluorescence versus the 
fluorescence intensity for each of the dyes (Figure 4-6B and C) or by 
gating each population separately (Figure 4-6D and E). By focusing on 
each of the two populations and drawing dot plots of Annexin vs 7-AAD 
fluorescence both apoptotic and dead cells could be easily distinguished. 
This feasibility study showed that the combination of four dyes could be 
employed to discern between two differently labelled populations of cells 
and determine their health status separately without overlap.  
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Section 4.4  Preliminary experiments with etoposide 
After the labelling procedure was established a few exploratory 
experiments were performed with etoposide and the VCR cell line 
cultured in monolayers and as heterogeneous spheroids in non-adherent 
flasks. These studies aimed to establish the effects of etoposide on the 
tumours and whether etoposide incubation led to an increased 
percentage of dead and apoptotic cells. Dead and apoptotic gates were 
identified from unstained control samples by drawing a region around the 
7-AAD intermediate, Annexin-high population for apoptotic cells and 7-
AAD-high, Annexin-high population to identify dead cells. Healthy cells 
were defined as the ones exhibiting low Annexin and 7-AAD fluorescence. 
It was anticipated that dead and apoptotic cells would detach form the 
spheroids and the monolayers and great care was taken to preserve 
those fragile cells by keeping the supernatants of the monolayers and the 
washing fractions from the spheroid samples along with the main cell 
fractions. Nevertheless the percentage of dead and apoptotic cells did not 
appear to change with increasing concentrations of etoposide (Figure 
4-7) and (Table 4-6). 
 
Figure 4-7 Flow cytometry analysis of monolayers and spheroids of non-stained VCR cells 
exposed to etoposide for 24h. Top row VCR cells exposed to etoposide as monolayers in 
cell culture treated flasks. Bottom row VCR spheroids exposed to etoposide in non-treated 
flasks. Cell viability percentages are given in Table 4-6 
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Sample 
Cell count, 
 cells x104 
Apoptotic  
% 
Dead 
% 
Monolayer Control 119 1 12 
Monolayer 50 µM 56 7 4 
Monolayer 150 µM 50 6 4 
Spheroid Control 128 3 6 
Spheroid 50 µM 72 5 3 
Spheroid 150 µM 70 6 3 
Table 4-6. Table summarising cell counts of VCR cells exposed to increasing 
concentrations of etoposide as determined by direct haemocytometer counts and 
percentage of dead and apoptotic cells determined via flow cytometry in Figure 4-7. 
Table 4-6 shows the change in cell count and the percentage of apoptotic 
and dead cells after exposing the VCR cell line to increasing levels of 
etoposide. It is notable that despite the significant drop in number of cells 
with increased etoposide concentrations the percentage of dead and 
apoptotic cells did not appear to increase after 24h of etoposide 
exposure. A possible explanation of this apparent cell loss may lie in the 
dissociation procedure involving steps of enzymatic digestion and 
numerous washes. The trypsin treatment used to detach monolayer cells 
and the combined Accutase digestion and mechanical agitation may have 
led to the digestion of the fragile apoptotic and necrotic cells. The steps 
required to prepare the cells for analysis were likely influencing the 
percentage of dead and apoptotic cells and the number of living cells was 
emerging as a more robust analysis parameter. A complimentary 
interpretation of the results takes into account the relatively quick nature 
of apoptosis compared to the assay timing (48 with the drug and then 
another 48 hours in drug-free media). Apoptosis levels may remain 
largely unchanged for most concentrations due to the constant shedding 
of apoptotic cells. Moreover as the cells in the spheroid are not all in the 
same phase of the cell cycle they will enter and finish apoptosis at a 
different time thereby contributing to the small change in the percentage 
of apoptotic cells within the spheroids. 
A few important conclusions could be made from those preliminary 
experiments. First, the exposure time of around 24h was not enough to 
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reveal the full extent of the effects of etoposide. Second, the VCR cell line 
showed signs of etoposide resistance which could interfere with future 
proof-of-concept studies and was later replaced by UW228-3. Third, the 
percentage of apoptotic and necrotic cells that made it to the flow 
cytometer may have been influenced by the dissociation procedure and 
therefore constituted an unreliable measurement to quantify drug effects 
in spheroids. Next, the number of living cells offered a more accurate 
representation of cytotoxic action and was prioritised. Nevertheless the 
elimination of excess dead and apoptotic cells from the analysis through 
the use of 7-AAD and Annexin-APC remained an important feature 
preventing noise interference in viability estimations. 
To sum up, despite the fact that the experiments described above were 
performed in a suboptimal setting with heterogeneous spheroids 
produced in non-adherent flasks, the right combination of labels and 
viability stains was established. The pieces of the puzzle were slowly 
coming together and while the critical factors of dye concentration, drug 
exposure and time of culture remained to be optimised for UW228-3 cell 
as well as NSCs. The utilisation of ultra-low attachment plates greatly 
facilitated the process of spheroid health monitoring, culture and 
quantification. 
Section 4.5  Marking normal brain cells and UW-228-3 
with CDCFDASE and CellTrace Violet 
The second phase of developing the medulloblastoma model commenced 
with a dye optimisation experiment. It aimed to establish the most 
favourable concentration to label the cells specifically without pronounced 
toxic effects. UW228-3 and NSC cells were marked with CDCFDASE and 
CellTrace Violet in concentrations ranging from 2.5 to 20 µM. Figure 4-8 
shows the impact of dye concentration on the frequency distribution of 
cellular fluorescence in the fluorescent channels of CDCFDASE and 
CellTrace Violet. As seen in Figure 4-8A-B the optimal staining 
concentration for the tumours was 10 µM for both dyes and little was 
gained from increasing dye levels to 20 µM. Despite the low mean 
fluorescence of non-marked UW cells, dye concentrations lower than 
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10 µM did not shift the population’s fluorescence distribution at day 7 far 
enough to achieve a good separation from the control. The normal brain 
cell population on the other hand showed a very pronounced difference in 
the distribution of the fluorescence signal with increasing dye 
concentrations. Figure 4-8C illustrates the gradual shift of the 
fluorescence for the whole normal cell population and clearly shows that 
CellTrace Violet can effectively mark the cells at levels as low as 5 µM. 
CDCFDASE followed a similar trend in Figure 4-8D although the shift was 
less pronounced when compared to CellTrace Violet. Overall, in the 
conditions tested, CellTrace Violet was superior in marking the cells 
compared to CDCFDASE because it elicited a more pronounced shift in 
the fluorescence of both cell types.       
 
 
Figure 4-8. Histograms of the frequency distributions of long-term fluorescent labelling for 
UW and NSC cells labelled with CellTrace Violet and CDCFDASE (Green). A- UW cells 
marked with CellTrace Violet, B-UW cells marked with CDCFDASE, C-normal cells marked 
with CellTrace Violet, D-normal cells marked with CDCFDASE 
These results were confirmed when the relative percentages of cells with 
fluorescence brighter than control were compared in Table 4-7. While 
5µM CellTrace Violet was enough to render over 90% of normal brain 
cells brighter than the unstained control, the same effect could only be 
achieved in tumours by using a two-times higher concentration of the 
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dye. Likewise, CDCFDASE levels of 5µM achieved effective labelling for 
more than 90% of normal cells but only marked 77% of the UW cell line. 
The data demonstrates that levels of 10 µM were needed to stain tumour 
cells and 5 µM were sufficient for normal cells for both dyes. Although 
these data indicated a combination of 10 µM CellTrace Violet for the UW 
and 5 µM CDCFDASE for the NSC might be advantageous, the superiority 
of this combination became visually apparent after comparing the dot 
plots in Figure 4-9. 
 
 
Condition % Positive cells 
UW228-3 NSC 
Control 2 2 
 CellTrace 2.5 µM 63 74 
CellTrace    5 µM 71 94 
CellTrace  10 µM 90 99 
CellTrace  20 µM 96 100 
CDCFDASE 2.5 µM - 50 
CDCFDASE     5 µM 77 93 
CDCFDASE  10 µM 86 98 
CDCFDASE  20 µM 85 99 
   
Table 4-7. Marking UW-228 and NSC cells with supravital dyes CDCFDASE and CellTrace 
Violet. Percentage of positive cells is given compared to unstained control. 
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Figure 4-9. Two dimensional dot plots showing single and mixed populations of UW and 
NSC cells marked with both dyes. X-axis shows intensity of fluorescence in the CDCFDASE 
channel, Y-axis fluorescence intensity in the CellTrace Violet channel. Quadrants are 
defined by the autofluorescence intensity values for the unstained stem cell population 
which are within the lower left quadrant of the plots A- UW marked with 10 µM CellTrace 
Violet, B- NSC marked with 5 µM CDCFDASE, C- mix of UW-CellTrace Violet and NSC-
CDCFDASE, D-NSC marked with 5 µM CellTrace Violet, E- UW marked with 10 µM 
CDCFDASE, F- mix of UW-CDCFDASE and NSC-CellTrace Violet 
Figure 4-9 shows the results of using NSC-cells marked with Cell trace 
violet or CDCFDASE mixed with UW cells marked with the opposite dye. 
Complete and effective resolution of the two populations is only achieved 
by using CDCFDASE for the foetal tissue and CellTrace Violet for the 
tumours (Figure 4-9C). In contrast the small shift in UW cell fluorescence 
achieved by CDCFDASE was sufficient to distinguish them from unstained 
tumour cells but not enough to differentiate them from the stem cells 
(Figure 4-9F). This cell discrimination achieved in the former case can be 
explained with the higher autofluorescence of stem cells compared to 
tumours. CellTrace Violet achieves a more pronounced shift in 
fluorescence for the tumours which, combined with their intrinsically low 
autofluorescence in the CDCFDASE channel, leads to better separation 
from the stem cell population 
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In order to investigate the effect of marking the cells with fluorescent 
dyes on spheroid viability and growth, the volume and metabolic activity 
of stained spheroids were compared to unstained spheroids of UW and 
NSC cells. Figure 4-10A shows that stem cells treated with increasing 
concentrations of each dye yielded smaller spheroids after 7 days of 
culture compared to untreated controls. This effect was less pronounced 
for UW spheroids which were only affected at concentrations above 
10 µM. Nevertheless, metabolic activity (Figure 4-10B) for all spheroids, 
as determined by Resazurin reduction, was above 80% when dye 
concentration was kept below 10 µM. Figure 4-10C shows the volume of 
marked spheroids made of UW of NSC cells marked with 10 µM CellTrace 
Violet and 5 µM CDCFDASE respectively. The results of five independent 
experiments showed that while stem cells produced 30% smaller 
spheroids than unstained controls, tumours were less affected by the 
marking procedure and only had 10% lower volume compared to 
controls.          
 
Figure 4-10. Volume and metabolic activity of spheroids marked with the supravital dyes 
compared to unstained controls A-Volume of UW and NSC spheroids marked with 
different levels of fluorescent dyes after 7 days of culture compared to unstained controls. 
B- Metabolic activity of the same spheroids measured as resazurin reduction compared to 
control. C- Volume of normal cell and tumour spheroids stained with 5 µM CDCFDASE and 
10 µM CellTrace Violet respectively compared to unmarked controls 
Section 4.6  Analysing the effects of etoposide 
After the initial optimisation experiments the marked tumour and normal 
cells were seeded and co-cultured together mimicking the interaction 
between normal brain and tumour tissue (Figure 4-11). These co-cultures 
were allowed to grow for 3 days before they were exposed to etoposide 
for 48h followed by another 2 days in etoposide-free media. The right 
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panel in Figure 4-11 shows light microscopy images of the spheroids after 
7 days of culture along with the conditions in each column.  
 
 
Figure 4-11. Medulloblastoma in vitro model experimental setup. Left panel- co-culture 
formation in overlay and etoposide exposure. Right panel- 96-well plate experiment phase 
contrast microscopy image after 7 days of culture along with conditions for each column. 
Figure 4-12 shows the light and multiphoton microscope images of the 
co-cultures and the flowchart for flow cytometry gating and analysis. The 
multiphoton images reveal the spatial distribution of the two cell 
populations while flow cytometry was used to quantify the proportion of 
each cell type. Despite seeding the cells together in the form of a mixed 
single cell suspension, the cells organised themselves into polarised 
spheroids with discrete tumour-dominated and normal brain cell-
dominated regions. As seen in the images, there were tumour cells 
detectable within the normal brain cell part, resembling metastases, and 
a fraction of double positive cells whose origin could not be identified 
solely on the basis of imaging. Flow cytometry after spheroid dissociation 
was used to quantitate the ratio of tumour and normal cells within the 
mixed cultures and monitor the effects of etoposide. The normal cells 
were well segregated from the tumours due to the bright CDCFDASE 
staining. The double-positive cells, which were highly fluorescent in both 
channels, were clearly separated from the tumour population and 
clustered with the normal cells. Each population was further examined for 
apoptosis-related phosphatidylserine externalisation using Annexin V-APC 
[330] and for 7-AAD uptake [328] to infer cell death. 
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A feasibility study similar the one with VCR cells was undertaken in order 
to check the suitability of using the combination of dyes to distinguish 
between normal stem cells and tumours and monitor their viability at the 
same time. Figure 4-13  shows the viability determination for the 
unstained and the labelled populations of tumour and neural stem cells. 
The samples which did not contain AnnexinV-APC and 7-AAD (Figure 
4-13A-D) did not give rise to a signal in those channels indicating the 
lack of interference between the cell marking and cell viability stains. 
Upon the addition of Annexin and 7-AAD two new populations emerged in 
addition to the main cell population (Figure 4-13E-H). The apoptotic cells 
had intermediate 7-AAD permeability and high fluorescence in the 
Annexin-APC channel, while the dead cells were highly fluorescent in both 
channels when compared to the unstained control. The percentage of 
apoptotic and dead cells in the untreated controls (Figure 4-13E-F) was 
lower than that in etoposide treated spheroids (Figure 4-13G-H). 
Although the percentage of apoptotic and dead cells rose with increasing 
concentrations of etoposide, the spike in dead and apoptotic cells could 
not account for the fall of healthy cell numbers. As mentioned before, 
dead and dying cells often detach from the spheroids and can be lost 
during washes or digested during the dissociation process. In this regard, 
it was decided that the percentage and ratios of surviving cells will be 
used in subsequent analyses in order to minimize the influence of the 
dissociation procedure on the dose-response results. 
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Figure 4-12.Medulloblastoma co-culture model analysis. Top left- phase contrast microscopy image of co-culture spheroid. Darker sphere is made up of 
UW cells while brighter cells are NSC. Bottom left multiphoton average intensity z-stack projection image of co-culture spheroids. Green cells represent 
NSC, blue cells –UW228-3 and Cyan-double positive cells. Scale bars 200 µm. After dissociation into single cells spheroids were analysed using flow 
cytometry. Middle dot plot panel shows that tumour and normal stem cell populations can be gated separately owing to their different fluorescence in 
both channels. Double positive cells in middle dot plot appear to cluster with stem cells. Right dot plots show tumour (top panel) and stem cells (bottom 
panel) assayed separately for viability using Annexin-APC for apoptotic cells and 7-AAD to mark dead cells. Note that living cells have low 7-AAD 
fluorescence, apoptotic medium and dead-high as described by Zembruski et al., 2012 
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Figure 4-13 . Dot plots showing compatibility of cell labelling and determination of health status. Samples A to D did not have any added 7-AAD or 
Annexin-APC and were therefore negative for the stains. Samples E-F had both Annexin-APC and 7-AAD added (+/+). Note that apoptotic cells also have 
a slightly higher permeability for 7-AAD as well. Control and treated cultures had similar levels of apoptotic and dead cells which was attributed to the 
loss of fragile apoptotic and dead cells during enzymatic and mechanical dissociation of the spheroid. That is why only Annexin-APC and 7-AAD negative 
(healthy) cells were used in subsequent analyses.  
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Etoposide addition profoundly altered the ratio of tumour to normal cells 
in the spheroids. Although both populations started at similar numbers, 
increasing concentrations of etoposide primarily targeted the tumours 
and at 10 µM the spheroids were composed predominantly of normal 
cells. As seen in Figure 4-14, with increasing etoposide levels the tumour 
cell proportion dropped significantly and reached its lowest point at 
10 µM etoposide. This is in agreement with the results from the two 
photon confocal microscopy shown in the bottom panel. The average 
intensity z-stacks show a progressive elimination of the tumour cells with 
only traces of these cells left at the 10 µM concentration. Nevertheless, 
the decrease in tumour burden was not wholly advantageous and higher 
etoposide concentrations elicited a shrinkage of the spheroid as a whole, 
indicating toxicity to the normal cells as well. 
 
Figure 4-14 Co-cultures exposed to different levels of etoposide. Dot plots and 
multiphoton images. The top panel shows dot plots for the live cells in the spheroid. Top 
left plot represents the living cells in the controls, cultured in media and DMSO. The dot 
plots are marked with the relevant etoposide concentration in µM.  The proportional 
increase of normal stem cell to tumours shown in the dot plots is represented by the pie 
charts of the middle row. The decrease in spheroid size is also represented by a decrease 
in the pie chart diameter. Increasing concentrations of etoposide gradually eliminated the 
tumours cells. Bottom row shows multiphoton microscope average intensity z-stacks of 
spheroids cultured at the above conditions. Blue cells are UW tumours, green cells are 
normal stem cells and scale bars are 200 µm.   
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A similar trend was also seen in a different experiment where the starting 
ratio of tumours to normal stem cells was 4:1 (Figure 4-15). The use of 
fluorescent beads to determine absolute cell numbers was pioneered in 
this experiment. The beads had distinct size and scattering characteristics 
and were fluorescent in all channels making them easy to distinguish 
from the cells. The same concentration of fluorescent beads was added to 
each sample and the absolute cell concentration calculated and compared 
to the control to express viability. Despite the starting advantage in 
numbers for the tumours, increasing etoposide levels affected them in a 
dose-dependent manner and at levels of 10 µM etoposide the tumour to 
normal cells ratio was reversed in favour of the normal cells. The decline 
in tumour viability was similarly followed by a decrease in the volume and 
number of cells in the spheroid as a whole. Although the normal cells 
were the dominating cell type in the spheroids exposed to 10 and 30 µM 
etoposide, the spheroid viability expressed as cell numbers compared to 
control was below 10%.  
When the percentage of apoptotic and dead cells from Figure 4-15 was 
plotted against etoposide concentration the points of departure for both 
death and apoptosis were visualised (Figure 4-16). Significant increases 
in the percentage of apoptotic cells for both tumours and normal cells 
was seen at etoposide concentrations above 3 µM and dead cells 
increased at levels exceeding 30 µM. This was in stark contrast with the 
substantial drop in viability at etoposide concentrations below 3 µM 
detectable by both spheroid volume decrease and absolute cell counts 
and serves to further emphasize the possible underestimation of 
etoposide’s effects by relying solely on apoptosis and cell death. This 
effect was most probably linked to the extensive sample preparation 
procedure involving multiple washing steps, mechanical and enzymatic 
dissociation rather than a specific biological phenomenon. 
Despite the successful first experience with absolute cell counts 
determined with the help of fluorescent beads, later experiments 
highlighted the high variability in the bead addition procedure and 
spheroid volume was used instead of cell counts in the final analysis of 
the data combining all experiments to plot the dose-response curves for 
etoposide.  
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Figure 4-15. Dot plots showing the change of viability after etoposide treatment of the spheroid as a whole (top percentage next to title) and the 
percentages of healthy neural progenitors and UW228-3 tumour when the starting ratio is 80% tumours to 20% normal stem cells. Concentrations 3 to 
30 µM were the most favourable for the neural progenitors. Even though the spheroids were composed mainly of tumour tissue at the start, at 10 µM the 
neural progenitor cells were almost twice as numerous as the tumours. Absolute cell numbers in this experiment were determined using BD Fluorescent 
microbeads which were added to each sample and the counts for the beads compared to cell counts. This procedure was highly dependent on the control 
samples and could not be applied to all experiments due to variation in bead counts in non-treated controls in some setups.
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Figure 4-16 Percentage of apoptotic and dead cells in the UW228-3 tumour and neural 
progenitor populations after treatment with etoposide. Percentage is calculated as a 
fraction of the number dead or apoptotic cells from all cells of the same type. 
Dose-response curves were extrapolated by using the volume of the co-
culture spheroids and the proportion of progenitor cells to tumour cells 
determined by flow cytometry in order to fully describe the effects of 
etoposide on both populations. The resultant values were normalised to 
the initial values for progenitor cells and tumours respectively and the 
results plotted in Figure 4-17A. Despite the variability between the 
different experiments there was a clear dose-response trend in which 
normal cell viability was lower or equal to that of tumours below 3 µM 
and higher at etoposide levels between 3 and 10 µM. The most 
favourable etoposide concentration 10 µM when the viability of NSC 
(41%) was 6 times higher than tumour viability (6.5%) as shown in 
Figure 4-17B. This was a statistically significant difference as determined 
by a two-tailed t-test with Welch’s correction for unequal variance 
(p=0.0257). The observed higher viability of progenitor cells at 10 µM 
etoposide is in agreement with the results from our previous study in 
separate cultures of unlabelled normal cell and tumour spheroids [331]. 
Co-culture model of medulloblastoma 
 141   
  
 
Figure 4-17 Dose-response data for co-cultures of neural stem cells and UW 
medulloblastoma cells exposed to etoposide. A-Comparison of viability for each 
population calculated from the total volume of the co-culture spheroid (image analysis) 
and the ratio between normal cells and tumours (flow cytometry). Error bars represent 
SEM for n=4 independent experiments B- comparison of the viability of normal cells and 
tumours at 10 µM etoposide, dots represent separate experiments. Note the high inter-
experimental variability of the data for the normal cells and the narrow distribution for 
tumours. IC50 for stem cells was calculated to be 3 µM (95%CI=2-7 µM) and 1 µM (95% 
CI=0.8-2 µM) for UW228-3 cells. 
 
Figure 4-18 Imaging flow cytometry- representative examples of the different cell 
populations 
In addition to the conventional flow cytometry experiments, imaging flow 
cytometry was employed in order to visualise and better characterise the 
separate populations (Figure 4-18). The normal stem cells gave a bright 
signal in the green channel whereas the tumours were positive for 
CellTrace Violet fluorescence. The membrane distribution of 
phosphatidylserine in apoptotic cells was also visualised. In addition the 
double positive cells were confirmed to be normal cells that had small 
particles attached to them responsible for the high-fluorescence in the 
violet channel.  
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Section 4.7  Discussion and conclusions 
Through the use of CDCFDASE and CellTrace Violet in this co-culture 
model cellular fluorescence was maintained for 7 days. CellTrace Violet 
yielded a bigger shift in fluorescence compared to CDCFDASE and did not 
affect the medulloblastoma spheroid volume or metabolic activity. 
Although the final stem cell neurosphere volume was 30% lower than the 
unstained controls, the decreased sphere volume did not translate to 
reduced metabolic activity up to levels of 10 µM of CDCFDASE and 
CellTrace Violet. 
Remarkably, both successful dyes emerging after the labelling 
optimisation series rely on the same mechanism to stain the cells. 
Namely, they enter as acetate esters, which are then hydrolysed in the 
cytosol and subsequently react with cellular amines with their 
succinimidyl groups. This staining strategy can be used on any cell type 
and is substantially less toxic compared to chloro- and bromo-methyl 
reactive dyes that bind to cellular glutathione. Marking proteins in the 
cytosol would also potentially result in diminished dye exchange between 
adjacent cells compared to labels that bind to cellular membranes. 
Spheroid co-cultures have been extensively used for invasion 
experiments in glioblastoma [311], [319], [332]–[334]. These studies 
have highlighted the importance of having a normal tissue component as 
well as the tumour cells. However, these experiments relied on 
techniques like agar overlay which produced spheroids of varying, poorly 
reproducible sizes. These limitations necessitated manual sorting and 
resulted in decrease in throughput. In most of these studies the tumour 
spheroids were exposed to the drug alone and only afterwards co-
cultured with the normal tissue.  
The tumour cells within the co-culture were organised in a main tumour 
mass and multiple smaller foci, thus mimicking the in vivo situation. 
Strikingly, although the tumours and progenitor cells were seeded as a 
mix, they organised themselves in two poles- one enriched for tumour 
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and one for normal tissue. Spontaneous organisation of spheroids has 
been reported before[335] as is probably driven by oxygen and nutrient 
gradients as well as cell-cell recognition mechanisms. These interactions 
can be linked to the ‘seeds and soils’ hypothesis regarding the recognition 
between cancer and normal cells and the spread of metastasis to specific 
parts of the body[336].  
The combination of two dyes made it possible to assess the proportion of 
each cell population within the spheroid using flow cytometry after 
spheroid dissociation into single cells. The quantitative analysis of 
multiphoton images revealed the presence of double positive cells whose 
identity was investigated by conventional and imaging flow cytometry. 
The double positive cells visible in Figure 4-12 and Figure 4-14 clustered 
with the normal cell population in conventional flow cytometry dot plots. 
Moreover, the image-based flow cytometer visualised those cells as 
normal cells with uniform green fluorescence and small particles with 
bright violet/blue fluorescence attached to the outside of the cells (Figure 
4-18). These flow cytometry results were confirmed in the images of 
intact spheroids from the multiphoton microscope. With increasing 
etoposide concentration the main tumour mass was almost completely 
eliminated but some small groups of tumour cells remained within the 
core of the spheroid. 
The 3D co-culture model described here is made by simply mixing the 
NSC and UW cells in a high-throughput compatible 96-well format. No 
manual sorting, spheroid transfers or mixing are required and all steps 
could potentially be automated to increase productivity. The 96-well 
format allows the screening of a large number of formulations and the 
elucidation of dose-response relationships. Furthermore, the model 
includes human foetal brain tissue that shows the off-target effects of 
local chemotherapy on the developing brain and puts the inhibitory drug 
concentrations into clinical perspective. By harnessing these advantages 
a therapeutic range was identified for etoposide. Levels between 3 and 
10 µM maximised toxicity to tumours while normal cell viability remained 
6 times higher. This concentration of etoposide can be achieved in 
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patients by employing local intrathecal therapy [120], [121], for 
example.  
The results from this study are supported by the work reported in 
Chapter 3 where both cell types were cultured separately without 
previous labelling [331]. Despite the slight differences in the calculated 
IC50s and the loss of resolution to detect the biphasic NSC response, the 
general viability differences remained unchanged. In agreement with the 
single culture studies, normal cell viability was higher compared to 
tumours only at levels around 10 µM. Although the normal cell population 
was slightly less affected by etoposide when co-cultured with tumour 
cells, the interaction between normal and tumour tissue did not appear to 
cause enormous shifts in drug sensitivity.   
The toxicity to neural progenitors shown by the model has also been 
reported in mice [337]. These findings are in agreement with studies that 
have demonstrated the damaging potential of cytotoxic drugs to 
progenitor cells in the subventricular zone (SVZ), dentate gyrus and the 
corpus callosum [338]. It should be noted, however, that the 
neurodevelopmental toxicity effects demonstrated by this in vitro model 
would only be replicated in patients if etoposide were to diffuse into the 
SVZ and dentate gyrus at high enough levels. In the context of local 
delivery of nanoparticles this would seem unlikely unless the 
nanoparticles are picked up by the CSF and etoposide is released 
prematurely. 
As far as intrathecal administration of etoposide is concerned, 
leptomeningeal tumour metastases would be in direct contact with the 
CSF and would potentially receive the highest exposure to etoposide. In 
contrast progenitor cells in the SVZ are located tens of micrometres away 
from the wall of the lateral ventricle behind a layer of ependymal cells 
and a hypocellular layer [339], [340]. Neurotoxic side effects in patients 
have been reported for other cytotoxics like cisplatin [341], methotrexate 
[135], [136] and cytarabine [342] but not for intrathecal etoposide 
yet [119]–[121].  
Nevertheless, the findings in this chapter confirm that etoposide can 
damage proliferating cells regardless of their origin and illustrate the 
failure of conventional chemotherapy to distinguish between normal and 
tumour cells.  To this end, the next chapter describes the efforts to load 
biodegradable nanoparticles with etoposide in order to improve selectivity 
and limit off-target toxicity. 
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Chapter 5.  Etoposide loaded Poly (glycerol adipate) 
nanoparticles 
Section 5.1  Introduction 
As seen in Chapters 3 and 4 etoposide is not very selective in its 
cytotoxic effects on tumour cells and adversely affects the health of 
normal proliferating neural progenitors. As a low Mw drug, etoposide is 
distributed in most cells throughout the body by diffusion. Physically 
entrapping the drug in a macromolecular carrier would change its 
distribution pattern and etoposide would reach its intracellular target 
(topoisomerase II) only after endocytosis and subsequent dissociation 
from the carrier. If tumour cells with their altered endocytosis state[192] 
were to take up more nanoparticles than normal brain tissue, that could 
be exploited to increase the selectivity of etoposide. In this regard, the 
ideal carrier would resemble conventional biomacromolecules in order to 
enhance endocytosis and exhibit rapid degradation to non-toxic products 
in the endosomal compartment to release the entrapped drug. It would 
demonstrate good loading capacity as well as sustained release of the 
drug to prevent premature leakage.  
As was mentioned before, poly(glycerol adipate) (PGA) was selected as a 
promising polymer with reported biodegradability and biocompatibility as 
well as favourable results for the incorporation of certain drugs[179]. 
Meng et al demonstrated that 40% stearoyl-substituted C18-PGA 
nanoparticles are taken up 6 times more in tumour spheroids compared 
to normal rat brain tissue[177]. In a parallel study Sanyogita Puri found 
that etoposide can be encapsulated in octanoyl-substituted C8-PGA 
nanoparticles in levels up to 3%[180]. 
This combination of selective uptake, reasonable loading capacity, 
biocompatibility and rapid lysosomal degradation encouraged the 
development of etoposide loaded PGA-based nanoparticles. This chapter 
aimed to reproduce and improve the previously reported etoposide 
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loading results for nanoparticles in order to test the delivery systems in 
the in vitro models described in Chapters 3 and 4.  
Section 5.2  Chapter methods 
5.2.1 Synthesis of poly(glycerol adipate) PGA: 
The polymer was synthesized according to the method reported in 
Section 2.8.1 
5.2.2 Analysis of polymer 
Backbone polymers were characterised using NMR and GPC as described 
in Section 2.8.2. 
5.2.3 Acylation of poly(glycerol adipate):  
The polymers were substituted with 40% stearoyl chloride or 100% 
octanoyl chloride as shown in Section 2.8.3 
The C18 and C8-substituted polymers were used without purification in 
most experiments as carried out in the historically accepted standard 
protocol[176]. A precipitation procedure was later tried in order to see if 
the removal of unconjugated acyl chloride and the respective acid would 
make a difference in etoposide loading. For the C18 substituted polymer 
this involved dissolving the polymer in acetone and precipitating with 
petroleum ether. The precipitation procedure for the C8-substituted 
polymer was done with acetone as the solvent and cold methanol as the 
non-solvent for the polymer. The NMR spectra given are for the purified 
polymers.  
5.2.4 Production of nanoparticles via nanoprecipitation 
Nanoparticles were produced via the nanoprecipitation method[176], 
[180], [343] (Section 2.9.1). A solution of PGA (2 mL, 10mg/mL) was 
slowly added dropwise to a buffered aqueous phase (7 mL, 10 mM 
HEPES) under magnetic stirring. The solution was stirred overnight and 
acetone was allowed to evaporate, and was then filtered through a 1 μm 
sized filter. For RBITC nanoparticles the procedure described by 
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Meng[179] was followed where the ratio between the organic and 
aqueous phase was 2:7 and Tween 80 (0.1%) in HEPES(10mM, pH=7.4) 
was used in the aqueous phase to stabilise the nanoparticles and prevent 
aggregation. 
Etoposide loaded nanoparticles were prepared as described by Puri [180] 
using the nanoprecipitation with a reconstituted matrix method. 
Etoposide (2 mg) and polymer (10 mg) were dissolved in acetone (1 mL). 
The acetone was left to evaporate by blowing a stream of dry nitrogen 
and left for at least 2h in the dark afterwards. The matrix was 
reconstituted in acetone (1 mL) and was added to distilled water (5 mL) 
under magnetic stirring and left overnight for the acetone to evaporate.  
The loaded nanoparticles were separated from the free dye or drug via 
low pressure gel permeation chromatography using a SepharoseCL-4B 
column (2.5x25 cm, General Electric) as outlined in Section 2.9.3.  
Nanoparticle radius was determined using dynamic light scattering 
(Section 2.9.4.) using the Viscotek 802 instrument (830 nm laser, 
60 mW, 10% power). At least 10 measurements were performed on each 
sample with a duration of 4s per measurement.  
The zeta potentials and the diameter of the nanoparticles were 
determined in HEPES Buffer (10mM, pH=7.4) using Laser Doppler 
Electrophoresis (Zetasizer NanoZS, Malvern). At least three 
measurements were performed on each sample. 
5.2.5 Imaging the interaction of fluorescent nanoparticles 
and medulloblastoma cells  
Confocal laser scanning microscopy (CLSM) was used to image tumour 
and NSC spheroids and determine nanoparticle uptake in cells in the 
periphery and the core of the spheroids. CLSM was performed using a 
Leica SP2 microscope equipped with a 405 nm (diode), 488 nm (Ar) and 
543 nm (He/Ne) lasers. Images were analysed with Volocity and Leica 
LAS AF Light software. Background reduction in the red channel was 
performed on all confocal images by applying a lower threshold value of 
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70 units of fluorescence pixel intensity and alpha correction (α=1.1) in 
Adobe Photoshop (v14). 
The spheroids were grown in hanging drop culture, harvested from the 
bottom of the plates and pipetted onto poly-D-lysine/albumin cover slips. 
They were incubated on the cover slips in full culture media with or 
without 25% nanoparticle suspension in 10 mM HEPES for 24h in order to 
attach. Afterwards the attached spheroids were washed with PBS, fixed 
with 4% PFA for 15 minutes, dyed with 4',6-diamidino-2-phenylindole 
(DAPI, 1 μg/mL) for 5 minutes and washed twice with PBS. The cover 
slips were mounted on cavity slides with fluorescence mounting medium 
and sealed with clear nail polish. They were kept protected from light at 
2-8 °C. 
5.2.6 Etoposide-loaded nanoparticles: drug loading 
determination 
Drug loading was determined by freeze-drying a set volume of 
nanoparticle suspension (1 mL) in a preweighed amber HPLC vial. The 
weight difference was recorded and the nanoparticles were dissolved in 
DCM (1 mL). Fluorescence spectrophotometry (Varian Cary Eclipse, 
Agilent) with excitation (λ=284 nm), emission (λ=325 nm) and slit 
(5 nm) was measured against freshly made standards. The standard 
curve for etoposide fluorescence had a hyperbolic shape due to 
fluorescence quenching at etoposide levels above 30 µg/mL and a linear 
standard curve was fitted up to that level. For concentrations higher than 
30 µg/mL the hyperbolic equation fit from GraphPad prism was used. 
Quality control samples of nanoparticles spiked with known amounts of 
etoposide were subjected to the same treatment and used to assess the 
suitability of the method. 
Section 5.3  Polymer synthesis and characterisation 
5.3.1 Synthesis of polymer backbone 
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The synthesis of poly (glycerol adipate) is a polycondensation reaction 
that results in polymers with a broad distribution of molecular weights as 
seen in the GPC (Figure 5-1): 
 
Figure 5-1. GPC chromatogram of PGA polymer synthesized in house. The average 
molecular weight was 12kDa and the distribution was broad as expected in 
polycondensation reactions GPC trace obtained from Liverpool setup 
The target for the mean molecular weight of the peak was 8-12 kDa 
because that had been previously reported to maximise drug 
loading[176]. Molecular weight determinations were initially carried out 
at Nottingham using a Polar-Gel M column.  However, these 
determinations seemed to give quite random molecular weights and a 
possible interaction between the packing material and the polymers was 
suspected. When the same polymer samples were analysed using the 
original polystyrene/divinylbenzene columns in Liverpool, employed in the 
inceptive work on the polymer, the molecular weight determinations were 
consistent with the previously reported results (Table 5-1). 
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Sample GMHHR-N column 
Polystyrene/divinylbenzene  
PolarGel- M column 
(name) Mw(kDa) Mw(kDa) 
PGA 130106 13.6 1.4 
PGA 130205 13.8 0.73 
PGA 130708 22.7 11.5 
PGA 130710 12 4.3 
PGA 130716 18.4 12 
Table 5-1. Mean molecular weight determinations for five different batches of poly 
(glycerol adipate) determined by GPC with two types of columns- GHHHR-N PS/DVB and 
PolarGel-M.  
5.3.2 Substitution 
Substitution reactions were performed with stearoyl (C18) and n-octanoyl 
(C8) chloride in order to synthesize 40%-C18 and 100%-C8 substituted 
polymers. The C18-derivative had previously shown promise in 
dexamethasone formulations[176], while the 100%C8 was the polymer 
that performed the best out of a selection of substituted PGA polymers in 
a screening study with etoposide performed by Puri[180]. The 
representative NMR spectra for the unsubstituted PGA, 40%-C18PGA and 
100%C8-PGA are given in Figure 5-2, Figure 5-3 and Figure 5-4 
respectively. 
Figure 5-2 shows that despite the extensive drying procedure there was 
still some residual THF trapped in the polymer. The peaks at 5.1 and 
5.3ppm are indicative of substitution of the secondary hydroxyl group of 
glycerol showing that although the enzymatic reaction is regioselective it 
is not completely specific. 
Figure 5-3 and Figure 5-4 show the NMR spectra of the substituted 
polymers. The NMR spectra were used to determine the degree of 
substitution by exploiting the fact that the substituted part(x) of the 
polymer has 6 protons attached to carbons vicinal to carbonyl groups, 
while the non-substituted part(y) has only four. 
6x+4y=d+d’ protons, and if x=1 
 
Equation 5-1 
𝑦 =
𝑝𝑟𝑜𝑡𝑜𝑛𝑠(𝑑+𝑑′) − 6
4
 
 
Equation 5-2 
𝑥 % =
1
1 + 𝑦
𝑥100 
 
Equation 5-3 
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Figure 5-2. NMR spectrum for non-functionalised poly (glycerol) adipate.  
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Figure 5-3 NMR spectrum for the C8 substituted PGA. Although the theoretical substitution percentage was 100% the actual substitution achieved was 
81% 
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Figure 5-4. NMR spectrum for C18-substituted polymer. 31% substitution was achieved. 
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Section 5.4  Nanoparticle preparation and optimisation 
5.4.1 RBITC loaded nanoparticles- size, zeta potential, 
confocal with spheroids 
Upon the substitution of the pendant hydroxyl groups of the polymer 
backbone with stearoyl chloride the resultant new polymer was used to 
make Rhodamine B isothiocyanate (RBITC) loaded nanoparticles as 
described by Meng[179]. After separation of the free dye via low pressure 
gel-permeation chromatography the size and zeta potential of the 
nanoparticles were determined in 10 mM HEPES buffer: 
Sample name 
Diameter, 
Viscotek 
Diameter, 
Malvern ZS 
Zeta potential 
RBITC NPs 250±40nm 230±50nm -36±10mV 
Table 5-2. Characterisation of RBITC-loaded fluorescent nanoparticles. Values for size and 
zeta potential are given with the population range 
Both the Malvern ZS and the Viscotek DLS placed the size of the 
nanoparticles in the 230-250 nm range. The size and zeta potential of the 
nanoparticles were consistent with the previously reported values by 
Meng and Puri[179], [180]. Despite their negative charge the particles 
had a tendency to aggregate when freeze-dried and that is why they 
were stored as a colloidal suspension in 10 mM HEPES in the fridge 
protected from light. The nanoparticles used for uptake experiments were 
stored for less than 48h. 
The fluorescent label RBITC was used in order to image the depth and 
extent of nanoparticle uptake in tumour spheroids. Imaging the 
distribution of nanoparticles within the intact tumour spheroids was 
performed using confocal laser scanning microscopy (CSLM). Even 
though CSLM can successfully be used to quantify the distribution of the 
nanoparticles the tissue was not optically transparent and both the 
excitation and the emission signal were scattered and dampened further 
into the spheroid. The physical depth limit of CSLM is around 150 μm, 
however there are studies which suggest that this value can be 
significantly improved with tissue clearing procedures[344]. The nuclear 
stain DAPI proved useful for locating the spheroids and focusing. 
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Furthermore, the cytoplasmic dye- Carboxyfluorescein diacetate 
succinimidyl ester (CFDA SE) was used to stain the cytoplasm of the 
tumour cells (Table 5-3). 
Stain Excitation Emission Colour 
DAPI- nuclei 360 460 Blue 
CFSE DA- cytoplasm 492 517 Green 
RBITC- nanoparticles 554 575 Red 
Table 5-3 Fluorescent dyes used in confocal imaging experiments. The tumour 
cells were marked with CFDA SE in monolayer, trypsinized and allowed to form 
spheroids in the Perfecta 3D hanging drop plates. The spheroids were harvested, 
allowed to attach to PDL/albumin coated cover slips and exposed to RBITC 
loaded nanoparticles for 24h. They were then fixed, stained with DAPI and 
imaged on the confocal microscope. 
VCR spheroids were cultured on poly-D-lysine/albumin coated cover slips 
in full culture media either in the absence or presence of nanoparticles as 
described in the methods section. This was done to ensure the 
attachment of the spheroids to the cover slips in order to enhance 
imaging. Both the spheroids (Figure 5-5, Figure 5-7) and the monolayer 
of cells spreading from the spheroids on the cover slips were imaged 
(Figure 5-6, Figure 5-8). In the control group which was not exposed to 
nanoparticles no fluorescence was expected in the red channel apart from 
the normal levels of autofluorescence. Although red fluorescent spots 
could be seen in some of the control images (Figure 5-5 and Figure 5-6) 
these artefacts were always fluorescing in the green channel as well 
which indicated autofluorescence rather than nanoparticles (highlighted 
in Figure 5-9C and D). The diminishing fluorescence in deeper sections 
(Figure 5-5D) indicates the need for sectioning or tissue clarification in 
order to image the spheroid core. In contrast, images of spheroids 
exposed to RBITC (Figure 5-7 and Figure 5-8) loaded nanoparticles 
exhibited more intensive diffuse red fluorescence and the spots identified 
as nanoparticles did not fluoresce in any other channel apart from the 
red. The RBITC loaded nanoparticles are seen either as red fluorescent 
aggregates or diffuse higher levels of red fluorescence in the spheroids. 
The relative fluorescence intensity in the red channel was over around 2 
times higher in treated spheroids (Figure 5-7) compared to the control 
images (Figure 5-5). This suggests that there may be free nanoparticles 
within the cells imaged as diffuse red fluorescence (Figure 5-9A and B). 
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Figure 5-5 Control images(x40) of a tumour VCR spheroid attached to a coated cover slip. The blue, green and red fluorescent channels are first shown 
separately and then overlaid. A-Section 6 μm deep into the spheroid showing autofluorescent artefacts in both the red and the green channel. B-Section 
30 μm into the spheroid displaying diminishing brightness and contrast in the blue channel. White rectangles are shown expanded in Figure 5-9D;  C-Section 
80 μm into the spheroid, both contrast and brightness are greatly diminished.Scale bar 200µm  
 
Figure 5-6 Control image(x40) of a VCR monolayer without nanoparticles showing the cells which support the spheroids’ attachment to the cover slip. Scale 
bar 50µm. 
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Figure 5-7. Confocal images(x40) of a VCR spheroid after 24h exposure to RBITC loaded nanoparticles. Fluorescent channels are shown separately and 
afterwards overlaid. A- Section 6μm into the spheroid where many fluorescent nanoparticle aggregates can be seen. B-Section 20 μm into the spheroid- 
most nanoparticles are in the periphery of the spheroid and very few (white arrow) were detected into the deeper layers. Expanded version shown in Figure 
5-9A and B; C- Section 60μM into the spheroid, loss of contrast and brightness due to the opaque nature of the spheroids. Scale bar 200µm. 
 
Figure 5-8 Confocal image(x63) of the monolayer of cells supporting the tumour spheroid after 24h nanoparticle exposure. Nanoparticles have accumulated 
into the endosomal compartments and also contribute to an increase in diffuse fluorescence when compared to the control. Artefacts (white arrows) are 
easily distinguished by appearing in both the green and the red channels. Highlights of the white rectangles shown in Figure 5-9C. Scale bar 50µm. 
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Figure 5-9. Highlights from the confocal images of nanoparticles interacting with medulloblastoma spheroids and monolayers. A (red channel) and B(overlay) 
of the 20µm section from Figure 5-7B, nanoparticles are fluorescent only in the red channel; C-Expansion of overlay image from the white rectangle in Figure 
5-8 nanoparticles (red) can be easily distinguished from double-positive artefacts (white arrows) in VCR monolayers incubated with nanoparticles; D-
Expansion of the rectangles in Figure 5-5B showing autofluorescence artefacts exhibiting fluorescence in both channels in untreated spheroid controls. 
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The confocal images show that the nanoparticles were taken up by the 
tumour cells and aggregated around the nucleus. These findings are in 
agreement with the studies done by Meng et al[177], [179]. The increase 
of diffuse red fluorescence in the images of spheroids exposed to 
nanoparticles may indicate that, although too small to pinpoint, the 
nanoparticle presence can be detected using confocal microscopy. Most 
nanoparticles were visible in the first cell layer of the spheroid with very 
little detected in the core. Despite the acceptable brightness and contrast 
in the spheroid sections up to 50μm in depth, the deeper sections were 
considerably darker and the nuclei were impossible to distinguish. This 
may be due to the fact that the nuclei were dyed with DAPI after the 
spheroids had been formed or because of the increased scattering of blue 
light compared to longer wavelengths. Nevertheless sectioning the 
spheroids or trying to increase the optical transparency of the tissues 
must be attempted in order to the true picture of the nanoparticle 
distribution and penetration depth. CSLM images can be quantitated and 
the diffuse fluorescence in the control and spheroids exposed to 
nanoparticles can be compared. However every time a new slide is 
inserted in the confocal microscope the difference in the distance to the 
objective and other optical variables could contribute a significant 
variation in fluorescence intensity within the same experiment. Therefore 
the confocal microscopy experimental setup did not have the power to 
quantify nanoparticle distribution within the spheroids. 
5.4.2 Etoposide loaded nanoparticles- size, zeta potential, 
loading, stability  
Etoposide loaded nanoparticles were made with the crude and purified 
polymers and their drug loading was measured using fluorescence 
spectrophotometry. To validate the suitability of the method a standard 
curve was constructed (Figure 5-10) and empty nanoparticles spiked with 
known amounts of etoposide were used as quality controls for the 
method (Table 5-4).  
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Figure 5-10. Standard curve for etoposide determination using fluorescence 
spectrophotometry. Fluorescence was linearly related to sample concentration up to levels 
of 30µg/mL etoposide (straight line). At higher concentrations fluorescence quenching due 
to inner filter effect absorbance was observed causing the hyperbolic shape of the 
standard curve at high concentrations (dashed line). Drug-loaded nanoparticle samples all 
clustered below the 1 µg/mL level. Empty nanoparticle samples were spiked with known 
amounts of etoposide and the percent of etoposide recovery was quantitated for quality 
control purposes Table 5-4. 
Etoposide level Recovery % 
1 µg/mL 137% 
10 µg/mL 113% 
30 µg/mL 90% 
Table 5-4. Recovery of known amount of etoposide in nanoparticle samples. These 
samples were prepared to test the suitability of fluorescence to be used for etoposide 
determination at the expected levels. 
 
Figure 5-11. Etoposide drug loading for nanoparticles made with C8 and C18-PGA. Red 
dots are experiments performed with the crude polymers, while black dots represent 
batches made with the purified polymers. Polymer purification did not exhibit any 
detectable influence on loading. 
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As seen in Figure 5-11 the drug loading was below 1% and it did not 
match the 3% loading reported by Puri[180]. A comparison of 
nanoparticle parameters achieved in this study with the historical data 
from Puri is given in Table 5-5: 
Parameter Present NPs Historical data[180] 
Particle size, r, nm 132±15 126±5 
Zeta potential, mV -57±103 -31±0.84 
Drug loading, % 0.06 3 
Table 5-5. Comparison of etoposide-loaded nanoparticles made with the 100%C8-PGA 
from the present study with historical data from Puri[180]. 
Despite the similarities between nanoparticle size and zeta potential 
when compared to the results reported by Puri, the present work could 
not achieve the same drug loading.  
Although Puri used polymers synthesized in Liverpool which had the same 
mean molecular weight (12 kDa) the broad Mw distribution of the 
polycondensation process may yield polymers with similar molecular 
weight but very different characteristics. It may be that the polymers 
synthesized in Nottingham and used in the present study differ in some 
way to the polymers made in Liverpool and used by Puri.  
The cell culture experiments in Chapters 3 and 4 indicated that a 
cytotoxic level of 10 µM (6 µg/mL) etoposide would be most effective in 
destroying tumour tissue while preserving normal cell viability to a 
certain extent. A formulation with 0.06% loading would require 10mg/mL 
nanoparticle suspension concentrations to deliver that load. At these 
extremely high levels extensive aggregation, physicochemical instabilities 
and toxicity of the carrier may be exhibited. In contrast to that, a loading 
of 3% drug would require 200 µg/mL nanosuspension levels which may 
be achievable and have been reported to be non-toxic for PGA[176]. In 
order to find a solution a wide literature search into new nanoparticle 
production methods, polymers and etoposide analogues was undertaken. 
The literature search, analysis of the literature and subsequent studies 
are reported in the next chapter.           
                                       
3 Determined in 10mM HEPES, pH=7.4 
4 Determined in PBS 
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Chapter 6.  Screening and evaluation of a nanoparticle 
library 
Section 6.1  Review of etoposide and teniposide 
submicron delivery systems 
The low drug loading results and the problems with etoposide formulation 
described in Chapter 5 necessitated a different approach towards 
formulating a successful delivery system for use in medulloblastoma and 
other brain tumours. Instead of focusing on a single polymer (PGA) and a 
single drug (etoposide), the search was expanded to include a library of 
polymers and etoposide analogues.  
In this respect it is vital to take a closer look at podophyllotoxins and 
their development path up to now. Examining the tortuous path of their 
past is crucial for understanding the future of these mainstay anticancer 
drugs.   
The development of the semi-synthetic drugs etoposide and teniposide is 
a captivating story spanning from ancient folk medicine to modern drug 
discovery, catalysed by a serendipitous aldehyde condensation 
reaction[345]. The American Podophyllum peltatum and the Indian 
Podophyllum emodi (or hexandrum) are two closely related plants which 
have been used in folk medicine for their emetic, purgative, anthelmintic 
and cholagogue effects[346]. The parent compound, podophyllotoxin, 
was isolated from the roots of the plants and sparked interest in the 
cancer field after demonstrating activity against benign genital 
warts[347]. Podophyllotoxin (Figure 6-1) was shown to act on the mitotic 
spindle similarly to colchicine[348], blocking cell division in 
metaphase[349]. 
Unacceptable gastrointestinal toxicity precluded the use of 
podophyllotoxin in cancer therapy and in an effort to improve its 
pharmacological properties around 600 derivative compounds were 
investigated for over 20 years by the group of Stähelin and von Wartburg 
in Sandoz[345]. The chemists hypothesized that the pharmacokinetics 
and toxicity of the lignan aglycone podophyllotoxin would be improved by 
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conjugating it to sugars to form glycosides in analogy with the Digitalis 
cardiac glycosides. The initial compounds were less toxic and more water 
soluble but also less active. One of the strategies to stabilise the 
glycosides against hydrolases was to form acetals with aldehydes. The 
benzaldehyde adduct of the non-purified extract (SPG) was less toxic, 
orally active and increased survival in leukemic mice which led to its 
market approval. In contrast to the tubulin interference demonstrated by 
the parent podophyllotoxin, the SPG mix acted via a different mechanism 
and prevented the cells from entering mitosis rather than blocking them 
during cell division. However, none of SPG’s known components could be 
identified as responsible for its effects. An extensive search led to the 
discovery that a small percentage of the compound 
demethylepipodophyllotoxin benzylideneglucoside (DEPBG) was the 
active component responsible for the anti-leukaemia action of SPG. 
The most important characteristics required for the improved anticancer 
activity were identified as epi-configuration at C-9, free hydroxyl group at 
C-4’ and an aldehyde-protected sugar in the glycoside. As pointed out by 
the leading scientists of the team[345], the cell culture studies were vital 
in establishing the presence of DEPBG in SPG, elucidating its new 
mechanism of action and understanding the structure-activity 
relationships of the various other aldehyde compounds in the chemical 
screen. Etoposide and teniposide (Figure 6-1) were taken forward based 
on their in vitro and in vivo potency. 
 
Figure 6-1. Chemical formulas of the parent drug podophyllotoxin and its semi-synthetic 
epipodophyllotoxin derivatives etoposide and teniposide. Notice the different conformation 
of the OH group at C-9 and the free phenol moiety at C-4’. Etoposide phosphate 
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(etopophos) is a water soluble prodrug of etoposide that is rapidly hydrolysed by 
phosphatases in the blood after infusion. 
The clinically used etoposide, its water-soluble phosphate prodrug, and 
teniposide act by disrupting the mammalian topoisomerase II[350]. 
Topoisomerase II is responsible for unwinding knots and tangles in DNA. 
It relieves chain tension by introducing transient double strain breaks in 
the DNA and requires ATP to function[351]. Etoposide and its analogues 
do not inhibit the catalytic function of the enzyme but rather stabilise the 
normally transient covalent complex between topoisomerase II (TopoII) 
and DNA. This effectively poisons the enzyme turning it into a genome 
disruptor by introducing single and double DNA strand breaks and DNA-
protein complexes. These breaks and complexes lead to chromosome 
aberrations, disruption of transcription and replication culminating in 
S/G2 blocks, apoptosis and cell death[352]. There are two forms of the 
TopoII enzyme in humans- α and β[353]. While α is mainly expressed in 
dividing cells, β is constitutively expressed in quiescent cells. The 
epipodophyllotoxins target both forms of the enzyme and their action 
towards TopoIIβ has been implicated in causing secondary malignancies 
like acute myeloid leukaemia[354]. Moreover, the lack of selectivity 
towards normal cells is the reason behind the dose-limiting toxicity of 
epipodophyllotoxins towards the bone marrow and gastro-intestinal 
tract[355]. Therefore, delivering TopoII inhibitors at the right place with 
a carrier system that offers improved selectivity can enhance their 
therapeutic index by increasing tumour exposure and minimizing off-
target toxicity and side effects. 
The importance of schedule and chemotherapy dosing is especially 
apparent for topoII inhibitors. Early in the development of 
epipodophyllotoxins it was reported that their effects are dependent on 
the dosing regimen[356]. Afterwards other reports and reviews have 
demonstrated that prolonged low-dose regimens can have a profound 
influence on etoposide’s activity[357]–[359]. Even though this has raised 
hopes for the inclusion of metronomic antiangiogenic regimens in the 
treatment of brain tumours[122], [141], long term topoII chemotherapy 
has been linked to an increased risk for secondary malignancies[360]–
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[362]. These side effects further stress the importance of delivering 
chemotherapy agents to the right cells using an appropriate formulation.  
Etoposide is very slightly soluble in water (140-200µg/mL) and its 
octanol-water-partition coefficient is 9.94 (logp=1)[363]. As seen by its 
chemical formula (Figure 6-1), it is a lactone and is therefore most stable 
at pH 5-6 and unstable in pH<3 or pH>8[363]. Due to its limited 
aqueous solubility, etoposide for injection is formulated with benzyl 
alcohol, PEG 300 and polysorbate 80 in ethanol[364]. Those excipients 
are not completely benign and have defined pharmacological effects. 
Benzyl alcohol has been implicated in anaphylactoid reactions[365], 
[366]. Additionally this excipient can accumulate in infants and cause the 
fatal ”gasping syndrome”[367], [368]. Moreover, neurotoxicity of benzyl 
alcohol has been reported when delivered to the brain[369], [370]. The 
use of PEG 300 has been linked to cracking of ABS (acrylonitrile, 
butadiene and styrene) plastic infusion devices[371]. In addition to 
causing hypersensitivity reactions, polysorbate 80 in the etoposide 
formulation is also blamed for the leakage of phthalates from PVC 
infusion bags and catheters[372]–[374]. 
The prodrug of etoposide, etoposide phosphate, is water-soluble up to 
20mg/mL and its formulation does not contain extra solvents or 
solublisers. In this regard, etoposide phosphate would appear more 
suitable for local delivery to the brain and CSF. However, the prodrug 
requires phosphatase-catalysed activation to etoposide to exert its action 
because the free 4’-OH is crucial for topoisomerase inhibition[375]. 
Although the conversion to etoposide is rapidly achieved in the blood 
stream by plasma phosphatases, there is very limited data regarding 
phosphatase activity in the CSF and the conversion of phosphate 
prodrugs to the parent compounds in the brain. One study looking at 
intrathecal administration of dexamethasone phosphate found that the 
prodrug was hydrolysed in the CSF within 40 minutes[375]. Despite 
those encouraging results, additional studies are needed in order to 
establish whether that can be replicated for etoposide phosphate. For the 
purposes of nanoparticle delivery, the phosphate prodrug is less 
attractive because of its higher hydrophilicity and aqueous solubility 
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which may limit loading and increase release rates from hydrophobic-core 
nanoparticles. 
The pharmacokinetics of the epipodophyllotoxins can reveal some crucial 
considerations regarding their delivery to the brain. Both etoposide and 
teniposide are more than 90% albumin-bound and this is thought to be 
the reason behind their poor penetration through the blood-brain barrier 
[376]. Upon intravenous and oral administration of 50-150 mg/m2 
etoposide or teniposide,  the  intratumoral concentration was found to 
vary for both drugs, ranging from virtually undetectable to biorelevant 
levels 1-2 µg/g (10-14% of plasma levels) in some brain tumours[377]–
[379]. The concentrations in the bordering normal tissue were generally 
two times lower and CSF levels were 0.7% of the plasma concentration. 
Considering the demonstrated poor capacity to cross the BBB, barrier 
disruptions in brain tumours have been postulated to be behind the 
response to low dose oral etoposide therapy in medulloblastoma[202]. A 
useful illustration of BBB disruption in brain tumours is given in a study 
looking at methotrexate concentrations using microdialysis probes. The 
authors found 17-times higher concentrations of the drug in contrast 
enhancing regions compared to regions with intact blood-brain 
barrier[380]. Those blood-brain barrier disruptions can vary between 
different tumour types, between patients and also between the regions of 
the same tumour. Nevertheless, in the case of epipodophyllotoxins the 
need to maintain ten times higher plasma levels in order to achieve 
cytotoxic concentrations in tumours would come at the expense of severe 
haematological toxicity and increased risk for secondary malignancies.  
In this regard, local therapy in the brain will bypass the blood brain 
barrier and require doses which are much lower compared to systemic 
treatment. For example, a feasibility study by Fleischhak[120] 
demonstrated that a 0.5 mg etoposide dose delivered intraventricularly 
maintained CSF levels >1 µg/mL for 4 hours. In contrast, even with 
400 mg/m2 systemic etoposide CSF levels were below 0.1 µg/mL. An 
important limitation was that etoposide was quickly cleared by bulk flow 
and penetration into the brain was minimal judging by the volume of 
distribution which matched that of the CSF. The rapid clearance would 
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necessitate frequent administration to the brain via an Ommaya reservoir 
or an infusion pump that would diminish patient comfort and increase 
risks of infectious meningitis, especially in immunocompromised patients. 
A possible route for improvement may be a slow-release submicron 
formulation of etoposide analogous to the liposomal cytarabine product 
Depocyte[381], [382]. It should be noted, however, that increased drug 
exposure of the tumour tissue would always lead to increased exposure 
of the normal brain as well. In the case of Depocyte this manifests as 
chemical arachnoiditis and requires dexamethasone pretreatment[382]. 
Therefore, apart from an extended release profile, an improved 
formulation should also display preferential uptake and toxicity in tumour 
cells compared to normal tissue. 
In summary, epipodophyllotoxins are not specific towards cancer cells, 
they are poorly distributed in the brain and their action strongly depends 
on prolonged drug exposure. An ideal drug delivery system would be 
administered locally, would display an extended release profile and a 
certain amount of selectivity towards tumour tissue. This should warrant 
improved therapeutic profile with enhanced safety and efficacy. 
Based on the abovementioned considerations, the cell culture results for 
etoposide described in Chapters 3 and 4 along with the requirements for 
nanoparticle delivery, acceptance criteria for etoposide loaded 
nanoparticles were set as: 
1. Drug loading > 3%  
2. Particle diameter < 300 nm 
3. Drug release over 48h 
4. At least 2X potentiation of toxicity in vitro compared to etoposide 
5. Relatively non-toxic nanoparticle carrier. 
An initial literature search was undertaken in order to pinpoint successful 
etoposide formulations in addition to important polymer characteristics 
and nanoparticle preparation methods. The search included the PubMed, 
Web of Science, Scopus and Scifinder databases using the keywords 
“etoposide nano*” or “etoposide formulation”. Over 40 original research 
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articles were identified that described the preparation, purification, in 
vitro and/or in vivo testing of various drug delivery systems. 
The results are summarised in Table 6-1 and are colour-coded using a 
traffic light system, based on whether the results from the study could be 
practically implemented in-house. Loadings above 3% and size below 
300 nm received green rating. Nanoparticle purification, release, cell 
culture and comments were classified using an integrated approach 
combining reliability of methodology, possibility for reproduction and the 
relevance of the cell model reported. In these categories red means a 
rejection for further consideration, amber- proceed with caution and 
green-acceptance.  
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Year Ref Type of DDS Method Load 
ing% 
Size 
d, nm 
Clean 
up 
Release Cell-culture Comments 
2010 [383] 
PEG-PSA 
microspheres 
E 40 1800 C/W Not sink ETO not particles 
improved survival 
in vivo 
2013 [384] 
Mesoporous 
CaCO3 
binary 
solvent 
39 2000 C/W 
Sustained days 
depending on pH; 
Not sink 
Non-toxic- HEK293T; 
Potentiation in gastric 
cancer 
Not in polymer NP scope 
2012 
2014 
[385] 
[386] 
Dextran 
stearate  
micelles 
D 30 170 D 
Not sink; Burst 40% 
in 12h; 60% in 24h 
Potentiation of tox. in 
cell culture. Micelles 
toxic as well 
only IC50 given, statistical analysis 
not disclosed Less than one molecule 
stearic acid per dextran chain, 5-
6ug/mL CMC,CMC higher than 
quoted cytotoxicity figures 
2010 [387] 
MePEG-PCL 
micelles 
D 25 264 D 
48% released in 24h; 
60% by 48h 
Higher tox in low doses same tox as etoposide after 3-
10ug/mL etoposide 
2005 [388] 
PEG-PCL Star 
micelles with 
PAMAM core 
Solid 
extraction 
22 
17 
and 
60 
N/A N/A Cytotoxicity same as etoposide 
2013 [389] 
nanohybrids 
hydrotalcite 
co-
precipitatio
n 
20 60 C/W 300 minutes  Very quick release 
2013 [390] Conj. with Hyaluronic acid 17.00 32 Col/D 2% per day 4.2 times potentiation of  tox 
2014 [391] PLGA-PEG E/ NP 12 / 7 
173 / 
146 
C/W 11% Burst 40% 24h In vivo- higher AUC No cell culture studies 
2013 [392] PEG-PLGA E 12.00 170 C/W N/A In vivo studies 
Limited data on proportions, 
surfactants, loading 
2011 [393] 
Polyhydroxy-
alkanoate NPs 
E 10 200 C/W Not sink HeLa cells, modest effect 
2010 [394] 
PLGA-MPEG; 
PLGA-Pluronic 
E 10.00 148 C/W 
26% in 12h  
50% in 48h; 
Cell uptake data in follow-up study; barely better than 
etoposide- data interpretation questionable[395] 
2011 [396] Solid lipid NPS NP 10.00 
130 / 
500 
N/A 24h N/A 
Obscure journal, data very scarce, 
may not be genuine 
2013 [397] 
Albumin 
nanosusp. 
E 8.65 190 N/A 24h 
In vivo pK –lung, 
spleen 
Chinese patent [398] 
2013 [399] 
PLGA/Pluronic 
F68 NPS 
NP 7.70 130 C/W 
60% in 6h 
80% 48h 
Potentiation 
Glycofurol, PEG, Benzyl alcohol may 
have interfering effects 
2010 [400] PLGA 50:50 E 7.5 160 C/W 24h, 55% Formulation optimization study- no cell culture 
2013 [401] PLA E 6.03 163 C/W 
20% burst, 60% in 
48h 
Polymer appears as toxic as etoposide? 
2012 [402] 
NP butyl-
cyanoacrylate 
E 6.00 160 C/W 80% 6h Quick release 
2012 [403] 
micellar 
formulation 
PEG-PCL 
NP 
5.32 
4.5% 
86 Filt 50% 48h 
Loading more than theoretical; Volume in dialysis bag for 
release not disclosed 
2012 [404] 
PEG-fatty acid 
micelles 
E 5.00 
13-
479 
C/ UF Burst in 5h No cell culture studies 
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Year Ref Type of DDS Method Load 
ing % 
Size 
d, nm 
Clean 
up 
Release Cell-culture Comments 
2014 [405] LNC E 3.35 
110-
450 
C/W N/A 
Toxicity of positively 
charged lipids 
Loading determined from 
supernatant 
2006 
[406] 
LNC E 3 370 C/W 
Not sink; 30% in 24h 
50% in 48,  
In vivo studies - estimate tumour growth by weigth gain 
[407] 
[408] 
[409] 
2007 [180] 
100%C8- 
Poly( glycerol 
adipate) 
NP 3.00 126 Col 
40% in 1 day 
50% in 6 
No cell culture Can't reporduce 
2007 [410] PVP-PDLLA E 2.00 200 C/W 
20-30% in 24h 95% 
in 13days 
No cell culture MgCl2 salting out to increase DL% 
2012 [411] LNC E 1.80 170 D Release in 6h Claimed, potentiation Blank NPs as toxic as etoposide 
2012 [412] NP PLGA 502H NP 1.50 150 C/W 
12h - 40%,  
48h- 50% 
Small potentiation 
After 72h 
2013 
[413]
. 
PLGA NP 1.45 105 
C/W 
48h; 50% in 24 
In vivo - Tc labelling may label PLGA as well/ not specific 
2008 [414] PLGA; PCL NP / E 1.45 
92-
257 
2013 [415] 
Poly(NVCL-co-
MMA) 
In situ 
Polym 
0.65 20 C/W 20-40% Burst 1h Less toxic than ETO 
2013 [416] LNC 
X Phase 
inversion 
0.57 50  NPs toxic even w/o etoposide 
2014 [417] LNC E 0.30 
121( 
50-
650) 
C/W 
60% in 12h; 
Sustained for 24h 
Same in cell culture and in vivo 
2006 [418] LNC E 0.10 
25-
100 
Filt. 
Sustained 60% in 
48h 
Potentiation of tox in 
cell culture 
Etoposide measured from 
supernatant/ Filtration to clean up 
2008 [419] LNC E 0.10 178 N/A Sustained for 24h Potentiation of tox in cell culture 
Table 6-1 Literature review of nanoparticle delivery systems using etoposide. Red, amber green classification is based on acceptance criteria for 
loading and size of submicron delivery system, quality of experimental design, probability for being reproducible, amount of data disclosed by 
authors and whether claims expressed in the paper match the results shown. LNC- lipid nanocapsules. Most common methods were emulsification 
based (E- emulsification-solvent evaporation and melt emulsification for LNC), nanoprecipitation (NP) and dialysis (D). Loading>3% is classified as 
green, between 1-2%- amber and below 1%-red. Size is green below 200nm, amber below 1000nm and red for microparticles. Effective 
nanoparticle clean-up methods were classified as green (D-dialysis, Col-gel column), amber(C/W-centrifugation and washing) and red (filtration or 
none) 
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As seen from Table 6-1 there is a considerable amount of research 
dealing with etoposide encapsulation in nanoparticles. While there were 
about 6 articles up to 2007, the number published in 2013 was over 10 
and more publications are expected in 2014. Despite the large amount of 
data published, most of the drug delivery systems described have not 
been taken forward for further development. 
Since the difficulties in extracting robust data from the published 
literature have been recognised in the preclinical and clinical 
settings[420]–[422], the RAG (red, amber green) coding system was 
employed to simplify the decision-making process in selecting 
reproducible reports. Emphasis was paid to articles that could be reliably 
used to establish a strategy for nanoparticle preparation. Some of the 
main considerations behind the ratings are given in the paragraphs below. 
A common, but rather unhelpful, way to present nanoparticle loading data 
is by using encapsulation efficiency. This parameter is derived from the 
loaded amount of drug in the NPs divided by the starting amount of drug: 
𝐸𝐸% =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔
𝑥100 
 
Equation 6-1 
𝐷𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔% =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
𝑥100 
 
Equation 6-2 
Equation 6.1 shows that encapsulation efficiency is a useful measure of 
drug waste during the process of nanoparticle manufacture, but it does 
not convey any information about the amount of drug in the delivery 
system. Although reporting entrapment efficiency of 90%, some 
nanoparticle delivery systems have an actual loading of 3%[409] and 
0.3%[417]. In this regard, encapsulation efficiency is a misleading way to 
present nanoparticle formulation data and its use without the explicit 
statement of drug loading can indicate selective reporting. 
After preparation, the nanoparticles need to be separated from the 
unencapsulated drug in order to distinguish their effects from those of the 
free drug. This can be achieved using several methods- centrifugation and 
washing, size exclusion chromatography by using a gel packed column or 
dialysis. Centrifugation and washing is a quick and easy procedure, 
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however it can leave a considerable amount of surface-bound 
unencapsulated drug on the nanoparticles. The adsorbed drug would 
serve to boost reported loadings but would ultimately lead to a quick 
burst release. A good example of the limits of the centrifugation/washing 
process is the study by Gaucher et al.[410], where they used a 20% 
MgCL2 solution to limit the solubility of etoposide in the aqueous phase 
while making the nanoparticles. Despite centrifuging and washing their 
particles three times, they still had 5.5% MgCl2 in the “clean” 
nanoparticles. Striving for better separation some authors have opted for 
dialysis[385]–[387], [411], while only two of the etoposide studies report 
the use of a column to separate the nanoparticles from the free 
drug[180], [390]. Strikingly, there are a number of papers where no-
clean up at all was reported or plain filtration was used for removing the 
unencapsulated etoposide[388], [397], [403], [418], [419]. Omitting the 
separation step raises considerable doubts that the reported loadings 
would remain as high as reported after a thorough clean-up procedure is 
applied. 
The next step in the in vitro characterisation of nanosized delivery 
systems is the determination of drug release which aims to establish how 
long the drug remains associated with the carrier. The release profile can 
serve as a prediction tool for nanoparticle performance in cell culture and 
animal experiments when a biorelevant release medium is used. An 
important prerequisite for correctly assessing release is the experiment to 
be performed under sink conditions. Sink conditions approximate infinite 
dilution and are satisfied when the concentration of the released drug is 
low enough so that it does not influence the release profile. According to 
the EU Pharmacopoeia[423] sink conditions are achieved when the 
released drug is at levels 5 to 10 times below the solubility limit. As 
etoposide’s solubility is quite low, many of the studies reviewed did not 
satisfy these criteria[383], [385], [393], [408].  
Determination of drug release from submicron delivery systems is a 
difficult task because of the small size and relatively fragile nature of 
some platforms like liposomes and micelles. A number of methods have 
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been proposed ranging from dialysis[424], centrifugal ultrafiltration[425], 
pressure ultrafiltration[426] and ultracentrifugation[427].  
The dialysis technique is the most popular method to study drug release 
from submicron systems and has almost exclusively been used in the 
etoposide studies. The usual set up involves a small donor compartment 
filled with a solution containing the delivery system which is separated by 
a dialysis membrane from a sink acceptor compartment, containing the 
bulk of the release media. The release of the drug from the delivery 
system is compared to a control sample containing the drug in solution. 
Serious concerns have been raised regarding the reliability of dialysis in 
determining drug release. As shown by Washington[428], [429] the 
appearance of drug in the receiving compartment can be significantly 
influenced by the interaction of released drug and the surface of the 
colloid carrier system. The bias in results produced from release 
experiments using dialysis has been discussed in a number of 
publications[430]–[432]. Some authors have proposed solutions to the 
violation of sink conditions in the donor compartment by using the 
inverted dialysis method[433] or by extensive dilution in the dialysis 
tube[434]. Even with these augmentations, the influence of the surface 
interaction between free drug and the carrier system needs to be 
accounted for. That can be achieved by including an additional control of 
empty carrier supplemented with a solution of the drug in an amount 
equivalent to the one encapsulated in the delivery system. Nevertheless 
dialysis should be used with caution and the results interpreted carefully 
in nanoparticle systems showing release faster than a few days[429]. 
The other methods of determination of drug release involve sampling a 
sink compartment with the colloidal system and separating the continuous 
from the disperse phase. Ultracentrifugation can be used when the 
particles are approaching the micrometre range[384] or when there is a 
sufficient difference in density between the two phases[435].  However, 
the use of ultracentrifugation may be limited when the particle size is 
below 100nm, or the densities of the disperse phase and continuous 
phases are similar as this would lead to very long centrifugation times and 
may disrupt the carrier causing a premature leakage of drug[430]. This is 
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why many researchers have turned to centrifugal ultrafiltration which 
uses centrifugal force to filter a small amount of sample through a 
membrane with Mw cut-off of 10-300 kDa. There are a number of devices 
available, normally used for protein purification, which offer a small 
working volume (0.5 mL) and a variety of membrane sizes and materials 
(polyethersulfone, regenerated cellulose, cellulose esters). Additional 
checks for nanoparticles appearing in the filtrate[430] and non-specific 
drug adsorption[425] should be included when these systems are utilised. 
Similarly to the centrifugal filtration devices, the tangential flow filtration 
cells use a filter membrane to separate the dispersed from the continuous 
phase. However, instead of relying on centrifugation force, they utilise a 
tangential pressure gradient in order to minimise membrane fouling[426]. 
The pressure filtration units are bigger than the centrifugal ultrafiltrators, 
starting at 3 mL, and while their design ensures minimal membrane 
fouling, interaction and binding of hydrophobic drugs to the membranes 
still pose a problem[430].  Other more creative and elegant solutions 
include the utilisation of electrochemical monitoring[436], [437], 
microdialysis probes[438], fluorescence quenching[439] and 
bathochromic shift[440] methods. Since epipodophyllotoxins are 
electrochemically active[441] it would be feasible to determine etoposide 
and teniposide release from nanocarriers using electrochemical methods. 
The next step after successful drug release profile characterisation is to 
test the nanoparticle system in an in vitro cell line that would be relevant 
for the intended use. Ideally, the carrier would not exhibit pronounced 
toxicity, and the drug delivery system would display superiority in either 
potency or selectivity when compared to the free drug. While many 
tumour cells are relatively easy to culture in vitro, finding a suitable 
model for normal tissue is a challenge. It can be argued that the 
adenovirus transformed HEK293[384] and the murine fibrosarcoma cell 
line L929[393] cannot be used as reliable proxies for normally behaving 
human tissues.  
Designing a nanoparticle delivery system is often a multidisciplinary effort 
involving experts from different fields. That is why it is easy to imagine 
how some studies, interested in nanoparticle delivery, have managed to 
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include cell culture data with little information on the methods used to fit 
dose-response relationships or how they calculate and compare IC50 
values[385], [386], [399], [401], [411]. In their 2011 article Yadav et 
al[395] claim that their drug delivery system offers a three-times 
reduction in IC50 for L1210 cells and 1.6 times for DU145 cells compared 
to etoposide. Surprisingly, they have not disclosed the equation used to 
model their dose-response data and have apparently based their IC50 
determination on a single measurement (Figure 1a, 5 µM concentration). 
Moreover, it can be argued that the DU145 cells are resistant to etoposide 
and the differences in IC50s may be statistically significant but are 
negligible in practice. A few of the carrier polymers and surfactants used 
in the nanoparticle delivery systems appear quite toxic[385], [386], [405] 
sometimes as potent as etoposide itself[401], [411]. At the very least 
that makes critical analysis of the in vitro data very difficult and brings 
into question the claimed effects. 
Section 6.2  Nanoparticle screening strategy 
Despite the heterogeneity and the patchy nature of the information 
collected, a few conclusions can be made from the papers discussed in 
Table 6-1: 
1. Emulsification / solvent evaporation has higher reported drug 
loadings than nanoprecipitation. 
2. PEGylated block copolymers(PCL-PEG, PLGA-PEG) have higher 
reported drug loadings 
3. Micellar systems have higher reported drug loadings but some are 
toxic and others not much different to free etoposide[387], [388] 
It is feasible to conclude that the problems of incorporating etoposide in 
poly (glycerol adipate) nanoparticles described in Chapter 4 are partly due 
to the method of nanoprecipitation and partly because of etoposide’s 
limited affinity for the polymer. Although often being called poorly soluble 
etoposide has 200 µg/mL solubility in water, logP ~1 and it has multiple 
sites suitable for H-bonds. Moreover, it is not very soluble in lipids[442] 
and tends to dissolve in PEG400, Tween and Cremophor EL[443], [444]. 
Hence a more accurate description of etoposide would be that it is a very 
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slightly water soluble amphiphilic molecule. With that in mind it may be 
possible that during nanoprecipitation with a water-miscible solvent 
etoposide is further solubilised in the aqueous environment and upon 
acetone evaporation deposits on the surface of the polymer particles or as 
separate crystals in the aqueous solution. 
  
Figure 6-2. Comparison of the two most common methods for nanoparticle preparation. A-
Nanoprecipitation: polymer and drug are dissolved in a water miscible solvent and added 
dropwise under stirring to the aqueous phase. B-Solvent-emulsification: water immiscible 
solvent (DCM, Benzyl alcohol or Ethyl acetate) is mixed with the aqueous phase with the 
help of surfactant (emulsifier) and homogenised to form a course emulsion with a rotor-
stator homogenizer. Nanoemulsion is formed in a third step using sonication or high-
pressure. The final step is solvent removal usually under reduced pressure.  
The term nanoprecipitation (Figure 6-2) is often used interchangeably 
with the original “interfacial deposition method” described by Fessi[445]. 
In contrast to conventional nanoprecipitation, the Fessi method employs 
an additional excipient, namely an oil phase in which the drug is soluble, 
to make nanocapsules rather than polymer nanospheres[176], [177], 
[180].  Fessi et al. have relied on the solubility of the drug in the oil phase 
and its tendency to stay there rather than distribute in the aqueous 
phase. The polymer merely makes a protective film on the oil/water 
interface and hence the name “interfacial deposition method”. It seems 
that given etoposide’s solubility in water, tendency to crystallise and drop 
out of solution and its low solubility in lipids[442]–[444] neither the 
nanoprecipitation nor the interfacial deposition methods are going to be 
suitable. 
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The solvent-emulsification method (Figure 6-2) where the drug is 
emulsified in a solvent which is immiscible (CHCl3, CH2Cl2) or has limited 
miscibility with water (Ethyl acetate, Benzyl alcohol) may be a better 
alternative for drugs like etoposide. The limited miscibility of solvent and 
water will serve to keep etoposide in the organic phase and limit 
solubilisation in the aqueous one. The emulsification solvent-evaporation 
usually yields microparticles[446], [447] and the addition of water-
miscible solvents like acetone or methanol[448] or surfactants like sodium 
cholate[449], human albumin[397], TGPS[391], Pluronic F68[394] have 
been suggested to achieve particle diameters below 200nm. For self-
assembly PEGylated systems the issue with size appears to be less 
problematic although the use of Pluronic F68 in the aqueous phase was 
still reported[394]. In addition, most of the successful examples for 
nanoparticle drug delivery systems that have reached clinical trials 
BIND-014[449], [450], GenexolPM, and NK105[451] employ self-
assembly systems with PEG and are focused on the very poorly soluble 
taxanes. 
Etoposide’s aqueous solubility (200 µg/mL) may be the reason for the low 
loadings reported in Chapter 4 and a more hydrophobic analogue 
(teniposide) could achieve higher levels of incorporation. Teniposide has 
aqueous solubility of 0.54 µg/mL[452] and has been reported to be more 
potent compared to etoposide against medulloblastoma in vitro[453]. 
Cremophor EL in the formulation of teniposide[454] has been implicated 
in anaphylactic reactions and neurotoxicity[455]. In addition the 
formulation contains benzyl alcohol and dimethylacetamide[456] making 
it even less suitable for intra-CSF administration and local brain 
therapy[369], [370].  
Compared to etoposide there is much less data on teniposide 
incorporation into nanoparticles and submicron delivery systems. One 
study looked at PLGA loaded nanoparticles and has claimed 12% loading, 
however the authors seem to confuse nanoprecipitation and emulsification 
methods and had drug degradation during the release[457]. Most other 
studies have looked into emulsion formulations trying to substitute 
Cremophor EL and organic solvents for safer alternatives[452][458]. 
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Zhang et al. have reported 2% loading in an emulsion formulation with 
medium chain triglycerides, solutol HS and tocopherol polyethylene glycol 
1000 succinate[459]. While the improvement shown in the in vivo results 
looks impressive, the authors have used centrifugation to clean up the 
emulsion and have not disclosed enough details about the release. 
Moreover the drug-free delivery system seems at least as toxic as 
teniposide to MCF-7 cells in the in vitro screen. 
A screening plan for finding a successful nanoparticle formulation was 
established based on the literature search and the previous experiments. 
The polymers 100%C8-PGA, 40%C18-PGA and a PEGylated version of 
PGA were chosen from the poly(glycerol) adipate library. In order to 
increase the diversity of the screen four additional polymers were supplied 
in collaboration with Prof Cameron Alexander.  Two were block 
copolymers of polyethylene glycol (PEG) with poly(caprolactone) and 
poly(decalactone). In addition two other thermoresponsive block 
copolymers of poly(ethyleneglycolmethacrylate) with poly(lactic acid) and 
poly(caprolactone) were included as well. The first phase of the screen 
was envisaged to compare all polymers with etoposide and teniposide 
using nanoprecipitation. If loadings above 3% were not achieved, then 
solvent-emulsification would be attempted. Finally an optimisation 
program with different solvents and surfactants would pinpoint the right 
formulation that can meet the criteria of 3% loading, lower than 300nm 
size and a sustained release profile. 
Section 6.3  Materials and methods 
6.3.1 Materials 
Poly(glycerol adipate) (PGA) , 40% C18-substituted poly(glycerol adipate) 
(40%C18-PGA), 100% C8-substituted poly(glycerol adipate) were 
synthesized by the author during this PhD project. PEG-poly( glycerol 
adipate) (PEG-PGA) was synthesized in Prof Martin Garnett’s lab. Kuldeep 
Bansal synthesized and characterised poly(caprolactone)-PEG(5kDa-
5kDa,PCL-PEG)) and poly(decalactone)-PEG(6kDa-5kDa, PDL-PEG), while 
Lee Moir prepared and characterised poly(lactic acid)-co-
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poly(ethyleneglycolmethacrylate) (PLA-PEGMA) and poly(caprolactone)-
co-poly(ethyleneglycolmethacrylate) (PCl-PEGMA) block copolymers. 
Sodium cholate, resazurin and polysorbate 80 were obtained from Acros 
organics (Loughborough, UK) 
Teniposide was acquired from Sequioia Research Products (Pangbourne, 
UK) 
Etoposide, tocopherol polyethylene glycol 1000 succinate, polyvinyl 
alcohol (88kDa) were purchased from Sigma-Aldrich (Dorset, UK) 
All solvents were purchased from Sigma-Aldrich (Dorset, UK) or Fisher 
Scientific (Loughborough, UK) 
6.3.2 Polymer characterisation 
1H-NMR spectroscopy (Bruker 400Mhz, CDCL3), was used to calculate Mw 
and percent of polymerisation for PCL-PEG, PDL-PEG, PLA-PEGMA and 
PCL-PEGMA. 
Gel permeation chromatography (GPC) was performed on a Polymer Labs 
GPC 50 Plus system with a refractive index detector. Separations were 
performed on two PL-gel Mixed-D columns. Chloroform-triethylamine 95/5 
was used as the mobile phase (flow rate of 1 mL.min-1). Polystyrene was 
used as calibration standard (160 Da–240 kDa, Polymer Labs, UK). 
Molecular weights and polydispersity indices were calculated using 
Polymer Labs Cirrus 3.0 software. 
The change of absorbance of nanoparticle suspensions (PBS) in response 
to change of temperature was investigated using UV/VIS 
spectrophotometer (Beckman, DU 800). Turbidity measurements were 
taken at 550 nm and cycles were run from 20–90 °C at ramp rate of 
1 °C.min−1. 
6.3.3 Nanoparticle preparation 
All activities with etoposide and teniposide were performed under 
conditions protecting the substances from light either by using amber 
glassware or aluminium foil. 
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6.3.3.1 Nanoprecipitation 
Etoposide or teniposide (1.5 mg) and polymer (10 mg) dissolved in 
acetone (1 mL) were mixed with water (2 mL) using a chamber mixer 
(Pharmacia, 50-60 Hz, 5 MPa). The aqueous (4 mL/min) and organic 
(2 mL/min) phases were delivered to the mixer using two peristaltic 
pumps (Pharmacia). Acetone was left to evaporate for 8 hours and the 
suspensions were filtered through a 0.45 µm syringe filter before 
separation of the free drug.  
6.3.3.2 Solvent emulsification 
Etoposide or teniposide (3 mg) and polymer (17 mg) were dissolved in 
dichloromethane (DCM, 1 mL) and mixed with water (4 mL) with or 
without the addition of different surfactants using a high-shear mixer 
(Ultra-Turrax, IKA T25) for 1 minute at 24000 rpm. The resultant course 
emulsion was immediately sonicated with a probe sonicator (Bandelin 
UW2070, 60% power, 2 minutes). The Nanoemulsion was evaporated 
using a rotary evaporator at 30 ˚C. The resultant nanoparticles were 
filtered through a 0.45 µm syringe filter and rapidly transferred for 
separation of the free drug. 
6.3.4 Separation of nanoparticles and free drug 
Sephadex GH25 desalting columns (PD-10, GE Healthcare) were used to 
separate the nanoparticles from the free drug. Briefly, the columns were 
washed with 10 volumes of pure water before loading with nanoparticle 
suspension (2.5 mL). Pure water (3.5 mL) was used to elute the 
nanoparticles and the columns were then washed with another 30-50 
volumes of water before reuse. Either fluorescence spectrophotometry or 
HPLC was employed to ensure lack of etoposide/teniposide in the column 
eluent before nanoparticle clean up. Separation of the free drug from the 
nanoparticles was verified using a solution prepared in the same way as 
the nanoparticles but omitting the polymer. No etoposide/teniposide was 
detected in the fraction normally collected for the nanoparticles. 
6.3.5 Size and zeta potential characterisation 
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The hydrodynamic radii of the nanoparticles were determined via dynamic 
light scattering at 90° angle using a Viscotek 802 instrument (830 nm 
laser, 60 mW, 10% power). At least 10 measurements were performed on 
each sample with a duration of 4s per measurement. While intensity 
measurements were used to measure particle size, mass and number 
distributions were examined to investigate the presence of multiple 
populations.  
The zeta potentials of the nanoparticles were determined using Laser 
Doppler Electrophoresis (Zetasizer NanoZS, Malvern) in 10mM HEPES 
buffer. At least three measurements were performed on each sample. 
6.3.6 Drug loading 
Drug loading was determined by freeze-drying a set volume of 
nanoparticle suspension (0.5-1 mL) in a preweighed amber HPLC vial. The 
weight difference was recorded and the nanoparticles were dissolved in 
DCM:DMSO (1 mL, 50:50). Absorbance was recorded at 284 nm with a 
UV spectrophotometer (Varian Cary Bio 50, Agilent). Fluorescence 
spectrophotometry (Varian Cary Eclipse, Agilent) with excitation 
(λ=284 nm), emission (λ=325 nm) and slit (5 nm) was measured against 
freshly made standards.  
6.3.7 Drug release 
6.3.7.1 Kinetic solubility of teniposide in release media 
Kinetic solubility of teniposide in PBS and PBS with added surfactant (1% 
sodium cholate or Polysorbate 80) was determined by adding teniposide 
(1000X stock in DMSO) to the aqueous buffers and noting the appearance 
of visible nanosuspension. Drug concentrations resulting in cloudy 
solutions were labelled as above the kinetic solubility. Levels which 
yielded clear solutions were kept for a 24h stability test. They were 
monitored for the appearance of cloudiness, crystals or decrease in 
absorbance of fluorescence. At the time of preparation the clear solutions 
were assayed for UV absorbance at 240 and 284 nm and fluorescence 
(Excitation 240 or 284, emission 325, slit 5). The measurements were 
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repeated on the next day and samples with change in signal were 
classified as above kinetic solubility.  
Limit of quantitation (LOQ) and limit of detection (LOD) in the 
spectrophotometric determinations experiments were determined using 
the standard deviation of the y-intercept and the slope of the linear 
regression as per the EMEA and ICH analytical validation guidance[460]. 
𝐿𝑂𝐷 = 3.3 𝑥 
𝑆𝑇𝐷𝐸𝑉 𝑜𝑓 𝑦 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡
𝑆𝑙𝑜𝑝𝑒 𝑜𝑓 𝑙𝑖𝑛𝑒𝑎𝑟 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛
  
Equation 6-3 
 
𝐿𝑂𝑄 = 10 𝑥 
𝑆𝑇𝐷𝐸𝑉 𝑜𝑓 𝑦 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡
𝑆𝑙𝑜𝑝𝑒 𝑜𝑓 𝑙𝑖𝑛𝑒𝑎𝑟 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛
 
 
 Equation 6-4 
Release experiments were performed in release buffer containing 1% 
sodium cholate in PBS. 
6.3.7.2 HPLC determination of teniposide 
Teniposide release was determined via HPLC (HP Agilent 1050) with UV 
detection (λ=240 nm) using an isocratic method with a C18-reverse 
phase Lichrospher (250/4 mm) column at 40˚C.  The mobile phase was 
Acetonitrile (55%), aqueous phosphate buffer (45%, 50 mM, pH=7) and 
the flow rate was 1.2mL/min. The retention time for teniposide was 
2.9 min and the area of the peak was used for concentration 
determination. The noise range at 2.4 to 2.5 min and 3.2 to 3.4 min and 
was used to determine limits of detection and quantitation as 3 and 10 
times Signal/Noise respectively. Accuracy and specificity were assessed 
by the resolution of the teniposide peak to that of the other components 
of the release media. Precision was assessed by repeatability (intra-
assay) and intermediate precision (inter-assay variation) using the 
coefficient of variation with acceptance criteria CV<15% for all samples 
and CV<20% for the lowest levels. The robustness of the assay was 
explored by determination of recovery for teniposide samples after flash 
freezing and thawing. 
Screening and evaluation of a nanoparticle library 
 183   
  
6.3.7.3 Centrifugal ultrafiltration 
Centrifugal ultrafiltration devices (0.5 mL, Amicon, Vivaspin and Nanosep) 
with different membrane sizes (10-300 kDa) and membranes made of 
either polyethersulfone or regenerated cellulose were tested for their 
suitability in determining teniposide release from nanoparticles. 
Centrifugation forces ranging from 2000 to 14 000g were tested in effort 
to preserve nanoparticles integrity. 
Non-specific binding was quantified by analysing teniposide content 
before and after passing standards (0.025 µM to 30 µM) through the 
devices.  
Nanoparticle contamination of the filtrate was determined using dynamic 
light scattering. A standard curve was built from serial dilutions of a 
concentrated nanoparticle suspension in PBS using particle counts to 
determine relative nanoparticle concentration. The standard curve was 
used to determine the amount of nanoparticles passing through the 
membrane from suspensions in PBS. 
6.3.7.4 Dialysis 
Nanoparticle suspensions were diluted with release buffer to an equivalent 
sink concentration of teniposide (30 µM) and a small volume (0.5 mL) 
was placed in a dialysis tube (regenerated cellulose, 12 KDa, 5mm). The 
tube was sealed at both ends and placed in release medium (50 mL) 
under constant stirring at room temperature (25 ˚C). Control samples of 
teniposide (30 µM from 1000X DMSO stock) and empty nanoparticles 
supplemented with teniposide (30 µM from the same DMSO stock) were 
used to determine diffusion kinetics of teniposide and account for 
interactions between nanoparticles and free drug in the donor 
compartment. Samples (1 mL) were taken at 1h, 2h, 3h, 4h, 7h, 8h, 24h, 
48h and 72h. Sample volume (1 mL) was replaced with fresh media at 
1,2,3,7 and 8h while full media exchange was performed at 4h, 24h and 
48h. Samples were flash frozen with liquid nitrogen and stored at -20 ˚C 
until HPLC analysis. Before analysis thawing was performed at 37 ˚C and 
was followed by sonication for 1 minute.   
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6.3.8 Cell culture 
NSC (10000 cells/well) and UW cells (5000 cells/well) were seeded in 
ultra-low attachment plates (200 µL, neural stem cell media). The plates 
were centrifuged lightly at 100g for 3 minutes after seeding and the cells 
organised into one single spheroid per well within 24h. 
Spheroids were photographed and sized using the settings and macro 
described in Chapter 3 on days 3, 5 and 7. 
Freshly made nanoparticles were diluted (9:1) with PBS (10X) to form an 
isotonic nanosuspension. The theoretical teniposide equivalent of the 
initial nanoparticles suspension was estimated at 294 µM before dilution 
and 265 µM after dilution with PBS (2.4 mg/mL with approximately 8% 
loading). Actual concentrations were later measured 
spectrophotometrically and used to calculate equivalent teniposide 
exposure. Half-log dilutions (1 nM-30 µM drug equivalents) of the 
nanosuspension were made in media in for both cell types in parallel to 
teniposide dilutions (1 nM-30 µM) as well as controls with empty 
nanoparticles and media-only controls. 
6.3.9 Data analysis 
Results were analysed in Excel and Graphpad Prism version 6.0. All 
experiments were performed at least three times unless stated otherwise. 
Cumulative release was calculated from the concentrations of the 
samples, normalised to the highest value and plotted against time. Data 
were fit to first order release for comparison purposes and the 95%CIs for 
the time for 50% and rate constant compared after plotting. Dose-
response curves were analysed as described in Chapters 3 and 4. The 
logIC50 value determinations from the non-linear regression analysis 
along with the standard error of the logIC50 for the nanoparticle 
formulations and teniposide were compared in Graphpad Prism for each 
cell population using a t-test with Welch’s correction for unequal variance 
and P<0.05 was considered statistically significant. 
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Section 6.4  Polymer characteristics: 
The chemical formulas of the polymers used in the screening programme 
are given in Figure 6-3
 
Figure 6-3. Chemical structures of polymers used in the nanoparticle screen 
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Poly(glycerol adipate) polymers were characterised as described in 
Chapter 5 using NMR and GPC. The PDL-PEG and PCL-PEG polymers were 
characterised by Kuldeep Bansal using NMR, GPC and Differential 
scanning calorimetry, while Lee Moir prepared and characterised the PLA-
PEGMA and PCL-PEGMA polymers. The data is summarised in (Table 6-2): 
Polymer Mw Core Mw PEG(MA) Mw Tg Tm LCST 
kDa ˚C 
PEG-PCL 10 5 5 N/D N/D N/A 
PEG-PDL 11 6 5 -55 55 N/A 
PCL-PEGMA 27 15 12 N/D N/D 40 
PLA-PEGMA 20 12 8 N/D N/D 48 
Table 6-2. Characteristics of polymers used in the screening program. Molecular weight 
was determined by NMR and is given in kilodaltons, kDa. Glass transition temperatures 
(Tg) and melting temperatures (Tm) were measure using DSC. The Lower critical solution 
temperature for the thermoresponsive (LCST) was only investigated in the PEGMA-based 
polymers. 
The choice of polymers was made based on the analysis of Table 6-1 and 
the conclusion that block-copolymers incorporating a hydrophobic core 
and a hydrophilic corona have been reported to achieve higher loadings of 
etoposide and teniposide. Therefore block copolymers immediately 
available in the lab with a diverse set of chemistries were chosen in the 
search for formulations with higher drug loading.  
Section 6.5  Drug loading results 
The drug content of nanoparticles was measured directly by dissolving 
them in DCM and DMSO (50:50). Since they were a mix of polymer and 
drug and in some cases surfactant, fluorescence spectrophotometry was 
initially chosen as the preferred method of drug loading measurement. 
However the absorbance of the etoposide and teniposide standards at 
higher concentrations was quenching the fluorescence signal and resulted 
in a hyperbolic shaped standard curve. To account for this “inner filter 
effect”, fluorescence values were corrected using equation 6.3 in order to 
quantify nanoparticle loading as described in Lakowicz[461] (page56; 
Eq2.6): 
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𝐹𝑙𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐹𝑙𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑  𝑥 10
𝑂𝐷𝑒𝑥𝑐𝑖𝑡𝑎𝑡𝑖𝑜𝑛+𝑂𝐷𝑒𝑚𝑖𝑠𝑠𝑖𝑜𝑛
2   
Equation 6-5 
  
 
Figure 6-4 Standard curves for teniposide and etoposide and spread of fluorescence values 
for encapsulated drug samples made using nanoprecipitation  A-Etoposide; B-Teniposide 
Figure 6-4 shows that there was a linear relationship between the 
corrected fluorescence values and the concentration of both drugs.  The 
quantity of encapsulated etoposide was generally below 5 µg/mL for all 
formulations while teniposide levels were higher. The loading percentages 
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for the various formulations of etoposide and teniposide loaded 
nanoparticles prepared via nanoprecipitation are summarized in Figure 
6-5.  
 
Figure 6-5 Drug loading percentages for nanoparticles made using nanoprecipitation. A-
Etoposide; B-Teniposide; Dots represent separate individual experiments with at least 
three replicates per experiment 
While etoposide loaded nanoparticles made using nanoprecipitation 
showed loading below 0.3%, the formulation of PEG-PDL and teniposide 
had nearly 0.6% w/w encapsulated drug. The PGA-based polymers 
showed a lower loading for etoposide compared to PLA-PEGMA. Results 
for C8-PGA and PEG-PGA and teniposide were not obtained due to 
excessive precipitation of particles >1 µm. 
A screening program using solvent-emulsification was undertaken after 
nanoprecipitation did not achieve loadings above 1%. The initial plan was 
to prepare nanoemulsions without the use of surfactants and include 
surfactants only if there is significant phase separation and emulsion 
instability. However it was soon apparent that apart from PEG-PDL, PEG-
PGA and to a certain extent C8-PGA all other polymers required the 
addition of surfactant. Despite forming relatively stable DCM/water 
emulsions, there was a considerable loss of nanoparticles prepared using 
C8-PGA without emulsifier when they were passed through a 0.45 µm 
filter indicating micro- instead of nanoparticle formation. The 
abovementioned polymers are all viscous liquids or semi-liquids and it 
could be hypothesized that their molecules are able to quickly assemble 
at the interface of the DCM droplets to form metastable emulsions. The 
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solid polymers PEG-PCL, PLA-PEGMA, PCL-PEGMA and C18-PGA required 
emulsifier in the aqueous phase to prevent phase separation. Moreover 
even after the use of emulsifiers the particles formed from C18-PGA 
would only pass through a filter with pore size above 1 µm. That is why 
this polymer was excluded from later screen with the solvent-
emulsification method. 
Several surfactants were identified based on literature reports of their 
effectiveness in solvent-emulsification, especially in relation to etoposide 
and teniposide. Polyvinyl alcohol is the most common surfactant generally 
employed in the solvent-emulsification method but it can be hard to 
remove completely[462] and has been reported to affect 
biocompatibility[463]. Sodium cholate is a natural bile salt emulsifier that 
has been employed in the production of nanoparticles already in clinical 
trials[449], [450]. Tocopherol polyethylene glycol 1000 succinate (TPGS) 
is a Vitamin E analogue used as a surfactant, solubiliser and even a drug 
carrier[464]. More importantly it has recently been reported to improve 
the drug loading and release profile from etoposide-loaded PLGA-PEG 
nanoparticles[391]. Pluronic F68 was also included on the basis of 
favourable studies reported for etoposide nanoparticles made via the 
solvent emulsification method[394], [399], [400], [402].  
Surfactants, if used above the critical micelle concentration, may compete 
with the polymers for entrapping the drugs. Moreover the micelles would 
pass through the separation column along with the nanoparticles and 
artificially increase loadings. Therefore formulations of etoposide and 
teniposide without any polymer were prepared using the solvent-
emulsification procedure with plain water as well as various surfactant 
solutions to identify possible contamination with drug nanoparticles and 
drug-loaded micelles. 
Screening and evaluation of a nanoparticle library 
 190   
  
 
Figure 6-6 Concentration of drug passing through a Sephadex GH25 column (PD-10) after 
the solvent emulsification method. The drugs were dissolved in DCM without the addition 
of polymer. The aqueous phase contained either pure water, Sodium cholate (0.1%), 
TPGS(0.1%), Pluronic F68 (1%) or PVA(0.3%). Drug concentrations are determined using 
fluorescence spectrophotometry. None of the drug-free surfactants, with the exception of 
TPGS, showed a fluorescence signal. The fluorescence of drug-free TPGS was subtracted 
from the samples with drug to normalise signals.  
Surfactant 
Required emulsification 
concentration w/vol % 
Reported critical micelle 
concentration w/vol% 
Reference 
Sodium cholate 0.1 0.2-0.4 [465] 
TPGS 0.1 0.02 [466] 
Pluronic F68 1 0.03 [467] 
PVA 0.3 N/A  
Table 6-3 Concentrations used to form nanoemulsions and reported critical micelle 
concentration for the excipients used 
Etoposide and Teniposide dissolved completely in the aqueous phase 
during the solvent-emulsification method. However, the solutions were 
oversaturated and within less than an hour large visible needle-like 
crystals of both drugs appeared. To test for the presence and possible 
contamination of pure drug nanoparticles, the supersaturated solutions 
were loaded in a PD-10 column as soon as they were prepared and the 
amount of etoposide and teniposide passing through quantified. As shown 
in Figure 6-6, there was no etoposide or teniposide contamination in the 
volume fractions normally collected for nanoparticles. When sodium 
cholate was used at levels (0.1% w/vol a value below the CMC, Table 6-3) 
it stabilised the oversaturated solutions but that did not result in 
etoposide or teniposide appearing in the nanoparticle fraction. The 
fluorescence signal emitted from TPGS and its absorbance in the UV range 
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made quantifying the amount of etoposide and teniposide less reliable. 
The quantities for those samples have been derived by subtracting the 
signal of pure TPGS.  Nevertheless, direct methods using fluorescence and 
absorbance spectrophotometry would not be suitable to quantify TPGS 
containing nanoparticles without prior purification or chromatographic 
separation via HPLC for example. Both PVA (0.3%) and Pluronic F68 (1%) 
required higher concentrations than sodium cholate (0.1%) in order to 
emulsify the DCM/water mixture. In contrast to sodium cholate, the drug-
loaded samples prepared with Pluronic F68 and PVA resulted in drugs 
passing through the gel column in the nanoparticle volume fraction. 
Additionally, sodium cholate was superior to all other emulsifiers in terms 
of preventing phase separation when polymers were introduced in the 
DCM phase. The combination of superior emulsification properties along 
with compatibility with drug separation procedures made sodium cholate 
the surfactant of choice in the next experiments. 
 
Figure 6-7 Drug loading results for nanoparticles made with the solvent-emulsification 
method. PEG-PDL and PEG-PGA did not require surfactant while 0.1% sodium cholate in 
the aqueous phase was used for all other polymers. A-etoposide B-teniposide; Dots 
represent separate individual experiments with three replicates in each. Notice the 
difference in scale between the two graphs.  
Figure 6-7 shows the drug loading percentages achieved using the solvent 
emulsification procedure. Compared to nanoprecipitation (Figure 6-5), the 
process employing DCM achieved higher loadings with both drugs. While 
the drug loadings for etoposide were generally below 1%, the more 
hydrophobic and less water-soluble drug teniposide had loadings above 
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5% in the majority of nanoparticle formulations. In contrast to the 
relatively similar drug encapsulation for etoposide the formulations with 
teniposide differed in the amount of entrapped drug. The formulations 
with PEG-PDL and PEG-PGA were made without the use of surfactant. In 
order to compare the results for teniposide the data was tested for normal 
distribution. In the experiments which were repeated the most (PEG-PCl 
and PLA-PEGMA) the Prism’s D'Agostino & Pearson omnibus normality test 
K2 and the Kolmogorov–Smirnov test were used. The drug loading 
determinations for those two formulations passed both normality tests 
and a one-way ANOVA analysis using Holm-Sidak’s multiple comparison’s 
correction[468] was used to check for statistical differences between the 
formulations. The drug loadings for PEG-PCL, PEG-PDL, PLA-PEGMA and 
PEG-PGA clustered together and were found to have no statistically 
significant differences in the percentage of encapsulated teniposide. The 
PCL-PEGMA formulation exhibited statistically significant higher loadings 
compared to all other nanoparticle formulations and the delivery system 
with C8-PGA had the lowest entrapment percentage. 
The present studies have found much lower drug incorporation 
percentages for etoposide compared to the amounts reported in the 
literature. For example Mohanty et al.[387] have claimed an impressive 
loading of 60% with 68% encapsulation efficiency in the abstract of their 
paper for PEG-PCL micelles. A more careful examination of the manuscript 
reveals lower values increasing from 0.5% to 25% as more etoposide was 
added to the micelles. The amount of aqueous phase to form the micelles 
in their procedure has not been disclosed and a drug-only control to 
validate complete wash-out of free drug from the micelles has not been 
mentioned. Not surprisingly in this case, the encapsulation efficiency rose 
along with increasing the amounts of etoposide whereas it is more 
commonly found that encapsulation efficiency decreases with increasing 
drug concentration. The work presented here has aimed to exclude free 
drug contamination in the drug delivery system by employing size 
exclusion chromatography and validating the lack of free drug as shown in 
Figure 6-6. Therefore the low etoposide loadings are explained with more 
thorough removal of unencapsulated drug.    
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Particle size was investigated using dynamic light scattering (DLS) and 
the results are summarized in Figure 6-8 and Table 6-4. PEG-PCL formed 
the smallest particles which were composed of a single population with 
radius of around 30nm. Similarly to most other formulations the PEG-PCL 
particles did not significantly change in size after drug loading, as 
determined by ANOVA, followed by the Sidak test. On the other hand, 
PEG-PDL nanoparticles had a statistically significant shift in size from 56 
to 88nm after loading with teniposide.  
 
Figure 6-8. Radii of empty and teniposide-loaded nanoparticles determined by DLS. Dots 
represent mean peak radii for the main populations determined by DLS intensity 
measurements in individual independent experiments. PEG-PDL and PEG-PCL had a 
monomodal distribution of particle size. PLA-PEGMA, PCL-PEGMA and PEG-PGA showed 
two populations, a smaller population around 20nm and a larger population around 
100nm.  
Polymer 
Empty NPs  
Radius,nm 
Drug loaded 
NPs 
Radius, nm 
Empty NPs 
CV% 
Drug 
loaded NPs 
CV% 
PEG-PCL 33 
56 
28 
88 
12 10 
PEG-PDL 12 26 
PLA-PEGMA 99   and 22 92   and 24 15 and 2 9 and 29 
PCL-PEGMA 127 and 12   122 and 19 25 and 55 13 and 55 
PEG-PGA 95   and 22 81   and 20 20 and 48 7 and 30 
Table 6-4 Median sizes of empty and drug-loaded nanoparticles along with the coefficient 
of variation for each population. 
The DLS results from Figure 6-8 suggest that the PLA-PEGMA, PCL-PEGMA 
and PEG-PGA nanoparticles have a bimodal distribution. Dynamic light 
scattering has a number of limitations when it comes to the analysis of 
polydisperse populations[469]. The intensity (I) of scattered light using 
the Rayleigh approximation is proportional to the sixth power of the 
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radius (r6) which leads to overestimations in the percentage of large 
particles by intensity measurements. Since mass and number 
mathematical transformations are only accurate below 50 nm and without 
prior knowledge of the refractive index of the nanoparticles it was hard to 
elucidate what the real proportions of both populations were[268].  
 
Figure 6-9 TEM image of PLA-PEGMA nanoparticles (courtesy of Lee Moir). Scale bar is 
5000nm 
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Figure 6-10. PLA-PEGMA nanoparticle size distribution after image analysis using TEM. 
Size is given as particle radius in nm. 
Electron microscopy imaging (Figure 6-9) of the PLA-PEGMA nanoparticles 
revealed that there was a broad distribution of particles sizes ranging 
from 20 nm to 140 nm (Figure 6-10), which is probably due to the 
inherent limitations of the emulsification process using probe sonicators. 
Some aggregation was also visible but that could have been due to 
concentration artefacts in sample preparation. Similar pictures were seen 
for the teniposide loaded formulations as well (Figure 6-11).  
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Figure 6-11 TEM pictures of teniposide-loaded PLA-PEGMA nanoparticles  (courtesy of Lee 
Moir). Scale bar is 1000nm 
The presence of small nanoparticles with radii of around 20 nm (Figure 
6-11) may be considered disadvantageous for a drug delivery system 
aiming for sustained release. As the rate of drug release is inversely 
related to particle size, small nanoparticles may contribute to a significant 
burst release.  
In this respect, the next step in characterising the nanoparticles was to 
determine the drug release profile in a series of experiments. 
Section 6.6  Release experiments 
In order to investigate the solubility of teniposide in PBS and PBS with 
added surfactants (1% Sodium cholate or Polysorbate 80), drug solutions 
were prepared in PBS from thousand-fold stock solution in DMSO (Table 
6-5). The absorbance spectra of the resultant solution (λ<300nm) and 
the appearance of cloudiness were used to determine the solubility of 
teniposide in the different media. The observed kinetic solubility would be 
higher than the true thermodynamic solubility as metastable 
oversaturated solutions are often formed[470].  
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Media Kinetic solubility Change after 24h 
PBS 100 µM 30 µM 
PBS+1% Cholate 250 µM None even at 200 µM 
PBS+ 1% Tween 300 µM Interference in UV and Fl 
Table 6-5. Kinetic solubility of teniposide in different release media. Solubility was 
determined from 1000X stocks in DMSO. Changes in solutions were monitored with UV 
absorbance and Fluorescence 
The solubility of teniposide (Figure 6-12) was found to be 10 µM in PBS as 
30 µM solutions left for 24h experienced a decrease in fluorescence and 
absorbance if left undisturbed in the dark at room temperature (25˚C). 
 
Figure 6-12 Teniposide stability in PBS immediately after dilution from DMSO stock and 
after 24h. Stability was quantified using fluorescence measurements. Note the hyperbolic 
shape of the standards due to the inner filter effect and light scattering for the 100 µM 
concentration 
Sodium cholate and Tween were used to solubilise teniposide and direct 
spectrophotometric measurements were examined for their suitability to 
detect the drug during the release experiments (Figure 6-13). 
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Figure 6-13 Standard curves for teniposide in PBS and PBS with 1% cholate. UV 
Absorbance and Fluorescence were compared for their suitability to determine Teniposide 
in solutions of PBS and PBS cholate. Fluorescence measurements were corrected for the 
inner filter effect according to Eq. 6.3 In addition the absorbance and fluorescence of 
Polysorbate 80, DMEM and a mixture of DMEM:F12 were assessed for applicability to be 
used as release media. 
Parameter UV PBS UV Cholate Fl. PBS Fl. Cholate 
Slope 0.0088 0.0085 15.84 27 
Intercept -6.73E-06 0.021 4.4 -72 
R2  0.9995 0.9994 0.9996 0.973 
SD Intercept 0.0009 0.0076 1.46 150.9 
LOQ,  µM 0.3 3.0 0.3 18 
LOD,  µM 1.0 9.0 0.9 55 
Table 6-6. Linear regression fit parameters for the standard curves from Figure 6.8. Limit 
of quantitation(LOQ) and limit of detection(LOD) were determined from the standard 
deviation of the y-intercept and the regression slope using Eq 6.4 and 6.5[460].   
Sodium cholate was compatible with the determination of teniposide with 
both fluorescence and UV absorbance. In contrast, Polysorbate 80, and 
the culture media mixtures DMEM and DMEM-F12 interfered with both 
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types of measurement and were excluded from further screening. The 
linear regression parameters and the limits of quantitation and detection 
for the four standards curves are shown in Table 6-6. Although sodium 
cholate had negligible absorbance at 284 nm and was able to solubilise 
teniposide, the sensitivity of the spectrophotometric determinations was 
adversely affected. The 10 times increase in solubility was offset by a 
similar increase in the limit of quantitation for UV and an even larger 
deterioration for the fluorimetric determination. This necessitated the 
utilisation of HPLC in the determination of teniposide release from the 
nanoparticles. 
The HPLC method for teniposide determination was assessed for linearity, 
accuracy, precision, and robustness.  
 
Figure 6-14. Linearity of Teniposide determination using HPLC. Red dots show the 95% 
confidence intervals for the linear regression 
The method for teniposide determination was linear from 25 nM to 30 µM 
with r2=0.9952 as seen in Figure 6-14. The LOD was 10 nM and the LOQ 
25 nM as determined from the signal to noise levels. The representative 
chromatograms in Figure 6-15 show the specificity and accuracy of the 
method in the conditions tested. The drug peak was well resolved from 
the other components in the release media and it appeared as a single 
peak for the pure and released drug alike.   
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Figure 6-15 Representative chromatograms of blank release media solution and teniposide 
standards. Retention time of teniposide was 2.9 minutes and it appeared as a single peak 
well resolved from the polar sodium cholate peak at 1-2 minutes 
The intra-assay variation was below 1% for all drug levels and the 
interexperimental repeatability was assessed using the coefficient of 
variation for six concentrations on six independent sets of standards on 
different days (Table 6-7). CV was below 15% for all tested 
concentrations. 
[Teniposide],  µM Area CV% 
0.025 2 9 
0.05 4 11 
0.1 8 6 
1 78 9 
10 798 7 
20 1601 7 
Table 6-7. Inter-assay precision for 6 levels of teniposide measured in six independent 
experiments 
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The robustness of the method to measure teniposide and the stability of 
samples after freezing and thawing is illustrated in Figure 6-16. 
 
Figure 6-16 Teniposide HPLC assay robustness: Recovery of teniposide after freeze-
thawing 
Overall, the HPLC determination of teniposide satisfied all acceptance 
criteria and was suitable for the determination of teniposide in the release 
medium of PBS with 1% sodium cholate under the conditions of the 
assay. 
Centrifugal ultrafiltration was compared to dialysis for its ability to 
measure the kinetics of teniposide release from drug loaded 
nanoparticles. However, the hydrophobic teniposide exhibited non-specific 
binding to the membrane (both polyethersulfone and regenerated 
cellulose) of the filtration devices and was not detectable in the filtrates. 
Non-specific binding was circumvented by preloading the membrane with 
excess of sodium cholate by passing a 10% sodium cholate solution 
through the devices[471]. The centrifugal device was then run twice 
(0.5mL each time) with the sample of interest and only the second filtrate 
measured. The recovery of teniposide after this procedure was 80% as 
illustrated in Figure 6-17. After validating that the drug can be recovered 
from the devices, the passage of nanoparticles was quantified using the 
number of counts from dynamic light scattering as a proxy for 
nanoparticle concentration[430] (Figure 6-18). 
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Figure 6-17 Recovery of teniposide after passage through centrifugal ultrafiltrators 
 
Figure 6-18 Quantitation of amount of PEG-PCL nanoparticles passing through the 
Nanosep 300kDa ultrafiltration device 
About 25% of the PEG-PCL micelles were able to pass through the 
Nanosep polyethersulfone 300 kDa (35nm) membrane despite their 60nm 
diameter[472][473]. The same was true for the Amicon 100 kDa and 
Nanosep 30 kDa membranes.  
In an effort to limit nanoparticle penetration in the filtrate Amicon 10 kDa 
membrane devices were employed for the release studies. The drug 
loaded nanoparticles were suspended in release media in a concentration 
equivalent to 20 µM in order to maintain sink conditions and samples at 
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different time points were filtered through the filtration devices. Although 
the percentage of nanoparticles passing through was easy to quantify in 
PBS, the presence in sub-nanometre cholate micelles in the release media 
resulted in a noisy background limiting assay precision.  
Sample Before filt. After filt. Passing minus cholate  
(name) (kCounts) (KCounts) (%) (%) 
AST 13 456.5 73.8 16 2 
AST 14 277.2 72.2 26 3 
AST 15 291.9 121.5 42 25 
Table 6-8 Presence of nanoparticles in the filtrate of nanoparticle release samples after 
passing through Amicon 10 KDa filtration devices. Sodium cholate gave 66, 000 Counts 
which limited the ability to accurately quantify the amount of nanoparticles in the filtrate. 
AST13-15 are PEG-PCL nanoparticle release samples from three independent batches of 
teniposide-loaded nanoparticles 
As shown in Table 6-8, switching to a membrane with lower Mw cut-off 
did not completely eliminate nanoparticle contamination. Depending on 
whether sodium cholate counts are subtracted different percentages of NP 
contamination could be calculated. The samples before and after filtration 
were analysed for teniposide content and the results are summarised in 
Table 6-9. 
Sample Unfiltered Filtrate Recovery 
(name) (peak area) (peak area) (%) 
AST 13 26.3 21 80 
AST 14 16.2 12 74 
AST 15 20.4 15.7 77 
Table 6-9. Teniposide release from PEG-PCL micelles as measured by Amicon 10kDa 
ultrafiltration devices 1h after start of experiment. 
Since the recovery of free teniposide in the filtration devices is 80% the 
actual release can be quantified by dividing the values in the last column 
in Table 6-9 by 0.8 and subtracting the % of nanoparticles passing 
through the membrane. The release % results using the raw DLS values 
and the values after subtracting the background cholate are given in 
Table 6-10. 
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Sample 
% Release 
w/o background corr. 
% Release 
with background corr. 
AST13 84 98 
AST14 66.5 89.5 
AST15 54.25 71.25 
Table 6-10 Teniposide release from PEG-PCl micelles after correction for teniposide 
recovery and including the percentage of nanoparticles passing through the membrane as 
per Table 6.8. Incubation time was 1h in 1%-PBS cholate release media. 
Despite the issues with nanoparticles passing through the filters and 
cholate interference, approximate values for the release from teniposide 
loaded PEG-PCl nanoparticles were calculated. There appears to be a 
significant proportion of burst release, anywhere between 50 and 90%, of 
teniposide upon nanoparticle dilution according to the results from 
centrifugal ultrafiltration. 
In addition to the filtration setup, drug release experiments with dialysis, 
were undertaken at the same time in order to compare the results from 
both methods. Nanoparticle suspension samples equivalent to 30 µM 
teniposide were placed in the dialysis tubes thereby maintaining sink 
conditions in the donor compartment as well as the acceptor one 
throughout the experiment. A control for the release of free teniposide 
was included to assay the rate of diffusion of teniposide through the 
membrane. The extra control containing empty nanoparticles and a 
solution of teniposide was employed to account for the interaction 
between released drug and the nanoparticles during release. As seen in 
Figure 6-19 the release profile of teniposide-spiked nanoparticles looks 
quite similar to the release profiles for the drug-loaded systems. If the 
process is modelled as being first-order kinetics the confidence intervals 
of the time for 50% release and rate constant can be compared. Figure 
6-20 illustrates that although all drug loaded nanoparticle formulations 
exhibited slower release than the diffusion of teniposide out of the dialysis 
bag, the change in the release profile was due to interaction between the 
nanoparticles and the released drug. The release from those nanoparticles 
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systems was either slightly faster (PCL-PEG) or equal (PLA-PEGMA) to the 
profile of release of the spiked nanoparticle sample. 
 
Figure 6-19 Release from teniposide-loaded nanoparticles of PEG-PCL and PLA-PEGMA as 
determined by dialysis experiments. Black dots- free teniposide, Green squares-Teniposdie 
loaded PEG-PCl nanoparticles, Red triangles-Empty nanoparticle plus teniposide control; 
Blue triangles- PLA-PEGMA nanoparticles. 
 
Figure 6-20 Confidence intervals for the release half-time and time constant for 
teniposide, PEG-PCl, PLA-PEGMA nanoparticle and spiked nanoparticles. Left panel- 95CIs 
for time for 50% teniposide release; Right panel-CIs of the rate constants if the process 
was first-order  
The limitations of the dialysis method to properly resolve the release 
profile of nanosized systems[428], [429] have once again been 
confirmed. Nevertheless the similarity between the rate of release 
between the drug-loaded and the drug-spiked nanoparticles implies a 
near-complete release in the first hours of the experiment. In order to 
maintain detectable levels of teniposide the release media contained 1% 
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sodium cholate. However during the cell culture studies the nanoparticles 
will be suspended in serum-free media and in vivo they will distribute in 
the brain interstitium and the CSF where sodium cholate won’t be present 
to solubilise the drug. Therefore the release profile determined here can 
only serve as a proxy and may significantly under- or overestimate the 
rate of release from the nanoparticles. The true in vitro benchmark would 
be exposing the 3D cell culture models of medulloblastoma to the 
nanoparticle formulations and comparing the effects.   
    
Section 6.7  Nanoparticles in single spheroid cultures of 
foetal neurospheres and UW medulloblastoma 
The toxicity of the empty nanoparticles was assessed in three-dimensional 
separate spheroid cultures of UW medulloblastoma and normal human 
neurospheres by using volume and metabolic activity. Figure 6-21 shows 
that most carrier formulations were not toxic up to concentrations of 
300 µg/mL when applied for 48h followed by a 48h wash-out period. 
Among the polymers PEG-PDL appears to slightly lower the cell viability at 
high concentrations but cell health never falls below 75%. PEG-PGA on 
the other hand exhibited more pronounced effects as it aggregated in the 
media at high concentrations and formed microscopic droplets close to the 
spheroid surface. Both normal and tumour cells exhibited similar 
sensitivity towards the formulations. Moreover, nanoparticles prepared 
with surfactant (PLA-PEGMA, PCL-PEG, PCL-PEGMA) were equally non-
toxic to those prepared without surfactant (PDL-PEG, PEG-PGA). Thus 
none of these factors seemed to affect adversely the toxicity of the empty 
nanoparticles. 
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Figure 6-21 In vitro toxicity of empty nanoparticle carrier formulations. Green-normal 
neural stem cells; Black-UW228-3 medulloblastoma; A,A’-PCLPEG; B,B’-PDLPEG; C,C’-
PLAPEGMA; D,D’-PCLPEGMA, E,E’-PEGPGA; A-E- using volume measurements. A’-E’- using 
metabolic activity 
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Figure 6-22. Preliminary screen of teniposide-loaded nanoparticles using spheroid Volume reduction as surrogate measure of viability. Comparison of dose-
response curves with free teniposide for both neural stem cells and UW medulloblastoma cells. A- dose response curves. B- 95%CIs for the IC50 
determinations. 
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Figure 6-23. Preliminary screen of teniposide-loaded nanoparticles using resazurin reduction as surrogate measure of viability. Comparison of dose-response 
curves with free teniposide for both neural stem cells and UW medulloblastoma cells. A- dose response curves. B- 95%CIs for the IC50 determinations. 
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A preliminary screen (Figure 6-22 and Figure 6-23) with three replicates 
per condition was carried out initially aiming to narrow down the number 
of formulations for screening. Dose-response curves (Figure 6-22A and 
Figure 6-23A) for normal (green) and tumour cells (black) were plotted 
for teniposide and compared to the different nanoparticle formulations 
(various colours). The biphasic relationship, shown by etoposide, was 
much less pronounced for teniposide and a monophasic curve-fit was 
used for the normal cells as well. The logIC50 values from the non-linear 
regression along with their standard errors were compared using one-
way ANOVA with Sidak’s test. The 95%-confidence intervals of the IC50s 
were plotted on a log scale to visualise the shifts in IC50 (Figure 6-22B 
and Figure 6-23B). 
When spheroid volume (Figure 6-22) was used as a proxy for viability the 
dose response curves for each cell type were well separated. Teniposide 
was over 20 times more potent in decreasing the size of the 
neurospheres compared to the tumour tissue. In contrast, the 
nanoparticles appeared to be less toxic to the normal stem cells while 
maintaining the same activity towards the tumours. When the confidence 
intervals for IC50s of the nanoparticles are compared to the free drug in 
subplot C, it is easy to see the significantly higher IC50s for PEG-PCL, 
PLA-PEGMA and PEG-PGA for the normal cell population. The same plot 
for the tumours shows that the toxicity towards tumour tissue has 
remained at the same level as the free drug. 
The dose-response relationships uncovered by metabolic activity (Figure 
6-23) had a higher degree of variation and found no statistical differences 
between the various formulations. Although resazurin (Figure 6-23), 
similarly to volume (Figure 6-22), shows that the stem cell population 
was more sensitive to teniposide, the differences were much smaller. In 
illustration the dose-response curves for the nanoparticle formulations 
are overlapping for tumours and normal cells. This is even more apparent 
when the confidence intervals are compared in Figure 6-23B. The 
confidence intervals for resazurin reduction were much wider compared 
to the volume measurements and differences between the nanoparticle 
formulations were not observed. This has confirmed our observations in 
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Chapter 3 which showed that resazurin reduction is less sensitive 
compared to volume measurements in detecting small differences 
between treatments.   
The first notable conclusion from this preliminary screen was that 
teniposide was 5-7 times more potent against the UW228-3 cells and 
about 10 times more potent against proliferating normal progenitor cells 
when compared to etoposide (Figure 3-14).  
Second, as seen from the confidence intervals for the IC50 
determinations using volume (Figure 6-22B), most formulations were 
equally cytotoxic to the tumour cells. In contrast, formulations with PEG-
PCL, PLA-PEGMA and PEG-PGA were less toxic to the normal cell 
population compared to the free drug. The combination of this finding 
and the low toxicity and stability of the drug-free PEG-PCl and PLA-
PEGMA formulations in cell culture media led to further, more extensive 
screening for those two formulations. 
The second phase of the cell culture screen involved six replicates per 
concentration and the execution of more independent experiments – two 
more for PLAPEGMA and four more for PEG-PCL teniposide loaded 
nanoparticles. 
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Figure 6-24 Dose-response comparison of teniposide versus teniposide-loaded PEG-PCL 
NPs. A-Viability determined using spheroid volume; B-Viability determined by 
metabolism; C-comparison of the 95%CIs for the IC50s using volume; D-comparison of 
the 95%CIs for the IC50s using metabolism. The table lists the mean IC50 values for 
neural stem cells and UW228-3 cells for free drug and PEG-PCL NPs determined using 
Volume and Resazurin reduction. 
The teniposide-loaded PCL-PEG nanoparticles were 1.5 times less toxic to 
normal tissue while maintaining their toxicity towards the tumour cells. 
There was a statistically significant difference between the volume-
derived logIC50 values for teniposide and teniposide-PCL NPs as 
determined by a two-tailed t-test with Welch’s correction. This difference 
is also illustrated on Figure 6-24C where the 95% confidence intervals for 
both measurements do not overlap. While, for the NP-treated tumour 
cells, there was a visible shift towards higher activity in the resazurin 
dose-response curve, the 95% confidence intervals of the NPs and free 
drug overlapped. Consequently, the resazurin reduction assay did not 
yield any statistically significant differences in the t-test comparisons of 
logIC50s as well.   
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Figure 6-25 Dose-response comparison of teniposide versus teniposide-loaded PLA-
PEGMA NPs. A-Viability determined using spheroid volume; B-Viability determined by 
metabolism; C-comparison of the 95%CIs for the IC50s using volume; D-comparison of 
the 95%CIs for the IC50s using metabolism. The table lists the mean IC50 values for 
neural stem cells and UW228-3 cells for free drug and PEG-PLAPEGMA NPs determined 
using Volume and Resazurin reduction. 
Similarly to the PEG-PCL micelles, the PLA-PEGMA teniposide-loaded 
nanoparticles were equally toxic to tumour and less toxic to normal cells. 
The bigger difference in IC50s was offset by greater uncertainty in the 
calculation and wider confidence intervals (Figure 6-25C). Nevertheless 
the volume measurements yielded a statistically significant logIC50 
difference for the normal cell population. 
The selective decrease in toxicity can be explained by a lower uptake of 
the drug loaded nanoparticles by neural stem cells compared to tumours. 
It could be hypothesized that true effect of the nanoparticles is obscured 
by the quick drug release. A system that can reliably entrap teniposide 
until it is endocytosed by the cells is needed to prove that relationship. 
Although statistical significance was established using volume as a proxy 
for viability, the practical significance of this finding may be low. 
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Improving toxicity to the normal cell population by 1.5 or 3 times is a 
step in the right direction but a promising result would be at least a 10 
times shift. There is a lot to be desired from the release profile and the 
size-distribution profile of the nanoparticles. The release studies have 
shown a very fast dissociation of the drug from the carrier system.  That 
may be caused by the fraction of small 20nm nanoparticles or due to the 
weak interaction of polymer and drug. 
In summary, nanoparticles showing improved teniposide loadings were 
made and their drug release and biological activity were compared to the 
free drug. Despite suboptimal release profile the PLAPEGMA and PEG-PCL 
nanoparticles showed a decrease in toxicity towards normal tissue while 
maintaining the same activity against tumours. This is a small step 
forward in the improvement of the toxicity profile of podophyllotoxins and 
establishment of more selective drug delivery systems for the brain. 
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Chapter 7.  Summary, conclusions and future work 
This scientific work contributes to science with the establishment of an in 
vitro model of medulloblastoma that can be used in the screening of novel 
treatments for the disease. 
Chapter 3 has outlined the development of a battery of multiplexable, 
reliable and reproducible high-throughput assays for the culture of neural 
progenitor and medulloblastoma tumour cells in 3D. It has provided a 
framework for in-depth characterisation of 3D viability assays with 
stringent acceptance criteria and quality controls. The algorithm used to 
assess and compare the assays is broadly appropriate to validate various 
assays using different endpoints and diverse platforms. The in vitro 
models created were found fit for their intended purpose of comparing the 
relative safety and efficacy of local treatments for medulloblastoma.  
This convenient screening method can be implemented with standard 
equipment and reagents and can be used for screening new agents and 
drug delivery systems targeting CNS tumours. It offers the opportunity to 
compare the effect of drugs upon the tumour and brain thereby 
comparing efficacy against toxicity, enhancing the bio-relevance to human 
tumours in clinical practice [232], [300], [474], [475]. The correlation 
with previously reported experimental and clinical studies [299], [301]–
[304] and the practical convenience of this assay procedure suggest that 
it should be considered as a possible replacement for some animal testing 
experiments dealing with drug efficacy, particularly in brain tumour types 
relevant to childhood.  
The co-culture model described in Chapter 4 contributes to knowledge 
with a universally applicable cell labelling and analysis procedure that 
preserves tissue heterogeneity and allows the determination of cell health 
for two populations cultured together. In contrast to other studies, which 
have employed a single cell label[305], marking both cell populations 
increased the fidelity of cell type determination. Similarly, employing 
cytoplasmic dyes instead of membrane markers[321], [476] resulted in 
stable marking for over 7 days with decreased dye loss or exchange 
between the two populations. Although other researchers have 
demonstrated the feasibility of differential cytotoxicity determination in 
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co-culture spheroids[306], [307], their cell labelling strategy was only 
possible for cells with differential antigen expression and was not suited 
for heterogeneous cell populations. The co-culture models described in 
this work mimic the interaction between human tumours and normal 
human brain tissue thus eliminating the unknowns of interspecies 
differences[234]. This information is extracted without sacrificing 
throughput and the options for complete automation. The unique 
combination of a universal cell marking procedure along with flow 
cytometry and multiphoton imaging made it possible to visualise the 
interaction between tumour and host tissue and to quantify the effects of 
cytotoxic drugs on both populations. These proof-of-concept studies 
suggest how a robust method for co-culture creation and analysis can be 
developed in a universal way to study the interaction between any two 
types of tissue and drugs of interest. 
This work has a few important limitations. First of all, the choice of human 
foetal brain tissue and serum-free culture conditions with EGF and FGF 
supplementations encourages the enrichment for progenitor and stem 
cells. While that can be beneficial in studying the response of tumour stem 
cells, the models would have benefited from a more comprehensive 
characterisation of the differentiation and maturation state of the normal 
cells. In hindsight, growth factor withdrawal and differentiation agent 
supplementation could have been included in the protocol to encourage 
tissue maturation. In this respect, the normal tissue model created is 
probably a closer representation of the foetal brain and not the child’s 
brain with its more differentiated and mature neurons and glia.  
Second, as this was proof of concept work, most experiments have been 
performed with a single tumour cell line. While this approach is acceptable 
in  feasibility studies, further development of this model would depend on 
the inclusion of primary tumour tissue and additional cell lines 
representing each medulloblastoma cell type[477]. Furthermore the 
extent to which the tumour spheroids recapitulate the biology of the 
parent tumour has not been characterised and would need to be included 
in the validation of the model. 
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The use of the misidentified VC312R cell line represents a valuable lesson 
in the importance of cell line authentication. In this respect, the UW228-3 
cell line has been validated in-house to be both human and 
medulloblastoma[228], but STR profiling is still missing from the 
authentication portfolio. Nevertheless, the core of this thesis is method 
development, designed to be compatible with a variety of cell types.  
Another limitation comes from the use of simple cytotoxicity assays to 
compare normal and tumour tissue. It is possible that impairment of 
normal tissue performance could start well before any cytotoxicity is 
evident. Functionality may be better captured by measuring 
electrophysiological impulse activity[478], neurite outgrowth[479] and 
differentiation[480]. However, including these in a high-throughput 
compatible format may require extensive additional assay development. 
Moreover, in vitro models like the ones described here, generally fail to 
capture the full extent of drug pharmacokinetics. Postsurgical cerebral 
oedema and CSF flow were not included in this model and although the 
tumour tissue was cultured as spheroids, the interstitial pressure was not 
quantified and compared to in vivo data. The locally applied nanoparticles 
could be washed off by the CSF in the fourth ventricle and the increased 
interstitial pressure in tumours might potentially hinder their distribution 
within the tumour mass[481]. 
The cytotoxicity results for etoposide further stress the importance of 
pharmacokinetics in toxicity evaluation. Although etoposide has not shown 
any neurotoxicity in humans, it may be argued that this is mainly due to 
poor distribution within the CNS. The experimental results have 
demonstrated that, given the chance to reach the progenitors, etoposide 
will kill human neural progenitor cells. This further stresses the need for 
well-designed drug delivery systems to improve selectivity of 
chemotherapy. 
When it comes to the nanoparticle experiments, only some of the initial 
objectives were met during the course of this work. The preliminary aim 
to load poly(glycerol adipate) nanoparticles with >3% etoposide was not 
met possibly due to problems with reproducible polymer synthesis. 
Nevertheless the screening of 7 polymers and two drugs with multiple 
Summary, conclusions and future work 
 218   
  
nanoparticle production methodologies yielded encouraging drug loading 
results for teniposide. The importance of comprehensive characterisation 
for drug delivery systems was emphasized when the release profile 
indicated very quick release and cell culture studies showed only marginal 
improvement in selectivity towards tumours.  
The nanoparticle work contributes to science by showing a system for 
systematic critical review of the available literature, implementation of a 
broad characterisation strategy and the repeated demonstration of the 
limitations of dialysis to determine drug release from nanoparticle 
systems. The inclusion of an extra control sample with empty 
nanoparticles and a spike of free drug in the dialysis tube was established 
to be a necessary step in addition to sink conditions and free-drug control. 
Without these controls, most dialysis drug release experiments from 
nanocarriers would be meaningless. Moreover, the cell culture studies 
were used to complete the profile of the nanoparticles showing a 1.5-3 
times less cytotoxicity towards neural progenitors compared to free 
teniposide. 
At their current state the nanoparticle drug delivery systems developed 
here have met the acceptance criteria for drug loading and lack of 
cytotoxicity of the carrier. However, they have failed in the drug release 
studies and the improvement of selectivity has not been well pronounced. 
In this respect, the drug delivery systems as they stand should not be 
taken forward but need to go through further development to ensure a 
sustained release profile over 48h and confirm both selective tumour 
targeting and penetration. 
Major improvements are needed in the methodologies to determine drug 
release from nanoparticle carriers. Dialysis has proven once again to be 
ill-suited for the task because of its poor time resolution and the influence 
of interactions between the carrier surface and the released drug on the 
diffusion through the dialysis bag[429]. Although centrifugal ultrafiltration 
has potential advantages of quick spin times and easy sample 
preparation, it suffers from non-specific drug binding and penetration of 
nanoparticles through the membrane. Similar problems would be expected 
for pressure ultrafiltration as the membranes have been created to keep 
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most of the macromolecular carriers in, but they may have a minority of 
larger pores allowing nanoparticle escape. Methods like centrifugation, 
hollow fibre ultrafiltration, entrapping the nanoparticles in gels have their 
own limitations of long sample preparation or drug-binding to the device 
or carrier. That is why alternative methods employing electrochemical 
monitoring[436], [437] and microdialysis probes[438], may be more 
reliable. The electrochemical activity of epipodophyllotoxins[441] hints at 
the feasibility of release determination using electrochemical detection. 
Furthermore, the composition of the release media with inclusion of 
solubilisers, solvents or surfactants creates an artificial release profile that 
would not necessarily match in vivo release. In this respect, both release 
media and cell culture media employed in the characterisation of 
nanoparticles should be as close as possible to the in vivo fluids 
composition to ensure biorelevance. 
When it comes to biological selectivity improvement, a formulation that 
could shift the nearly 20-times higher toxicity of teniposide towards 
normal progenitor cells and completely abolish side effects to normal 
tissue would be ideal. In reality, that could only be achieved through a 
very selective and stable drug delivery system. Although more potent 
than etoposide, teniposide still requires close to micromolar 
concentrations to eliminate medulloblastoma cells. That necessitates high 
loadings which often come with the unwanted disadvantage of over-rapid 
release. A better approach would be to reliably encapsulate a drug (or 
toxin) active in the nano- or picomolar range and rely on the selectivity of 
the carrier system. 
One aspect of drug delivery that the current in vitro model cannot take 
into account is the pharmacokinetic distribution of the nanoparticles. It 
could be argued that, while the drug is associated with its macromolecular 
carrier, it would distribute in a smaller volume and would have a longer 
residence time in the adjacent tissue. The nanoparticles would also be less 
likely to cross multiple cell layers and reach the progenitor cells in the SVZ 
and hypothalamus. Nanoparticles can hypothetically dislodge from their 
location in the tumour bed and end up in the CSF of the fourth ventricle. 
However, it is unlikely that they would reach the lateral ventricles and the 
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hypothalamus. That is because CSF flows down from the fourth ventricle 
to the spine and also laterally around the back of the cerebellum and then 
superiorly towards the cerebral hemispheres. Therefore, possible side 
effects can be expected mainly in the subarachnoid space and the cells of 
the choroid plexus, but not in the progenitor cell niches within the brain.  
The future work, required to move this project forward, can be split in two 
streams. The first objective should focus on improving the physiological 
relevance and the information that the in vitro model can offer. The 
second direction would deal with improving the drug delivery system. 
The physiological relevance of this in vitro system would be further 
improved by including an additional differentiation and maturation step in 
the culture of human neural stem cells. Establishing the proportion of 
early progenitors, oligodendrocytes, astrocytes and neurons in the model 
and determining the effects of free drug on each population would further 
benefit understanding of the cytotoxic mode of action and neurotoxic side 
effects. Moreover, multiple drugs would need to be assessed, including 
controls with well-established neurotoxicity (vincristine, cisplatin, or 
methotrexate). Establishing the dose-response relationships for these 
drugs in the model will serve to set relative neurotoxicity thresholds. The 
inclusion of multiple drugs will also allow the calculation of minimum 
significance ratio[482] to further validate the sensitivity of each assay. 
Apart from using multiple drugs, more endpoints like differentiation, 
migration and electrophysiological activity can be explored to compare the 
effects of drugs and nanoparticles. As for the tumours, the utilisation of 
more representative cell lines[477] and patient-derived primary tumour 
tissue would allow for a better recapitulation of tumour heterogeneity and 
can be potentially used in personalising therapy. Finally, the extent to 
which the tumour spheroids recapitulate the behaviour of patient tumours 
remains to be characterised and validated. 
Regarding the nanoparticles, the employment of drugs active in the 
picomolar and nanomolar range would require less drug to be entrapped 
by the polymers. It can be argued that the required lower drug loadings 
could potentially result in an increase of the number of possible carriers 
and reduction of the premature drug release issues. A strong physical 
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interaction between the carrier and the drug would be needed in order to 
prevent rapid drug release and realize the potential benefit of nanoparticle 
targeting. Moreover, a more comprehensive exploration of the interaction 
between drugs and polymers can be modelled in silico[483] prior to 
starting lab experiments in order to pinpoint suitable chemistry and 
favourable interactions. Additionally, whether all medulloblastoma 
subtypes really have increased endocytotic activity will need to be 
confirmed both between and within patient-derived tumours. The question 
whether that potential increase in endocytosis would translate to a clinical 
benefit also remains unresolved. 
In conclusion, the in vitro models described here are the first step to 
building a comprehensive human model for assessing local chemotherapy 
for medulloblastoma. Further validation with more compounds, additional 
characterisation and optimisation of the differentiation procedures are 
needed to improve the models. Although the nanoparticles produced are 
not currently fit for their purpose, a variety of methods to test their 
suitability have been established and it is only a matter of time before the 
optimal formulation will be created.  
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Supporting information 
Supporting information macro S1: 
//This macro aims to automate spheroid size measurement in three-dimensional cell culture. It 
requires input and output folders with images only, processes the images, records a file with 
spheroid measurements (Area, Feret max, Feret min, etc.) and writes an image with the outline/s of 
the determined spheroid/s.  
//The spheroid detection and size determination function to be repeated for every image is defined 
below 
function action(inputFolder,outputFolder,filename) { 
open(inputFolder + filename); 
//sets scale to predetermined values from calibration slide 
run("Set Scale...", "distance=178 known=100 pixel=1 unit=µm global"); 
run("16-bit"); 
//run("Brightness/Contrast..."); 
run("Enhance Contrast", "saturated=0.35"); 
//Uses Yen thresholding algorythm  
setAutoThreshold("Yen"); 
setOption("BlackBackground", false); 
run("Convert to Mask"); 
//Gets the ratio between black (spheroid) and white (background) pixels. If we assume a single 
spheroid, the ratio between black and white pixels would allow us to estimate the size of the 
spheroid. 
getHistogram(0,hist,256); 
ratio = hist[255]/hist[0]; 
//If there are more pixels detected as spheroid(black) than background(white) then the spheroid has 
not been detected due to variations in background 
if (ratio>1) { 
 // closes the image, reopens it, subtracts the background and proceeds as normal 
 close(); 
 open(inputFolder + filename); 
 run("16-bit"); 
 // Subtract Background is not used in the default function because it can lead to merging of 
spheroids and debris or it can remove the core of the spheroid leaving a very thin interrupted edge. 
In certain cases where the edges of a spheroid are very bright removing the background can give 
better results. 
 run("Subtract Background...", "rolling=50 light"); 
 setAutoThreshold("Yen"); 
 setOption("BlackBackground", false); 
 run("Convert to Mask"); 
 run("Remove Outliers...", "radius=15 threshold=0 which=Dark"); 
 getHistogram(0,hist,256); 
 ratio = hist[255]/hist[0];}; 
 //The strategy here is to act differently according to spheroid size. The general pattern is to 
expand and then shrink back the spheroids in order to include all cells on the edges. Then a series of 
functions are used to remove noise and the Watershed function separates fused or superimposed 
particles. The Analyze particles function is targeted to the specific spheroid size according to the 
black/white pixel ratio. 
if (ratio<0.001) {  
 run("Maximum...", "radius=8"); 
 run("Fill Holes"); 
 run("Minimum...", "radius=8"); 
 //small spheroids require a more "gentle" function to clean up noise 
 run("Median...", "radius=2"); 
 run("Maximum...", "radius=25"); 
 run("Minimum...", "radius=25"); 
 run("Fill Holes"); 
 run("Watershed"); 
 run("Analyze Particles...", "size=4000-Infinity circularity=0.20-1.00 show=[Overlay 
Outlines] display exclude include summarize");}; 
if (ratio >=0.001 && ratio<0.01) { 
 run("Maximum...", "radius=8"); 
 run("Fill Holes"); 
 run("Minimum...", "radius=8"); 
 //slightly bigger spheroids and a more rigorous function to remove noise 
 run("Remove Outliers...", "radius=10 threshold=0 which=Dark"); 
 run("Watershed"); 
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 run("Analyze Particles...", "size=10000-Infinity circularity=0.20-1.00 show=[Overlay 
Outlines] display exclude include summarize");}; 
if (ratio>=0.01 && ratio<0.2) { 
 run("Maximum...", "radius=8"); 
 run("Fill Holes"); 
 run("Minimum...", "radius=8"); 
 run("Remove Outliers...", "radius=15 threshold=0 which=Dark"); 
 run("Median...", "radius=4"); 
 run("Watershed"); 
 run("Analyze Particles...", "size=20000-Infinity circularity=0.20-1.00 show=[Overlay 
Outlines] display exclude include summarize");}; 
if (ratio>=0.2 && ratio<1) { 
 //Very big spheroids generally do not need to be expanded much to fill up the edges.  
 run("Maximum...", "radius=3"); 
 run("Fill Holes"); 
 run("Minimum...", "radius=3"); 
 //Outliers and noise are removed rigorously 
 run("Remove Outliers...", "radius=50 threshold=0 which=Dark"); 
 run("Minimum...", "radius=30"); 
 run("Maximum...", "radius=30"); 
 run("Watershed"); 
 run("Analyze Particles...", "size=50000-Infinity circularity=0.20-1.00 show=[Overlay 
Outlines] display exclude include summarize");}; 
 if (Overlay.size > 0) { 
//Sends particles detected to the ROI manager 
run("To ROI Manager"); 
close(); 
//Reopens the original image and pastes the outlines of the determined particles onto it 
open(inputFolder + filename); 
run("From ROI Manager"); 
outputPath = outputFolder + filename; 
save(outputPath); 
close(); }  
else { 
 close(); 
}; 
call("java.lang.System.gc"); 
}; 
call("java.lang.System.gc"); 
run("Clear Results"); 
inputFolder = getDirectory("Choose the input folder!"); 
outputFolder = getDirectory("Choose the output folder!"); 
//Delete the next line if you want to see how the macro works on the images. However that will 
reduce processing speed. 
setBatchMode(true); 
images = getFileList(inputFolder); 
//Sets the measurements that are recorded for each spheroid 
run("Set Measurements...", "area centroid shape feret's display add redirect=None decimal=1"); 
//That is the cycle that runs through all images 
for (i=0; i<images.length; i++) {  
 action(inputFolder,outputFolder,images[i]); 
 showProgress(i, images.length); 
}; 
//Writes in the Results and Summary windows and saves the data. 
selectWindow("Results"); 
saveAs("Measurements", "" + outputFolder + "Results.txt"); 
selectWindow("Summary");  
saveAs("Text", "" + outputFolder +"Summary.txt"); 
setBatchMode(false); 
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